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EPIDEMIOLOGY 
Coronary heart disease is the most common cause of death in the United
Kingdom. In total, 220 000 deaths were attributable to ischaemic heart 
disease in 2007. It is estimated that the incidence of acute coronary
syndrome (ACS) is over 250 000 per year. 
Sudden death remains a frequent complication of ACS: approximately
50 per cent of patients with ST elevation myocardial infarction (STEMI) 
do not survive, with around two-thirds of the deaths occurring shortly
after the onset of symptoms and before admission to hospital. Prior to
the development of modern drug regimes and reperfusion strategies, 
hospital mortality after admission with ACS was 30–40 per cent. After the 
introduction of coronary care units in the 1960s, outcome was improved, 
predominantly reflecting better treatment of arrhythmias. Current therapy
has improved outcome further for younger patients who present early in 
the course of their ACS. The last decade has seen a significant fall in the 
overall 30-day mortality rate. Most patients who die before discharge do 
so in the first 48 hours after admission, usually due to cardiogenic shock
consequent upon extensive left ventricular damage. Most patients who 
survive to hospital discharge do well, with 90 per cent surviving at least 
1 year. Surviving patients who are at increased risk of early death can be
identified by a series of adverse clinical and investigational features, and 











ACUTE CORONARY SYNDROMES 
DEFINITIONS 
The term ‘acute coronary syndrome’ (ACS) has been developed to describe
the collection of ischaemic conditions that include a spectrum of diagnoses 
from unstable angina (UA) to non-ST elevation MI (NSTEMI) and STEMI.
Patients presenting with ACS can be classified into two groups according 
to their electrocardiogram (ECG) (Figure 1.1): those with persistent STEMI 
and those without (non-ST elevation ACS or NSTEACS). The treatment of
STEMI requires emergency restoration of blood flow within an occluded
culprit coronary artery. Patients presenting with NSTEACS often have
ECG changes including T-wave inversion, ST depression or transient ST
elevation, although occasionally the ECG may be entirely normal. This
group can be classified further according to the presence of detectable 
levels of cardiac proteins, troponins, in patients’ serum (see below). Thus, 
NSTEACS patients with undetectable cardiac troponins (UA) are 
distinguished from those in whom myocardial ischaemia is severe enough
to cause myocardial necrosis, leading to troponin release into the 
circulation (NSTEMI). Detection of cardiac troponin following ACS is a 
strong predictor of recurrent ischaemia. However, it should be remembered
that patients with UA are still at increased risk of further events, especially 











Management Reperfusion Invasive / Non-invasive 























ACUTE CORONARY SYNDROMES 
Myocardial infarction can also be classified with regards to underlying 
aetiology as defined by the European Society of Cardiology: 
Type 1 Spontaneous myocardial infarction related to ischaemia due to 
a primary coronary event such as plaque erosion and/or rupture,
fissuring or dissection. 
Type 2 Myocardial infarction secondary to ischaemia due to either 
increased oxygen demand or decreased supply, e.g. coronary artery 
spasm, coronary embolism, anaemia, arrhythmias, hypertension or
hypotension. 
Type 3 Sudden unexpected cardiac death, including cardiac arrest, 
often with symptoms suggestive of myocardial ischaemia,
accompanied by presumably new ST elevation, or new LBBB, or 
evidence of fresh thrombus in a coronary artery by angiography and/or
at autopsy, but death occurring before blood samples could be
obtained, or at a time before the appearance of cardiac biomarkers in
the blood. 
Type 4a Myocardial infarction associated with PCI (percutaneous
coronary intrervention). 
Type 4b Myocardial infarction associated with stent thrombosis as
documented by angiography or at autopsy. 
Type 5 Myocardial infarction associated with CABG (coronary artery
bypass graft). 
PATHOPHYSIOLOGY 
ACSs are caused by an imbalance between myocardial oxygen demand 
and supply that results in cell death and myocardial necrosis. Primarily,
this occurs due to factors affecting the coronary arteries, but may also
occur as a result of secondary processes such as hypoxaemia or
hypotension and factors that increase myocardial oxygen demand. The 
commonest cause is rupture or erosion of an atherosclerotic plaque that 
leads to complete occlusion of the artery or partial occlusion with distal
embolization of thrombotic material. 
Atherosclerosis is a disease of large and medium-sized arteries, affecting
predominantly the arterial intima. The precise mechanism responsible for
the generation of atherosclerotic arterial disease remains open to debate, but








































ACUTE CORONARY SYNDROMES 
the extent and stability of atherosclerotic lesions is influenced by the
common risk factors of smoking, hypertension, hyperlipidaemia and
diabetes. There are a large number of other modifiable risk factors, such as
homocysteine, oxidative stress, fibrinogen and psychosocial factors, which
may play an important role in atherogenesis in some individuals. Individual
susceptibility to the adverse effects of risk factors may relate to genetic
predisposition. 
Atherosclerotic plaques are complex structures consisting of a fibrous cap
and a core of lipid, connective tissue and inflammatory cells. The
morphology of plaques is variable, and those with a thin fibrous cap, a large
lipid core and an increase in inflammatory activity are highly unstable. An
increase in inflammatory activity within plaques may be triggered by
systemic infections (Chlamydia, cytomegalovirus (CMV), Helicobacter or
chronic dental sepsis) or stimuli such as stress, severe exercise and
temperature change. ACS is initiated when the fibrous cap of an unstable
atherosclerotic lesion ruptures (in 75 per cent of cases) or the overlying
endothelium erodes (in 25 per cent of cases). Plaque erosion is more
common in females. Both mechanisms expose highly thrombogenic
subendothelial and core components of the unstable plaque to the blood,
leading to localized platelet adhesion, activation of the clotting mechanism,
and formation of an intraluminal thrombus that occludes the coronary
artery. Prior to plaque rupture or erosion, other conformational changes
may occur as a result of endothelial injury. This causes a proliferation of
smooth muscle cells leading to a reduction of the luminal diameter, which
increases shear stress, and causes further endothelial injury. Intravascular
ultrasound studies have confirmed that unstable coronary plaques are
associated with more expansive arterial remodelling compared to stable
coronary lesions, which may imply a more marked recent progression in
extent and severity of plaque at the site of rupture/erosion. Angiographic
and intravascular ultrasound studies of culprit lesions have demonstrated
complex eccentric morphology consistent with ruptured plaque and
superimposed thrombus. Vulnerable plaques that fissure or rupture are
characterized by large eccentric lipid pools with foam cell infiltration and
tend to rupture at the border of the fibrous cap and adjacent normal intima.
This weakness in the integrity of the plaque is initiated by matrix
metalloproteinases secreted by macrophages, and ultimately rupture occurs
through an acute change in wall shear stress. 
The lipid core is a potent substrate for platelet-rich thrombus formation with
the initiation of the coagulation cascade through the interaction of tissue





























ACUTE CORONARY SYNDROMES 
the release of tissue factor and the expression of the vitronectin (α )vß3
receptors leading to platelet activation and aggregation through the expression
of the glycoprotein IIb/IIIa receptor is an important event in the development
of thrombus. Platelet-rich thrombus is associated with cyclical reductions in
coronary blood flow with additional coronary vasoconstriction resulting from
endothelial disruption, and thromboxane A2 (TXA2) and serotonin production
leading to reduced nitric oxide (NO) production. Inflammatory acute phase
proteins, cytokines and systemic catecholamines stimulate the production of
tissue factor, procoagulant activity and platelet hypercoagulability.
A number of factors that can trigger the onset of ACS have been identified, 
acting by initiating plaque rupture or promoting thrombus formation.
Some patients report heavy physical exertion or mental stress shortly
before the onset of ACS. Circadian variation in coagulation and 
autonomic nervous system activity contribute to an increased incidence of
ACS in the morning. Irrespective of this, the risk of an individual episode 
of exercise or stress precipitating the onset of ACS is low, and most
episodes have no identifiable direct triggers. 
Other non-athersclerotic causes for ACS include arteritis, trauma, 
spontaneous coronary dissection, thromboembolism, cocaine use and 
congenital abnormalities such as anomalous coronary arteries. Patients 
who present as a result of these rare causes will usually not have the 
classical risk factors associated with atherosclerosis; typically the
diagnosis is not established until after coronary angiography. 
Acute STEMI usually results from total occlusion of a coronary artery, with
subsequent myocardial cell necrosis occurring in as little as 15 minutes.
Continued occlusion results in a wavefront of necrosis spreading from the
subendocardium to the subepicardium. The amount of myocardial injury
depends on the duration of occlusion, the presence of collateral blood flow
and the degree of preconditioning of the myocytes to ischaemia. In animal
models, persistent occlusion of a coronary artery will usually result in
complete infarction of the area subtended after 6 hours. Subendocardial and
full thickness or transmural mycocardial infarction can be well
demonstrated with cardiac magnetic resonance imaging (MRI) using late
gadolinium enhanced images. These images correlate well with
macroscopic histological findings. 
NSTEACS are usually associated with partial or transient occlusion of the 
coronary artery that may result in ST depression or T-wave changes on
the ECG. Myocardial injury occurs as a result of a sudden decrease in






















ACUTE CORONARY SYNDROMES 
rupture/erosion and embolization of thrombotic material into the distal
coronary bed. Most individuals with atherosclerotic coronary artery disease
have a large number of minor lesions that do not significantly narrow the
coronary lumen, as well as a smaller number of severe lesions. The severe
lesions are more likely to intermittently limit antegrade blood flow during
exercise (leading to stable angina). An ACS is more likely to occur due to
instability in one of the more numerous minor lesions (two-thirds of ACS
are related to angiographically minor lesions). Intravascular ultrasound
studies have shown that patients with NSTEACS frequently have multiple
ruptured plaques often occurring in arteries other than the initial culprit. 
UA can be caused by the same mechanisms as NSTEMI, although the
detectable myocardial necrosis does not usually occur. UA may also be
caused by a reduction in coronary flow due to a decrease in luminal diameter
caused by increase in size of a non-ruptured plaque where endothelial
damage leads to smooth muscle proliferation. For these reasons, patients
even with negative biomarkers may still be at high risk of further events and
this reinforces the need for effective risk stratification. 
DIAGNOSIS 
P resentation 
Chest pain is a common reason for patients to attend hospital, accounting 
for up to 5 per cent of visits to the emergency department and 40 per cent
of hospital admissions. Around 50 per cent of patients presenting with
chest pain will have an underlying ACS, requiring hospitalization and 
intensive medical therapy. The remainder have other cardiac and 
non-cardiac causes for their symptoms, and require a different 
management approach. This section gives guidelines on diagnosing ACS,
and differentiating it from other common causes of chest pain. 
The diagnosis of ACS is usually made using a combination of clinical and 
ECG features. Cardiac troponin studies and functional tests can then be
used to further risk-stratify the patient. As a general principle, all patients 
with symptoms that may be due to an ACS should be admitted to hospital. 
These patients should preferably be admitted to a chest pain assessment 
unit or heart attack centre, as those at high risk of early adverse events 
need to be carefully monitored and selected for early invasive therapy. 
Clinical features 
Most patients with ACS present with chest discomfort; in STEMI and 
80 per cent of NSTEACS this is prolonged, lasting over 20 minutes.
6 DIAGNOSIS 
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Accelerated or recent onset angina is present in 20 per cent of patients 
with NSTEACS, where the pain is intermittent and related to stress or 
exertion. Typically, the discomfort is retrosternal, crushing and severe, 
radiating to the neck, arms or back. There is often associated nausea, 
sweating and vomiting related to the release of toxins from injured 
myocardial cells and autonomic activation. It is not usually affected by 
changes in posture, movement or respiration. The pain can be atypical 
(sited in the epigastrium, neck, arms or back or unusual in character). 
Particularly with inferior infarction, the pain can be difficult to 
distinguish from dyspepsia. Atypical symptoms are more likely to be 
present in the young (age 25–40), elderly patients (age > 75), females, those 
with diabetes, chronic renal failure and those with dementia. In some 
patients, the pain is minimal or absent, with the dominant symptoms 
consisting of nausea, vomiting, dyspnoea, weakness, dizziness or syncope 
(or a combination of these). Occasionally ACS is recognized coincidentally 
(and often retrospectively) by the presence of ECG abnormalities in 
addition to raised biochemical markers. It is also important to 
differentiate those with non-cardiac chest pain from those with anginal 
symptoms. Typical angina is defined by the presence of all three of the 
features listed: 
• 	 a constricting discomfort across the chest and/or neck, shoulders, 
jaw or arms 
• 	 being precipitated by physical exertion or psychological stress 
• 	 rel ieved by rest or by nitrogycerin within about 5 minutes. 
If only two of the above features are present, it is considered to be 
atypical angina. If one or none of these features are present, the patient 
is considered to have non-anginal chest pain. Angina is less likely if the 
pain is unrelated to activity, brought on by inspiration, or associated with 
syptoms such as palpitations, tingling or dysphagia. If non-anginal chest 
pain is diagnosed, another cause for the pain shoud be considered. 
Electrocardiographic changes 
The majority of patients with an ACS will have an abnormal ECG at some 
stage. An initial normal ECG does not rule out the diagnosis, as ECG changes 
can develop, evolve and resolve rapidly. Commonly, the first ECG performed 
during the course of the presentation (often by paramedics) is the one that 
shows evidence of myocardial ischaemia, prior to resolution with appropriate 
pre-hospital treatment. Patients with a suggestive history and a normal ECG 
should be admitted and the ECG monitored at regular intervals; if ECG 
changes then develop, appropriate treatment can be initiated. 
DIAGNOSIS 7 
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STEMI is diagnosed by the presence of characteristic chest pain for more 
than 30 minutes and ST-segment elevation of ≥ 2 mV (2 mm) in two 
or more contiguous precordial leads or ≥ 1 mV (1 mm) in two or more 
adjacent limb leads or new left bundle branch block. In patients with this 
type of evolving MI: 
• 	 ST elevation develops rapidly (30–60 seconds) after coronary 
occlusion, and is usually associated with prolonged total occlusion 
of a coronary artery. 
• 	The ST elevation resolves over several hours in response to 
spontaneous or therapeutic coronary reperfusion. Persistent 
ST elevation is a sign of failure to reperfuse, and is associated with a 
large infarct and an adverse prognosis. T-wave inversion, 
pathological Q waves and loss of R waves often develop in the 
infarct zone when reperfusion has been late or incomplete, 
indicating the presence of extensive myocardial necrosis. When 
successful reperfusion occurs early in the course of an evolving 
ST elevation MI, there may be little myocardial necrosis, 
preservation of the R waves and no Q-wave formation. 
Occasionally, reperfusion therapy may be administered so rapidly 
that any infarction is aborted. 
In a small proportion of patients with chest pain and evolving MI (around 
5 per cent) the presenting ECG demonstrates bundle branch block (usually 
left). This is commonly associated with extensive anterior infarction 
and a poor prognosis. The distribution of ECG changes provides some 
information on the area of myocardium involved: 
• 	Changes in V2–V6 indicate anterior ischaemia or necrosis in the 
territory of the left anterior descending (LAD) artery. Extensive 
infarction in this territory is associated with a high risk of heart 
failure, arrhythmias, mechanical complications and early death 
(Figure 1.2). 
• 	Changes in I, aVL, V5 and V6 indicate lateral ischaemia or necrosis 
in the territory of the circumflex artery or diagonal branches of the 
LAD (Figure 1.3). Infarction in this territory has a better prognosis 
than extensive anterior infarction. 
• 	Changes in II, III and a VF indicate inferior ischaemia or necrosis 
in the territory of the right coronary artery (Figure 1.4, page 12). 
Compared with patients with extensive anterior infarction, these 
patients have a lower incidence of heart failure, an increased 
8 DIAGNOSIS 

































ACUTE CORONARY SYNDROMES 
incidence of bradyarrhythmias (since atrioventricular (AV) nodal
ischaemia or vagal activation often accompanies occlusion of the 
right coronary artery) and a relatively good prognosis. 
• 	Tall R waves in V1–V3 associated with ST depression indicate 
ischaemia or necrosis in the posterior wall, often associated with
circumflex or right coronary artery occlusion (Figure 1.5, page 13). 
NSTEACS are associated with transient ST segment changes (≥ 0.5 mm)
that develop with symptoms at rest and which may resolve with the
resolution of symptoms. The degree of ST change correlates with the risk
of further events and death; those with ≥1 mm of ST depression have an
11 per cent risk of MI and death at 1 year whereas those with ≥ 2 mm 
have 14 per cent risk at 1 year. Transient ST elevation is also associated
with a poorer outcome. T-wave inversion and ST changes of < 0.5 mm
are less specific at indicating and predicting events, though deep T-wave
inversion in leads V2–V6 is associated with disease in the proximal
LAD. Older patients with widespread severe ST depression often have
multivessel disease and a poor prognosis. In one study of 773 patients
presenting consecutively to hospital within 12 hours of chest pain
(without ST segment elevation), 20 per cent had ST-segment depression,
26 per cent had inverted T waves, 11 per cent had a non-diagnostic ECG
(bundle branch block, paced rhythm) and 43 per cent had a normal initial
ECG. Those patients with normal and minor changes on ECG often have
ischaemia in the circumflex territory that may be better detected with use
of posterior and right-sided leads. 
Diagnostic biochemical markers 
Cardiac enzyme studies are employed to substantiate or refute a
provisional diagnosis of NSTEMI or UA, and guide further therapy.
Myocardial necrosis results in the release of intracellular proteins,
which can be detected in blood samples. Measurement of total
creatine kinase (CK) level has been employed as a common
biochemical test in patients with suspected MI, with a temporally
related increase to more than twice the upper limit of normal
regarded as diagnostic. CK is widely distributed in non-cardiac
tissues, and therefore has a significant rate of false-positive results.
The isoenzyme, CK-MB, is predominantly located in the myocardium,
and for this reason was previously the gold standard marker for
myocardial necrosis. A low-molecular-weight protein, myoglobin, is
released as a result of damage to any muscle. Whilst non-specific for



























































































od na ee t l  sn t
n
 i neoit r 
c
a ev  pel 5

























oet  Ca .s l dh agi e
H  lr 3 o. ri





































































































































































































































































 14 DIAGNOSIS 
ACUTE CORONARY SYNDROMES 
and levels can be detectable within 2 hours, making it a useful early 
biomarker in the triage of patients with chest pain in the emergency 
department. 
Within the last decade, cardiac troponins have superseded other 
biomarkers in the detection of myocardial necrosis by virtue of their 
sensitivity and specificity. Any patient who demonstrates a typical 
rise and gradual fall of troponin in association with ischaemic 
symptoms or ECG changes should be diagnosed as having had a 
definite MI. The troponin complex is an integral part of the cardiac 
myofibril and is released following damage to myocardium. Two 
regulatory components, troponin I and T, released by myocardial 
micro-infarction, can be detected peripherally, indicating that 
myocardial necrosis has occurred. As well as their specificity, cardiac 
troponins are highly sensitive, with detectable elevations occurring 
after necrosis of less than 1 g of myocardial tissue. Troponins are 
detectable 3–4 hours after the onset of infarction, peak at 12 hours, 
and can remain elevated for up to 2 weeks. False-positive results can 
be due to: 
• 	 renal failure 
• 	 pulmonary embolism 
• 	 septicaemia 
• 	 rhabdomyolysis 
• 	 acute neurological disease (stroke or subarachnoid haemorrhage) 
• 	 significant valvular disease (aortic stenosis) 
• 	 acute and chronic heart failure 
• 	 cardiomyopathy (hypertrophic, apical ballooning) 
• 	 infiltrative disease (amyloidosis, sarcoid, haemochromatosis, 
scleroderma) 
• 	 inflammatory disease (myocarditis or myocardial extension of 
pericarditis and endocarditis) 
• 	 cardiotoxic drugs (anthracyclines, herceptin and 5-fluorouracil) 
• 	 cardiac contusion 
• 	 tachycardia or bradycardia. 
Other causes of chest pain 
Non-cardiac chest pain can arise from: 
• 	The aorta in acute dissection. The pain of aortic dissection is 
severe and of sudden onset; it is tearing in nature, often radiates to 
the back, and may be associated with hypertension, aortic 
regurgitation, neurological signs and pulse deficits (see Chapter 5). 
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• 	The pleura in pneumonia, pulmonary embolism (PE) or 
pneumothorax. Pain arising from the pleura is unilateral, sharp 
and stabbing, and worse on inspiration. There may be associated 
signs of pneumonia, PE or deep venous thrombosis. The majority 
of patients with pulmonary embolus have no ECG changes apart 
from a tachycardia or atrial fibrillation (AF). The ‘classic’ ECG 
changes of S1Q3T3 or right heart strain are associated with large PE 
and are often transient and easily missed. In spontaneous 
pneumothorax, there may be central chest pain with few 
auscultatory signs. Spontaneous pneumothorax is a strong 
possibility in patients with chronic obstructive pulmonary disease 
(COPD) who present with chest pain and dyspnoea in the absence 
of ECG evidence of acute myocardial ischaemia. A chest x-ray is 
vital to rule out the presence of air in the pleural space. 
• 	The upper gastrointestinal (GI) tract in oesophageal reflux, peptic 
ulcer disease or cholelithiasis. Dyspeptic pain arising from the upper 
GI tract is usually burning in nature, may have a clear relationship to 
posture or food, and is often relieved by antacids. Oesophageal pain 
may, however, be very similar to the pain of cardiac ischaemia. 
Exercise-induced oesophageal pain mimicking angina has been well 
described. In some individuals, oesophageal spasm may occur in 
association with ST segment change. Nitrates and calcium 
antagonists will relieve the pain of oesophageal spasm. Correct 
diagnosis in these difficult patients requires coronary arteriography, 
investigations to rule out coronary spasm, myocardial perfusion 
imaging and ambulatory oesophageal pH and pressure monitoring. 
• 	The pericardium in pericarditis. Pericardial pain is retrosternal, 
sharp, eased by sitting forward, and may worsen with inspiration. It 
is commonly seen following MI, or in a young adult with acute 
post-viral pericarditis. A pericardial rub is common, although it 
may be intermittent. Diagnostic widespread concave ST elevation 
may be present. 
• 	The bones and muscles in musculoskeletal disorders. 
Musculoskeletal chest pain is usually unilateral, localized and 
sharp. It is exacerbated by movement or local pressure. There may 
be a history of trauma. 
• 	The skin in acute dermatological conditions. Acute skin conditions 
can (rarely) produce chest pain. The unilateral pain of shingles 
precedes the rash, and may confuse the unwary. 
DIAGNOSIS 15 
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• 	Outside the chest cavity. For example, referred pain from the neck. 
Pain referred from the cervical or thoracic spine will have features 
of musculoskeletal chest pain. 
Since acute chest pain can have many possible causes, a careful history 
and comprehensive physical examination along with inspection of 
the ECG and chest x-ray are mandatory in all cases where diagnostic 
uncertainty exists. 
Risk assessment in patients with acute chest pain 
Patients who present with chest pain and ischaemic ECG changes require 
admission and appropriate treatment. STEMI can be diagnosed quickly 
through characteristic ECG changes. However, ECG changes may be less 
obvious or absent in those with NSTEACS, which is why obtaining a 
good history is essential. If there is an unstable pattern of ischaemic chest 
pain (particularly pain at rest or lasting more than 15 minutes) admission 
is required for further evaluation and treatment; these patients have an 
ACS until proven otherwise. Troponin levels should be measured on 
arrival and after a further 12 hours. Patients with detectable troponin 
elevation are at an increased risk of early adverse cardiac events. They 
require prompt in-hospital treatment and continued monitoring. If the 
troponin levels are not elevated, patients with unstable symptoms and 
other high-risk features should still be investigated and treated as 
inpatients in the same way. Patients diagnosed with stable angina, with 
no elevation of troponin levels, are at lower risk of adverse cardiac events 
occurring early. They should be given appropriate treatment for their 
symptoms as well as for secondary prevention. They can then be risk 
stratified with functional testing such as an exercise treadmill test or 
with more sensitive imaging techniques such as dobutamine stress 
echocardiogram or myocardial perfusion scanning (e.g. via cardiac 
MRI or radioisotope scintigraphy). 
Approximately 50 per cent of patients who present with chest pain have 
a non-cardiac cause; a firm alternative diagnosis may be obvious (for 
example, pneumothorax with an abnormal chest x-ray, or pericarditis 
with widespread concave ST elevation). Where the diagnosis is not 
obvious, patients with clear non-cardiac chest pain can be discharged 
once other important causes have been excluded. Patients with non­
specific chest pain who have a non-diagnostic ECG and no detectable 
serum troponins should undergo further testing to establish or refute 
a diagnosis of coronary disease. Functional testing has its limitations 
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disease. Conversely, patients with coronary disease may have a false-
negative stress test if they have no flow-limiting coronary lesions.
Newer imaging techniques using computed tomography (CT) have
been used to risk-stratify patients through calcium scoring as well
as CT angiography to provide further anatomical information where
indicated. Recent studies of multi-slice CT have been published showing
its ability to quickly identify those without coronary disease (or other
conditions such as PE and aortic dissection), therefore allowing for a
safe and early discharge. 
INITIAL TREATMENT 
Background 
Patients with evolving MI often do not request medical aid until 
symptoms have been present for more than 1 hour. This patient delay
occurs at the most critical time in the course of the illness, when pain is
often severe and the risk of ventricular tachyarrhythmias and cardiac 
arrest is high. Therefore, any patient with chest pain suspected of having 
an ACS should be urgently transferred to hospital for assessment. Transfer 
should ideally take place by trained paramedics with cardiac monitoring 
and resuscitation facilities and the ability to obtain an ECG en route. 
Treatment and analgesia should be given en route to hospital if possible. 
Transmission of the ECG to the admitting hospital in advance will allow 
the diagnosis to be confirmed and allow for early initiation of further 
management. 
If a patient with suspected ACS arrives in hospital, rapid processing is 
necessary to establish an early diagnosis and allow effective emergency 
care to be instituted. An appropriately trained doctor should review 
patients who present to the emergency department with possible ACS 
as soon as possible. The initial assessment should be rapid, and aimed 
at establishing the diagnosis, assessing the haemodynamic state and 
determining suitability for reperfusion therapy. Patients with clear-cut 
clinical features of STEMI with an ECG that demonstrates ST elevation
or bundle branch block should enter a ‘fast track’ system, designed to
ensure that they receive appropriate emergency care; any reperfusion 
therapy required should be instituted within 90 minutes of the initial call 
for medical assistance. A successful fast track system is only possible if 
medical staff respond rapidly to calls from the emergency department, and 
the aim should be to review patients with a suggestive history and ECG 
changes within 10 minutes of their arrival. 
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Emergency care 
The main aims for treatment of ACS are to prevent continued ischaemia, 
limit myocardial damage, reduce the incidence of left ventricular 
dysfunction, heart failure and death. This is achieved with early 
identification of patients who require revascularization and treatment of 
complications of ischaemia including arrhythmia (VF/VT and 
bradycardia), heart failure and shock. Initially, in all patients with ACS, 
emergency care consists of symptom relief, administration of 
antithrombotic agents, and instigating reperfusion therapy as early as 
possible for STEMI. 
The priorities are to: 
• 	Establish venous access with a large-bore cannula in an arm vein 
providing ready access for drug administration, and institute 
rhythm monitoring to aid in the rapid detection and treatment of 
arrhythmias. 
• 	Provide adequate analgesia, which is vital. Uncontrolled pain and 
anxiety are associated with sympathetic activation, with resultant 
detrimental effects on cardiac performance, oxygen consumption and 
the arrhythmia threshold. Intravenous (IV) opioids are indicated to 
provide rapid relief of pain. Intramuscular injections should be 
avoided, as they have a slower onset of action, are associated with 
unpredictable absorption, may cause a haematoma if thrombolytic 
therapy is given, and can affect CK estimations. The agent of choice is 
IV diamorphine 2.5–5.0 mg, given with an IV antiemetic. The dose 
should be repeated every 5 minutes until adequate analgesia is 
achieved. If repeated administration of diamorphine fails to relieve 
the pain, IV beta-blockers or nitrates should be considered. 
Respiratory depression produced by diamorphine can, if necessary, be 
rapidly reversed by naloxone. 
• 	Treat pulmonary oedema with IV frusemide 40–80 mg. If 
pulmonary oedema is severe, an IV nitrate infusion (as detailed in 
Appendix A) should be commenced. 
• 	Consider supplemental oxygen. Hypoxia is common in patients 
with evolving infarction, and may increase myocardial necrosis or 
have adverse metabolic effects. Supplemental oxygen will optimize 
oxygen delivery and limit ischaemia, and should be given to all 
patients with breathlessness or features of heart failure. Since 






ACUTE CORONARY SYNDROMES 
uncomplicated infarct, pulse oximetry should be instituted in all 
cases, and oxygen given if saturation falls below 93 per cent. 
High-concentration (up to 60 per cent) oxygen can be given via an 
MC mask if necessary. If the patient has COPD, therapy with 24 or 
28 per cent oxygen via a ventimask is commenced, and the 
concentration adjusted depending on blood gas measurements to 
prevent CO2 retention in patients who are reliant on hypoxic drive 
to maintain ventilation. 
• 	Commence treatment with oral antiplatelets. Aspirin (loading dose 
of 300 mg) and a thienopyridine (currently usually clopidogrel 
600 mg, though recently published trials indicate that prasugrel 
60 mg and ticagrelor may offer significant benefits). The use of 
clopidogrel prior to reperfusion therapy is associated with greater 
patency rate of the infarct-related artery and is essential for the use 
of stents during angioplasty. 
• 	 STEMI patients should be considered for immediate reperfusion 
therapy. This ideally should be primary PCI, but where this is not 
available, thrombolysis with fibrin-specific agents should be used. 
• 	NSTEACS patients should be treated with low-molecular-weight 
heparin (LMWH) and antianginals such as beta-blockers, calcium 
channel antagonists and nitrates. If they are high risk, IV 
glycoprotein (Gp) IIb/IIIa inhibitors may be considered. They 
should have continuous rhythm monitoring and repeated 12-lead 
ECGs whilst in pain. If they develop ST elevation they should then 
be treated as a STEMI. If they remain in pain despite adequate 
treatment they should be considered for urgent coronary 
angiography with a view to revascularization. If the pain is 
continuous and severe, alternative diagnoses should be re-explored, 
in particular aortic dissection. 
TREATMENT OF ST ELEVATION MI 
Background 
Prior to the advent of thrombolysis or primary PCI, the only means of
achieving therapeutic reperfusion in patients with evolving MI was 
emergency CABG. Although no randomized trials have been performed,
good results were reported for large case series from the 1970s, with an
improvement in outcome compared to medically treated patients.
Hospital mortality in the surgically treated patients was around 5 per cent, 
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demonstrating that CABG can be performed in patients with evolving MI
with an acceptable risk profile. With the advent of thrombolysis and
primary PCI, emergency CABG is now rarely performed in patients with
evolving MI, unless there is an associated early mechanical complication
such as a ventricular septal rupture or acute severe mitral regurgitation.
Modern reperfusion therapy has reduced mortality due to STEMI over the 
last three decades. Achieving reperfusion as soon as possible is
fundamental to improving outcomes. Increases in time to reperfusion 
adversely affect early and late mortality in patients treated by either 
thrombolysis or primary PCI. In one study of primary PCI, there was a 
7.5 per cent increase in mortality at 1 year for every 30-minute delay. 
Patient education therefore plays an important role in order for the 
symptoms to be recognized early and to call for help. Early recognition of 
STEMI by health care workers allows for prompt triage and initiation of 
reperfusion therapy at the earliest opportunity. 
PRIMARY PCI 
The use of primary PCI to achieve reperfusion in STEMI was first 
reported in 1983. Early case series suggested that primary PCI was a safe
and effective means of restoring antegrade flow in the infarct-related
artery (IRA) of a patient with STEMI. Potential advantages compared to 
thrombolysis led to a series of randomized studies comparing the two 
treatment modalities. Primary PCI, when performed promptly by
experienced operators, has been shown to be superior to thrombolysis.
A meta-analysis of 23 randomized trials with 7739 patients revealed a
significantly lower rate of early death (0.7 per cent vs 0.9 per cent, 
p = 0.0002) in favour of primary PCI. Non-fatal reinfarction (3 per cent vs
7 per cent, p < 0·0001), and the risk of stroke (1 per cent vs 2 per cent, 
p = 0.0004) were also significantly reduced. There was an increased risk of
major bleeding in the primary PCI group related to the arterial access site. 
This may be minimized with newer combinations of antithrombotic
regimes and the use of the radial route for arterial access. 
Benefits over thrombolysis 
The efficacy of primary PCI is thought to predominantly result from
increased patency rates achieved in the IRA (90–95 per cent with primary 
PCI vs 30–40 per cent with streptokinase and 50–60 per cent with
fibrin-specific agents). In addition to maintaining patency, treating the
underlying culprit plaque reduces rates of reinfarction and reintervention, 
thereby reducing overall ischaemic and mechanical complications. The 
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contributes to the overall lower mortality in the primary PCI group. Up to 
20 per cent of patients may have a contraindication to thrombolysis and in
this group a significant proportion will be able to be treated by primary 
PCI. Finally, as successful primary PCI leads to significant reduction in
myocardial damage and reduces the incidence of ischaemic complications,
selected patients can be discharged earlier than if they had been treated
with thrombolysis alone. Overall, compared to thrombolysis, primary PCI 
is cost-effective despite requiring more personnel and higher initial per 
treatment costs.
Assessment prior to primary PCI 
Primary PCI involves arterial access, either via the femoral or radial
artery and passage of a catheter to selectively engage the coronary ostia 
under x-ray visualization. Once the culprit vessel has been identified a 
small guide wire is passed along the vessel and past the occlusion.
Balloons, stents and other devices can then be delivered to the point 
required in order to successfully treat the artery. This requires the patient
to be anticoagulated, usually with unfractionated heparin, to reduce the 
incidence of thrombus formation on the equipment in situ. 
The risk of bleeding from an angioplasty procedure should be balanced 
against the benefit gained. Bleeding after angioplasty, in addition to
anaemia at the time of angioplasty, is associated with increased mortality. 
It is therefore essential that a careful history and examination identify 
patients at risk of bleeding and that this is communicated with the team
undertaking primary PCI. This also allows for modification of the 
antithrombotic regime during and after the procedure. 
Reactions to iodinated contrast agents are rare, however, patients with
a history of allergy should be treated with IV hydrocortisone 200 mg
and IV chlorpheniramine 10 mg, at the time of the procedure. A more
common potential hazard is the use of contrast agents in those with renal 
impairment. Minimizing the amount of contrast agent used reduces the 
incidence as does maintaining adequate hydration. The effects of IV fluids 
need to be continually assessed to avoid the precipitation of fluid overload 
and pulmonary oedema, especially in patients with extensive anterior
infarction. 
Patients with complications of MI need to be identified early in order 
to manage them correctly. Ideally, echocardiography should be used to
confirm the diagnoses of mitral regurgitation due to papillary muscle 
rupture, ventricular septal defect or left ventricular wall rupture. Patients in 
this group should be considered for urgent surgical treatment. Hypotension 
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due to right ventricular infarct or cardiogenic shock should also be
identified, as this will influence treatment during and after angioplasty. 
Adjunctive therapy during primary PCI 
During primary PCI various mechanical and drug therapies have
been used to improve outcomes. Bare metal stents (BMS) have been 
shown to be superior to balloon angioplasty by reducing the risk of
reocclusion and the need for reintervention due to restenosis. The 
CADILLAC trial compared BMS to balloon angioplasty and found 
significant benefits in favour of using stents including a 22.2 per cent vs
40 per cent incidence of restenosis and a 5.7 per cent vs 11.3 per cent
incidence of IRA reocclusion. 
Drug eluting stents (DES) have been shown to be safe in primary PCI and 
to reduce the need for repeat revascularization (by reducing the frequency
of in-stent restenosis, ISR) when compared to BMS. Trials comparing
BMS and DES in primary PCI (DEDICATION, MULTISTRATEGY and 
HORIZONS-AMI) have shown that DES reduce the incidence of ISR 
by 30–60 per cent, with no significant difference in death or stent 
thrombosis. Use of DES requires dual antiplatelet therapy (DAPT) to 
continue for 1 year whereas BMS only require 1 month. In view of the 
lower rate of restenosis, use of DES is preferable to BMS in smaller 
diameter vessels and longer lesions. However, other factors about the 
patient need to be considered prior to deciding on the type of stent such as
the risk of bleeding, compliance with medication and the need for other 
long-term anticoagulents such as warfarin. 
Intravenous GpIIb/IIIa inhibitors initially showed benefit for routine use 
in primary PCI and are still recommended routinely in many guidelines. 
The use of stents and higher loading doses of clopidogrel (600 mg) as well 
as more potent oral thienopyridines (e.g. prasugrel) have reduced the need 
of routine adjuvant GpIIb/IIIa in modern STEMI angioplasty. However,
they should still be used in most STEMI patients where the bleeding risk is 
low, especially those at high risk of adverse events such as anterior infarcts 
and large thrombus burdens. Bivalirudin, a direct thrombin inhibitor, has 
shown to have a similar effect in reducing ischaemia when compared to
heparin and GpIIb/IIIa (HORIZONS-AMI) trial. Its main benefit is in 
lower bleeding rates when angioplasty is carried out via the femoral artery. 
This has been demonstrated in the ACUITY trial, which assessed bleeding 
and outcomes in NSTEACS patients. It showed no difference in access 
site-related bleeding when bivalirudin was used in patients undergoing 
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in bleeding when comparing the radial to femoral route (0.7 per cent vs 
2.7 per cent in the GpIIb/IIIa groups) and when comparing bivalirudin to
GpIIb/IIIa inhibitors in patients undergoing angioplasty via the femoral 
route (3 per cent vs 5.8 per cent). 
Aspiration catheters are fine bore catheters which can be passed along an
angioplasty wire into the IRA. They are designed to aspirate thrombus in
order to reduce distal embolization. Several randomized trials have shown
they improve ST-segment resolution and coronary flow. A meta-analysis
of randomized trials of thrombectomy in STEMI has shown a benefit for
manual aspiration catheters with a decreased combined end point of death
and MI. This was largely driven by the TAPAS trial, which showed improved
30-day and 1-year survival in cases treated with routine aspiration prior to
stenting, even when thrombus was not angiographically detectable. 
Early discharge after primary PCI 
Early discharge maintains mobility, improves quality of life and reduces 
the risk of hospital-acquired infection and deep vein thrombosis. 
Primary PCI, with use of stents and antiplatelet agents, has significantly 
reduced the risk of early coronary reocclusion and reinfarction after 
treatment for STEMI. In addition, patients can be risk stratified with
regards to coronary flow at the end of the procedure and to the rest of the 
anatomy found at angiography. Patients who undergo successful primary 
PCI soon after symptom onset and who do not have any residual 
threatening coronary anatomy can be safely discharged early. One 
randomized trial (PAMI-II) has shown that early discharge of
uncomplicated patients within 3 days of a primary PCI is safe and cost
effective. The PAMI-II trial defined low-risk patients as: <70 years old, 
one or two vessel coronary disease, left ventricular ejection fraction (EF)
≥ 45 per cent, successful intervention and no malignant arrhythmia post
angioplasty. The DVLA has recently changed its criteria with regards to 
driving and MI. Patients who have been successfully treated by primary 
PCI and who have an EF ≥ 40 per cent are allowed to drive after 1 week if
no further intervention is planned. 
THROMBOLYSIS 
Background 
Despite the advent of primary PCI, thrombolysis remains the initial
treatment for a large proportion of acute STEMI patients in the UK.
Thrombolytic therapy for acute MI was first used in 1958. Debate about
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its efficacy continued until 1986, when the publication of the first GISSI 
study clearly demonstrated the value of streptokinase. By the 
mid-1990s, more than 100 000 patients had been randomized into a 
series of large-scale thrombolytic trials, which have helped to optimize 
the use of thrombolytic drugs. These large-scale trials have 
demonstrated that: 
• 	 thrombolysis produces an important time-dependent reduction in 
mortality. Treatment within the first hour after symptom onset 
can prevent irreversible myocardial necrosis from progressing, and 
abort an evolving infarct. Treatment within the first 6 hours of 
symptom onset limits infarct size and reduces mortality by 
25 per cent. Treatment between 6 and 12 hours may help to salvage 
some ischaemic myocardium (particularly in the border zone of 
the infarct) and reduces mortality by about 10 per cent. Over 
12 hours from symptoms, PCI is the preferred treatment as it 
increases the chance of successful reperfusion and it does not carry 
the risks associated with late thrombolysis. Based on this first 
series of trials, thrombolytic therapy reduces 1-month mortality by 
17 per cent, preventing 18 deaths for every 1000 patients treated. 
This mortality benefit is maintained in the long term, with 10-year 
survival rates substantially improved in treated patients. Newer, 
more efficacious agents have improved on these 1-month and 
10-year survival figures 
• 	mortality reduction is present regardless of age, sex or infarct site 
• 	 aspirin has an additive beneficial effect of similar magnitude to 
that produced by thrombolysis, and should be given to all patients 
with evolving MI 
• 	 the concurrent use of unfractionated heparin and thrombolytic 
therapy has been extensively studied. There are no beneficial effects 
apparent when intravenous or subcutaneous heparin is used with 
streptokinase or with early rt-PA (alteplase) regimens but the risk of 
bleeding complications is increased. For accelerated rt-PA and the 
newer plasminogen activators, heparin [controlled by regular 
activated partial thromboplastin time (aPTT) monitoring] reduces 
coronary reocclusion rates, and should be given for 48 hours 
• 	 thrombolysis increases the risk of stroke in the first 24 hours after 
treatment, but this is offset by the much larger reduction in cardiac 
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75 years of age) and those with systolic hypertension. Bleeding 
from other sites can occur (particularly at the site of vascular
punctures) and may require blood transfusion 
• 	 the evidence for a beneficial effect in patients with ST elevation or 
bundle branch block is strong. There is no clear evidence that 
patients with ST depression, T-wave inversion or a normal ECG 
derive benefit. These patients are, however, at a similar risk of
bleeding complications, and should not initially receive 
thrombolytic therapy. For these patients, frequent or continuous
ECGs should be obtained, and thrombolysis only administered if
ST elevation evolves. 
The benefit with thrombolysis is even more time dependent than that
of primary PCI. Therefore minimizing the symptom-to-needle time 
is key to producing good outcomes where thrombolysis is used. If
thrombolysis is the default reperfusion strategy pre-hospital thrombolysis 
is recommended. The CAPTIM trial compared pre-hospital thrombolysis 
with primary PCI in patients presenting early (<6 hour of symptoms). 
The composite primary end point (death, non-fatal infarction, non-fatal 
disabling stroke) was the same in both groups. A high proportion 
(85.4 per cent) of the thrombolysis group also underwent coronary early 
angiography, which supports the use of early adjuvant PCI in patients who 
have had successful thrombolysis. 
Selection of thrombolytic agents 
The relative efficacy of different thrombolytic agents and regimens has been
compared in several trials. The early studies showed similar efficacy for
streptokinase and non-accelerated rt-PA regimens. In 1993, the Global
Utilization of STreptokinase for Occluded coronary arteries (GUSTO) was
published. This trial demonstrated that an accelerated rt-PA regimen (given
over 90 minutes rather than 3 hours) with a subsequent aPTT-controlled IV
heparin infusion yielded superior IRA coronary patency rates, as well as
reduced death rates. Most of the beneficial effect on mortality was obtained
in patients with anterior infarction treated within 6 hours of symptom onset. 
Newer plasminogen activators, produced by bioengineering techniques 
applied to rt-PA, have been developed to overcome disadvantages of
the earlier thrombolytic agents. Fibrin-specific compounds, reteplase 
(r-PA) and tenecteplase (TNK), have longer half lives than the original 
compound, allowing for single or double bolus administration. These 
simplified regimens have been shown to shorten door-to-needle times. 
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A series of trials enrolling more than 50 000 patients (INJECT, INTIME-2, 
GUSTO-3, ASSENT-2) has shown that TNK has equivalent efficacy to 
rt-PA, whilst reteplase has at least equivalent efficacy to streptokinase. 
Accordingly, accelerated rt-PA or TNK with concomitant heparin are 
the regimens with the best record for mortality reduction. The modified 
plasminogen activators have the simplest dosing regimens, helping to 
reduce door-to-needle time. 
Inclusion criteria 
Where primary PCI is not available or where an additional time delay to 
primary PCI of 90 minutes or more is expected, thrombolysis should be given if: 
• 	Presentation within 12 hours of onset of ischaemic cardiac pain in a 
patient with: 
– 	ST segment elevation of at least 2 mm in two adjacent chest leads 
– 	ST segment elevation of 1 mm in two adjacent limb leads 
– 	 true posterior infarction or new bundle branch block. 
If the presentation is >12 hours after onset of pain with ongoing symptoms 
and ECG evidence of evolving infarction, primary PCI should be 
considered first. Additionally, patients presenting with shock should be 
treated with primary PCI, rather than thrombolysis. The SHOCK trial 
showed a 20 per cent reduction in mortality at 6 months in those treated 
with PCI (see Cardiogenic shock). 
Exclusion criteria 
These continue to evolve, and are in general decreasing as our experience 
with thrombolytic agents increases. At present there are few absolute 
contraindications. Many are now regarded as relative, to be interpreted 
within the clinical context. Criteria include: 




• 	 active peptic ulceration, varices or recent GI haemorrhage 

(dyspepsia alone is not a contraindication)
 




• 	 traumatic cardiopulmonary resuscitation (CPR) (CPR performed 
by trained staff is not regarded as a contraindication) 
• 	 recent internal bleeding from any site (menstruation is not an 
absolute contraindication) 
• 	 previous haemorrhagic stroke at any time 
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• 	 ischaemic stroke within the last year 
• 	 transient ischaemic attack (TIA) in last 3 months 
• 	 surgery, major trauma or head injury within the last month 
• 	 pregnancy 
• 	 diabetic retinopathy (now only a relative contraindication, as 
the risk of intraocular bleeding is very small and the potential 
benefit of thrombolysis in diabetics far outweighs this risk). 
If in doubt about administering thrombolysis, a senior colleague should 
be consulted and if bleeding risk outweighs perceived benefits then the 




Allergic reactions to streptokinase are due to the effect of pre-existing 
an tistreptococcal antibodies. Mild urticarial reactions are the most common 
allergic response, and should be treated with 200 mg IV hydrocortisone and 
10 mg IV chlorpheniramine. If a more severe reaction with bronchospasm 
occurs, 250–500 mg of intramuscular adrenaline should be administered 
along with nebulized bronchodilators. Major anaphylaxis is very rare 
(0.1 per cent). If this occurs, with associated cardiovascular collapse, 5 mL 
of 1:10 000 adrenaline IV is first-line therapy, followed by rapid volume 
loading with IV plasma expanders, steroids and antihistamines. Allergic 
reactions to the newer plasminogen activators are very rare. 
Haemorrhage 
Minor bleeding at venepuncture sites is relatively common, but rarely 
requires any specific therapy other than direct compression at the site. 
Major haemorrhagic episodes requiring transfusion are rare. If a major 
bleed occurs consider the following action: 
• 	 stop thrombolytic infusion (or heparin) 




• 	 give two units of fresh frozen plasma immediately 
• 	 consider the administration of tranexamic acid 10 mg/kg by slow 
IV injection. 
Hypotension 
Hypotensive reactions to thrombolytic infusion can occur with any agent, 
but are more common with streptokinase. They should be treated initially 
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by tilting the patient’s head down and, in the case of streptokinase, the 
infusion should be slowed down or, if necessary, halted for 5 minutes. It
can usually be successfully restarted when the blood pressure recovers. 
Atropine 0.6 mg IV can be given if a bradycardia is also present. If the 
hypotension persists and is clearly associated with the infusion, then the 
drug should be stopped, and a plasminogen activator substituted for 
streptokinase, as it is less likely to cause hypotension. In the case of severe 
persistent hypotension, fluids and inotropes can be administered 
cautiously if necessary. 
Cerebrovascular events 
The overall incidence of stroke is only minimally increased, since 
thrombolytic therapy causes a slight increase in cerebral haemorrhages,
which is offset by a reduction in cerebral infarcts. Plasminogen activators
are associated with a greater risk of haemorrhagic stroke than
streptokinase. Stroke is more common in older patients. If a stroke occurs, 
thrombolytic or anticoagulant therapy should be discontinued. A CT scan
and neurological opinion will help to determine the mechanism of the 
stroke and guide therapy. 
Failed reperfusion 
Detection and implications of failed reperfusion 
Patients treated with thrombolysis who achieve effective reperfusion have a
good prognosis, with hospital mortality rates of less than 5 per cent.
Achievement of successful reperfusion is associated with IRA patency,
restoration of rapid antegrade blood flow into a patent microcirculation and
resolution of chest pain. In a substantial proportion of patients, however,
reperfusion fails. In some of these patients the IRA is persistently occluded
by an extensively disrupted plaque or residual thrombus. In other patients
(particularly those treated late), platelet microthrombi or capillary
disruption prevent reperfusion of myocardium at the tissue level despite
restoration of blood flow in the epicardial IRA. Failure of reperfusion is
associated with continuing chest pain, extensive infarction, electrical and
haemodynamic instability, mechanical complications and a poor prognosis. 
Detecting failed reperfusion in current clinical practice is based on
serial evaluation of ST segments. Persistent ST elevation occurs in about 
one-third of patients, and is associated with failure of reperfusion, and 
portends an adverse prognosis. Of the 1398 patients enrolled in the 
INJECT trial, those with no ST resolution had a 17.5 per cent hospital 
mortality, those with partial resolution a 4.3 per cent mortality and those 





















ACUTE CORONARY SYNDROMES 
Rescue angioplasty 
The REACT trial as well as meta-analysis of angioplasty strategies after 
thrombolysis support the role of rescue angioplasty for STEMI patients 
who fail to reperfuse after thrombolysis. The REACT trial recruited such 
patients presenting within 6 hours. The criterion used to diagnose failed
reperfusion was the presence of <50 per cent resolution of maximal ST
elevation on the 90-minute post-thrombolysis ECG. The original trial 
showed a significant reduction in reinfarction at 6 months in those 
undergoing rescue angioplasty when compared to repeat thrombolysis or 
conservative therapy (2.1 per cent vs 10.5 per cent vs 8.5 per cent).
Follow-up data at 1 year showed a sustained benefit with increased 
event-free survival in the rescue PCI group. Accordingly, all patients
should have an ECG recorded 90 minutes after commencing 
thrombolysis. Patients who have less than 50 per cent ST segment
resolution in the infarct zone should be considered for rescue angioplasty. 
Recurrent ischaemia and early PCI after thrombolysis 
Following successful thrombolytic therapy, patients are often left with a 
residual high grade stenosis or an ‘inflamed’ ruptured plaque. Recurrent 
ischaemia occurs in up to one-third of thrombolyzed patients, and is
associated with increased hospital mortality. Usually, early recurrent 
ischaemia is related to further thrombus formation at the site of the 
original unstable atherosclerotic plaque. The GRACIA-1 trial looked at 
patients who were successfully thrombolysed and compared routine 
angiography within 24 hours with an ischaemia-guided approach. Among 
the subjects undergoing early angiography, stenting of the IRA was 
performed in 80 per cent. This was associated with a significant reduction 
in a combined end point of death, reinfarction or revascularization
(9 per cent vs 21 per cent at 12 months). Index hospital stay was also
significantly reduced in the early group.
Recently, another trial (TRANSFER-AMI) of 1059 patients compared
immediate transfer for PCI after thrombolysis (with tenecteplase) with
standard treatment with rescue angioplasty if required. Angiography
was undertaken at a median of 2.8 hours in the immediate transfer
group and 32.5 hours in the standard treatment group. In the standard
group, 34.9 per cent underwent early angioplasty for rescue, shock and
reinfarction. Overall, early angiography was associated with significantly
reduced recurrent ischaemia (0.2 per cent vs 2.1 per cent), as well
as a reduced combined end point of death, reinfarction, recurrent
ischaemia, new or worsening heart failure or cardigenic shock within
30 days. 
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Trials of ‘facilitated’ angioplasty (where angioplasty is performed 
immediately after pharmacological treatment such as thrombolysis) have
shown significantly worse results compared to primary PCI; this is due to
an increase in bleeding and ischaemic events. For example, the ASSENT-4 
trial demonstrated a higher in-hospital mortality for facilitated PCI (after 
thrombolysis with tenecteplase) compared to primary PCI (6 per cent vs 
3 per cent), causing early termination of the trial. 
The higher ischaemic events were put down to suboptimal antithrombotic 
treatment after thrombolysis and the fact that thrombolysis itself leads to
a pro-thrombotic state. The higher incidence of bleeding in the facilitated 
group also contributed to the higher mortality. 
Overall, the data suggest that early angiography should be performed 
following successful thrombolysis, although very early intervention carries 
an increased risk of adverse events. A reasonable approach would be to
transfer the patient to an angioplasty centre as soon as practically possible 
with a view to angiography within 24 hours. This strategy would also 
allow for earlier invervention in the event of patients developing recurrent 
ischaemia or reinfarction. 
STEMI with normal coronary arteries 
Up to 20 per cent of patients with clinical features of STEMI may have
normal coronary arteries. Conditions which classically mimic STEMI
include myocarditis, takotsubo cardiomyopathy and coronary spasm. In
addition, thromboembolic disease may produce a temporary thrombotic
occlusion similar to that of classical STEMI. Therefore, it is important to
investigate further those patients who present without the usual risk
factors for STEMI. The function of the left ventricle should be assessed
in all patients with STEMI who turn out to have normal coronary
arteries preferably with cardiac MRI. This is the most sensitive way to
detect if myocardial damage is due to an ischaemic or myocarditic
process by the pattern of scarring on late gadolinium enhancement.
Patients with thrombotic occlusion with no evidence of coronary
disease should be investigated for a right to left shunt, commonly a
patent foramen ovale or secundum atrial septal defect. This can be
undertaken by contrast echocardiography with agitated saline.
Takotsubo (or stress) cardiomyopathy is a diagnosis almost exclusive to
females and occurs is association with severe stress such as recent
bereavement. Patients present with signs and symptoms exactly that of
acute STEMI; however, they have patent coronary arteries with
characteristic ballooning of the left ventricular apex. This recovers in all
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cases within 6 weeks; however, there is a risk or arrhythmia, shock and
death within the first few days of presentation. 
TREATMENT OF NON -ST ELEVATION ACS 
The management of NSTEACS is different from that of acute STEMI. 
Treatment is aimed at reducing persistent ischaemia and the risk of 
reinfarction as opposed to opening an occluded artery to abort an 
infarction. Medical therapy has limited impact on mortality but does lead 
to a reduction in subsequent infarction and persistent ischaemia by 
stabilizing coronary plaques. The addition of coronary angiography 
provides anatomical information on the culprit lesion, the extent of 
disease, global and regional left ventricular function and provides a 
starting point for subsequent revascularization. In deciding which 
patients should undergo early intervention, the risks of the procedure 
(bleeding, renal failure, stroke) have to be balanced against the risk from 
further ischaemia. This can be difficult, as often the patients at highest 
risk of complications are also at the highest risk of further ischaemia. 
Furthermore, there is a wide heterogeneity of patients presenting with an 
ACS. The initial assessment of risk is thus central to the decisions made 
regarding a conservative or invasive strategy and this should be made on 
presentation of the patient to the accident and emergency department. 
Although most patients stabilize with aggressive antianginal therapy, 
50–60 per cent of patients still go on to have ‘failure’ of therapy, either 
defined as further ischaemia at rest or on early exercise testing. 
The characteristics that increase the likelihood of failure of medical 
therapy are: 
• reversible ST segment change 
• previous angina 
• prior aspirin use 
• family history of premature coronary disease 
• increased age. 
If all these characteristics are present, medical failure occurs in 90 per cent of 
cases. If none is present, the majority of patients settle with medical therapy. 
Clinical features and the 12-lead ECG 
The medical history and physical examination provide some help for 
risk stratification. Patients with multiple risk factors for vascular 
disease are at increased risk of adverse events. Older age and previous 
aspirin use are also markers of adverse risk. A highly unstable pattern 
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of symptoms with recent rest pain is also an adverse risk factor. 
Evidence of haemodynamic instability or compromise indicates a 
poor prognosis. 
The PRAIS-UK study was a registry of 1061 patients admitted to 
56 hospitals in the UK, half of whom had immediate access to 
angiography. From this study, the 6-month risk of death or MI was 
estimated and stratified according to age, ECG changes and the presence 
of heart failure. Compared to subjects aged <60 years, the relative risk was 
2.1 for those aged 60–70, and 2.8 for those over 70 years. The registry also 
confirmed the value of the ECG in determining risk: compared to having 
a normal ECG, documented ECG T-wave inversion and ST-segment 
depression increased the relative risk of events at 6 months by three-fold 
and five-fold, respectively. The presence of heart failure increased risk by 
1.9, similar to the two-fold risk of being male. In another study, sequential 
risk for death or MI at 12-month follow-up was evaluated in 911 patients 
with unstable angina or non-Q-wave MI. The risk with a normal ECG, 
T-wave inversion, ST elevation, ST depression and both ST depression and 
elevation was 8 per cent, 13 per cent, 15 per cent, 17 per cent and 
25 per cent, respectively. The duration of the ischaemia also has a bearing 
on outcome. Episodes of ischaemia that are associated with ST segment 
change and persist for 10 minutes or more are associated with the worse 
prognosis. 
Based on these data, a successful algorithm has been developed to 
triage patients with acute, ischaemic-sounding chest pain. The 
primary ECG abnormality necessitating admission was ST-segment 
depression or elevation greater than 1 mm. In the presence of lesser 
changes such as 
• ST elevation 0.5–1 mm 
• ST depression 0.25–1 mm 
• T-wave inversion in >2 leads 
• Q waves 
• left ventricular hypertrophy 
• abnormal rhythm 
a diagnosis of cardiac chest pain was considered likely if the patient 
was male, or if pain radiated to the neck or left arm, or if there was 
associated nausea/sweating, or if the patient reported a history of 
ischaemic heart disease. Where the ECG was normal, three or more 
of these latter features would be required to increase suspicion of 
an ACS. 
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RISK SCORES IN NSTEACS 
Fundamental to the development of modern risk scores in NSTEACS is the
quantification of serum troponin. As described earlier, troponin
measurement is now the gold standard test for detection of myocardial
injury. In ACS, troponin levels rise about 4 hours after the onset of chest
pain in 30–50 per cent of patients with 100 per cent of infarct patients being
positive at 12 hours. In a review of 4000 patients with acute ischaemic
syndromes, troponin T levels were raised in 33 per cent of patients. A
strong relationship exists between the level of peak plasma troponin at
12 hours from the onset of pain and the extent of myocardial damage.
Furthermore, several studies have demonstrated that the absolute levels of
troponin have a strong relationship to clinical outcome such as death and MI
over the short- and medium-term period after presentation with an ACS. In
an early trial of 112 patients with unstable anginal symptoms, death or MI
occurred in 30 per cent of those with an elevated troponin T (>0.2 μg/L),
compared to 2 per cent in the remainder. In the larger GUSTO-IIa trial,
troponin T elevation was confirmed to strongly predict 30-day mortality.
Similarly, troponin I elevation was related to mortality in ACS: in a study
published in 1996, mortality at 42 days was 1.0 per cent with a troponin I
level <0.4 μg/L compared to 7.5 per cent with a troponin I level >9.0 μg/L
(Figure 1.6). In the FRISC study, 963 patients participating in a randomized
study of LMWH (dalteparin) in unstable angina had troponin T measured.
A total of 766 patients had a pre-discharge exercise test. Cardiac death or
MI at 5-month follow-up occurred in 5 per cent, 9 per cent and 13 per cent
of patients with a maximum troponin level of 0.06 μg/L, 0.06–0.2 μg/L,
and >0.2 μg/L at 12 hours, respectively. Similarly, exercise tolerance and
ST-segment depression stratified patients into low, intermediate and high
risk with death/MI in 5 per cent, 13 per cent and 29 per cent, respectively.
Combination of the two variables (troponin T and exercise test) predicted
adverse outcome in 1 per cent of low risk, 7 per cent of intermediate
risk and 20 per cent of high-risk patients (Figure 1.7). Thus, elevation of
cardiac troponin indicates the presence of minor myocyte damage, which
is associated with a high risk of subsequent progression to MI and death in
patients with unstable angina.
Risk assessment can be further refined using clinical scoring systems 
which have been developed from the analysis of large cohorts of patients 
with NSTEACS. They use features from the history, clinical examination, 
ECG changes and biomarkers to predict the risk of further events. The 
most sensitive for predicting events in hospital and up to 6 months is the 
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Figure 1.6 Mortality rates at 42 days according to the level of cardiac 
Troponin I measured at enrolment. (Reproduced with permission from














































Figure 1.7 Five-month risk of cardiac death or myocardial 
infarction (MI) in relation to exercise test response and 
maximal troponin T levels during the first 24 hours. 
(Reproduced with permission from Lindahl et al. (1997)) 
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NSTEACS is simpler to use though it is less accurate at predicting events 
than GRACE. However, it has an added advantage in that it is the only 
scoring system that has been shown to identify patients with a long-term 
benefit of an early invasive treatment strategy in a randomized trial. It 
assigns one point to each of the following risk factors: 
• 	 age ≥ 65 
• 	 three or more risk factors for coronary artery disease (family 
history/diabetes/current smoker/hyperlidaemia/hypertension) 
• 	 known coronary stenosis ≥50 per cent 
• 	 aspirin use in the preceding 7 days 




• 	 ST segment deviation on ECG of ≥0.5 mm 
• 	 elevated serum cardiac biomakers. 
The score predicts the recurrence of ischaemia within 14 days: 
0–1 = 4.7 per cent, 2 = 8.3 per cent, 3 = 13.2 per cent, 4 = 19.9 per cent, 
5 = 26.2 per cent, 6 = 40.9 per cent. Patients with a score of 3 or more 
are considered high risk and are likely to benefit from an early invasive 
strategy, especially if their biomarkers are positive. 
High-risk patients 
The American Heart Association/American College of Cardiology (AHA/ 
ACC) guidelines recommend an invasive strategy in NSTEACS in the 
following situations: 
• 	 recurrent angina/ischaemia at rest or low-level exercise despite 
intensive medical therapy 
• 	 signs or symptoms of heart failure or new or worsening mitral 
regurgitation 
• 	high-risk findings on non-invasive stress testing 
• 	 reduced left ventricular function (EF <40 per cent) 
• 	 haemodynamic instability 
• 	 sustained ventricular tachycardia (VT) 
• 	PCI within the previous 6 months 
• 	 prior CABG 
• 	high-risk score (e.g. TIMI or GRACE) 
• 	new or presumably new ST-segment depression 
• 	 elevated cardiac biomarkers (troponin I and T). 
Patients with recent PCI are likely to have a restenosis or stent thrombosis 
best treated with reintervention. Prior CABG represents another subgroup 
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where early intervention is of benefit due to the high rate of venous graft
failure. Patients with reduced left ventricular function, acute heart failure 
or previous anterior Q-wave MIs have sufficient risk to support a policy 
of early angiography. Patients with extensive co-morbidities and patients 
with chest pain with low-risk scores are unlikely to benefit from an
invasive strategy. 
Low-risk patients 
Non-invasive stress testing with a low-level treadmill exercise test (two
stages of the Bruce protocol) should be performed in patients free of 
ischaemia at rest or on minimal exertion for 12–24 hours. Should patients
be discharged prior to this, symptom-limited exercise testing may be done 
within 7–10 days of presentation. 
Where the baseline ECG has resting ST-segment depression (>0.1 mV), 
bundle branch block, left ventricular hypertrophy, an intraventricular 
conduction defect, a paced rhythm, or the patient is on digoxin therapy, 
stress perfusion imaging (radioisotope or MRI) or stress echocardiography 
may be done to identify a substrate for ischaemia. Those that subsequently 
have a positive stress test should undergo coronary angiography with a 
view to revascularization. 
REVASCULARIZATION STRATEGIES IN NSTEACS 
PCI has become the established treatment for NSTEACS. The
adjunctive use of intracoronary stents and GpIIb/IIIa inhibitors has
diminished the risk and improved the outcome associated with PCI. At
present, the rate of in-hospital mortality is still less than 1 per cent,
with indicators of infarction risk well defined in clinical and
angiographic terms. 
Historically, in unstable angina, CABG surgery has been associated with an
increased operative mortality at 3.7 per cent (much improved in FRISC-II 
with an in-hospital mortality of 1.2 per cent) with predictors of risk being 
left ventricular dysfunction, the need for pre-bypass intra-aortic balloon
pumping, and a history of previous CABG. With successful hospital 
discharge, the 5-year survival is 90 per cent with the greatest relative
benefit seen in those with reduced left ventricular function – in one study 
in patients with a left ventricular EF <50 per cent, the 3-year mortality 
was 6.1 per cent in patients after surgery, compared to 17.6 per cent in 

























ACUTE CORONARY SYNDROMES 
The FRISC-II study compared an early invasive and conservative
strategy in 2457 patients with unstable angina. The patients were of
mean age 66 years (70 per cent men). Angiography was performed
within 7 days in 96 per cent of the invasive group compared to only
10 per cent of the conservative group. Revascularization (55 per cent
PCI, 45 per cent CABG) was performed within 10 days in 71 per cent
of the invasive group compared to 9 per cent of the conservative group,
and within 6 months in 77 per cent and 37 per cent, respectively. At
6-month follow-up, the invasive group had a 22 per cent (9.4 per cent
vs 12.1 per cent, p = 0.031) reduction in the composite end point of
death/MI through a reduction in the rate of MI. Furthermore, there was
a reduction in readmission rate by 44 per cent, as well as a 36 per cent
reduction in the presence of angina compared to the conservative group.
The benefits were sustained to 5 years: the primary end point of death
or MI was reduced by 19 per cent, and there was a 27 per cent reduction
in the rate of MI alone in the invasive group. The FRISC-II study
also randomized patients to treatment with and without the LMWH
dalteparin. The benefit of the adjunctive use of dalteparin was seen in
the conservative group with a reduction in primary end point, although
it had no additional effect on the invasive arm.
The TACTICS-TIMI 18 trial also compared an early invasive and 
conservative strategy in patients with NSTEACS who were given the 
GpIIb/IIIa inhibitor tirofiban. Over half the patients had elevated 
troponin T levels and 48 per cent had ECG changes present, indicating
a high-risk population. Almost all (97 per cent) of the invasive group 
underwent coronary angiography at a median time of 22 hours after 
randomization. Revascularization was undertaken in 61 per cent of
patients in the early invasive arm (41 per cent PCI, 20 per cent CABG). 
In the conservative arm, 51 per cent underwent angiography during the 
initial hospitalization with 37 per cent undergoing revascularization. 
This resulted in a significant reduction in death and non-fatal MI in the 
invasive group of 35 per cent at 1 month (4.7 per cent vs 7 per cent, 
p = 0.02) and 26 per cent at 6 months (7.3 per cent vs 9.5 per cent, 
p < 0.05). Subanalysis also showed that those with a TIMI risk score of ≥3 
or a troponin T of ≥ 0.1ng/ml gained the most from an invasive strategy, 
whereas those with a score of ≤2 or troponin T of ≤ 0.1ng/ml had similar 
outcomes with either strategy. 
The RITA-3 study also showed benefit for an invasive strategy with
reduced refractory angina at 4 months (4.4 per cent vs 9.3 per cent). There 
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was no reduction in death or MI at 1 year, but analysis of the 5-year follow-
up data has shown a reduction of 26 per cent (p = 0.03) in cardiovascular 
death and MI. When stratified according to risk, the patients in the highest 
risk group appeared to benefit the most from intervention. 
A meta-analysis of seven trials involving 8375 NSTEACS (including 
RITA-3, TACTICS-TIMI 18 and FRISC II) patients showed a significant
benefit in survival at 2 years in those treated with early intervention 
(all-cause mortality 4.9 per cent vs 6.5 per cent, p = 0.001). 
With regards to timing of intervention, several trials have assessed early 
vs delayed intervention. The ISAR-COOL trial was a small (401 patients), 
double-centre study in which NSTEACS patients were randomized to
early intervention or prolonged antithrombotic treatment followed by
intervention. The median time to intervention was 2.4 hours for early 
intervention and 86 hours in the antithrombotic arm. Early intervention 
showed a significant benefit in reducing non-fatal MI or death at 30 days 
(5.9 per cent vs 11.6 per cent, p = 0.04), which was attributed mainly to
events whilst awaiting catheterization. The more recent TIMACS trial 
involving 3031 patients compared early (≤24 hours) vs delayed (≥36 hours) 
intervention. The median time to intervention was 14 hours in the early 
arm and 50 hours in the delayed group. Follow-up at 6 months revealed no 
difference in the primary end-point of death, MI or stroke. However, there 
was a reduction in refractory ischaemia in the early invasive group.
Overall, high-risk patients, without contraindications to intervention, 
should undergo an early invasive strategy ideally within 24 hours 
of presentation, and those patients with ongoing ischaemia despite 
optimal medical therapy should be considered for more immediate
revascularization. Patients who are high risk with positive troponin should 
receive GpIIb/IIIa inhibitors in the catheter laboratory. Up-front use of
GpIIb/IIIa inhibitors is recommended in many guidelines but routine 
use is associated with a signficantly increased risk of bleeding and the 
benefits in reducing ischaemia are mainly conferred at the time of PCI 
(see Glycoprotein IIb/IIIa inhibitors). 
BLEEDING RISK IN ACS 
Successful treatment of ACS involves the use of potent antithrombotic 
regimens allied with PCI. Unfortunately, bleeding is the most common
non-cardiac complication associated with coronary intervention. The use 
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bleeding, and non-access site-related bleeds such as gastrointestinal,
cerebral and retroperitoneal haemorrhage. There is a strong association 
between bleeding and adverse events with risks increased by five-fold for 
MI, four-fold for death and three-fold for stroke at 30 days. The 
mechanisms for this are mutifactorial including haemodynamic effects,
the cessation of antithrombotic drugs, and, possibly, adverse effects from 
blood transfusion. Bleeding is also commoner among older, more frail
subjects with significant co-morbidities, who are also at higher risk of
ischaemic events. Therefore the benefit gained from treatment has to 
balanced against the risks of bleeding and treatment needs to be tailored
to individual patients. Several risk scores have been developed to predict 
the risks of bleeding in an effort to assist with the decision-making. The 
CRUSADE score (http://www.crusadebleedingscore.org/) was developed
from a registery of 89 000 patients to predict the risk of in-hospital 
bleeding in NSTEACS. More recently another system from over 302 000
patients who underwent PCI has been developed, which assigns points to 
the following nine variables: 
The risk of bleeding on the current admission was classed as low if scores 
were ≤7, medium 8–17 and high ≥18 with prevalence of 0.63 per cent, 
1.8 per cent and 5 per cent respectively. 
Vascular access complications can be minimized by using the radial rather 
than femoral route. GI bleeding has been shown to be reduced by the 
use of gastroprotective medication in high-risk patients. Careful dosing 
of LMWH and unfractionated heparin (UFH) is required in those with
renal impairment. Similarly, in patients at high risk of bleeding, the use 
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of alternative agents can be considered. These agents are as effective as 
heparin and GpIIb/IIIa inhibitors at reducing ischaemic events while 
benefiting from lower rates of bleeding. These agents include bivalirudin, 
which can be used alone in patients undergoing intervention, and 
fondaparinux, which can be used alone in those being managed medically,
or with heparin among those undergoing intervention. 
Thrombocytopenia 
Thrombocytopenia can occur after treatment for ACS as a result of
exposure to heparins or GpIIb/IIIa inhibitors. Heparin-induced 
thrombocytopenia (HIT), is a serious, immunoglobulin-mediated 
complication that often leads to thromboembolic complications. It occurs
with UFH (incidence 5 per cent) and LMWH (incidence 0.5 per cent) 
usually after between 5 and 10 days of use (or sooner if there has been 
previous exposure to heparins), and is associated with a 50 per cent 
reduction in the platelet count or a drop to < 100 X 109 platelets/L. It should 
be treated with the cessation of heparin and introduction of another 
antithrombotic agent such as lepirudin or danaparoid. Bleeding 
complications of HIT are rare but 50 per cent of patients with HIT develop 
arterial or venous thrombosis which can be life threatening. Further 
exposure to heparins should be avoided in patients who have had HIT. 
GpIIb/IIIa-induced thrombocytopenia is often more profound with
platelet counts of < 50 X 109 platelets/L. It occurs more frequently with
abciximab (up to 2.4 per cent) and less with eptifibatide (0.2 per cent) and 
tirofiban (0.5 per cent). The GpIIb/IIIa inhibitor and heparin should be
discontinued. Most patients remain asymptomatic and platelet counts begin 
to improve within 24 hours. Platelet transfusions should be reserved for 
those with bleeding. Thrombosis is rare with GpIIb/IIIa inhibitor-induced 
thrombocytopenia; however, there is a higher incidence of adverse events, 
due to bleeding, repeat revascularization, recurrent ischaemia and death. 
ADJUNCTIVE MEDICAL THERAPY 
Aspirin 
Unless there is a contradidication, aspirin should be administered to all 
patients with NSTEACS and STEMI at presentation. It should be
continued indefinitely in all patients with suspected or proven coronary
disease. Aspirin inhibits the cyclooxygenase enzyme in platelets which 
leads to the formation of thromboxane A2, a potent stimulus to platelet 
activation. Data from the Veterans Administration Cooperative Study, the 
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Canadian Multicenter Trial and the Montreal Heart Institute Study 
confirmed that the use of aspirin in unstable angina reduced the risk of 
cardiac death and non-fatal MI by 51–72 per cent. From a meta-analysis of 
seven antiplatelet studies, a 35 per cent reduction in vascular events 
occurred over 20 months with aspirin. The body of evidence suggests that 
aspirin should be initiated at a dose of either 160 or 325 mg in patients not 
already receiving aspirin with subsequent daily dosing at 75–325 mg. 
With aspirin, however, only one pathway of platelet activation is inhibited 
and the platelet may also be readily activated by adenosine diphosphate 
(ADP), thrombin and collagen. Aspirin reduces platelet aggregation, 
enhancing recanalization in STEMI, and reducing the risk of further 
vascular events in patients with previous MI. The effect of aspirin on 
mortality in patients with acute MI has been studied in 15 trials, enrolling 
more than 19 000 patients (most of these patients were enrolled in ISIS-2). 
Overall mortality with aspirin therapy is reduced by around 20 per cent. 
This benefit is maintained with continued treatment over several years. 
A loading dose of 150 mg produces rapid and complete inhibition of 
thromboxane-mediated platelet inhibition. For long-term treatment, 
higher doses are more gastrotoxic. A dose of 75 mg/day maintains 
virtually complete long-term cyclooxygenase inhibition, and is suitable 
for chronic therapy. 
There are few contraindications to the use of aspirin, but it should not be 
given to patients with: 
• known hypersensitivity to aspirin 
• bleeding peptic ulcer 
• coagulation disorder 
• severe hepatic disease. 
There is no clear evidence of a relationship between effectiveness and time 
from onset of symptoms, and aspirin should immediately be given to all 
patients diagnosed to have evolving or recent ACS, even if presentation 
is late. In patients who do not tolerate aspirin through hypersensitivity or 
major gastrointestinal intolerance, a thienopyridine should be considered. 
Clopidogrel 
Clopidogrel is a thienopyridine which blocks ADP-mediated platelet 
aggregation and the activation of the GpIIb/IIIa receptor, which cross-links 
platelets through fibrinogen. It was shown to be of value in NSTEACS in 
the CURE trial: this randomized 12 562 patients with NSTEACS 
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(troponin negative and positive) to clopidogrel or placebo for 3–12 months
(mean of 9 months) in addition to aspirin. The trial was undertaken 
with a conservative ethos: only one-third of patients underwent
revascularization. Benefit with clopidogrel occurred within the first 
24 hours with a 20 per cent reduction in death/MI/cerebrovascular 
accident (primary end point), largely driven by a reduction in MI from
6.7 per cent to 5.3 per cent. This was consistent across subgroups and 
irrespective of revascularization. A relative increase in bleeding risk
occurred, 3.7 per cent on clopidogrel compared to 2.7 per cent on placebo.
The prospective substudy of patients undergoing percutaneous coronary
intervention, PCI-CURE, was reported in 2658 patients. Patients 
randomized to clopidogrel received it for a mean of 10 days pre-PCI, with
both groups receiving open-label clopidogrel for 4 weeks post-PCI usually 
because of stenting. Prior to PCI, the clopidogrel group had a reduced 
incidence of MI/refractory ischaemia (12.1 per cent vs 15.3 per cent),
which was maintained for the 30 days after PCI. Of interest, in CURE, the 
benefit with clopidogrel appeared to occur in addition to the use of GpIIb/ 
IIIa inhibitors. 
In STEMI patients, the COMMIT study showed that the addition of
clopidogrel 75 mg od to standard treatment produced a reduction in 
death from 8.1 per cent to 7.5 per cent (p = 0·03). Another STEMI trial, 
CLARITY, used loading doses of 300 mg followed by 75 mg od in patients 
treated with thrombolysis. Among those who eventually underwent
coronary angiography, the IRA was more likely to be patent in the 
clopidogrel group. In the PCI-CLARITY substudy, the 30-day incidence of
cardiovascular death, reinfarction or stroke after PCI was reduced from
6.2 per cent to 3.6 per cent (p = 0.008). 
Higher loading doses of 600 mg provide a more rapid onset of action and 
reduced ADP-induced platelet across a wider population. This has been 
shown to result in fewer adverse events in patients with NSTEACS (5 per 
cent vs 12 per cent, p = 0.02) with no increased risk in bleeding. Recently,
subanalysis of the HORIZONS and CURRENT OASIS-7 trials has also 
shown similar benefits for 600 mg in STEMI patients undergoing primary
PCI. Therefore, a loading dose of at least 300 mg should be given to all 
patients presening with ACS, with 600 mg being preferable in those likely 
to require urgent PCI. 
Other thienopyridines 
Recently two trials have shown favourable results with newer agents. 
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have a faster onset and be more potent than clopidogrel. The TRITON­
TIMI 38 study, undertaken in ACS patients (99 per cent undergoing PCI),
assessed prasugrel (loading dose 60 mg, followed by 10 mg maintenance)
in comparison to clopidogrel (loading dose 300 mg, followed by 75 mg 
maintenance). The primary end point of cardiovascular death, non-fatal 
MI and non-fatal stroke was reduced by 23 per cent at 30 days in the 
prasugrel group (9.9 per cent vs 12.1 per cent, p < 0.001). The benefit was 
sustained to 15 months though there was an increased risk of life-
threatening bleeding in those taking prasugrel (1.4 per cent vs 0.9 per cent, 
p = 0.01). The benefits of prasugrel were more pronounced in STEMI 
patients, in whom there was a 32 per cent reduction in the primary end 
point, and a decreased requirement for adjuvant GpIIb/IIIa therapy with
no observed increase in bleeding. 
Ticagralor was studied in the PLATO trial, where it was given as a 
loading dose of 180 mg followed by maintenance of 90 mg twice a day.
At 12 months there was a 16 per cent reduction in events (a composite of
death from vascular causes, MI and stroke) as well as significant reduction 
in all-cause mortality (4.5 per cent vs 5.9 per cent, p < 0.001). Overall 
bleeding rates were the same in the two groups though there was an
increase in non-CABG-related major bleeding with ticagralor.
Duration of antiplatelets 
Following NSTEACS, it is recommended that DAPT, with aspirin and
clopidogrel, should be continued for at least 1 year whether treated by
PCI or medically (CURE study). For STEMI, there is strong evidence
for benefit for DAPT up to 1 month (COMMIT and CLARITY studies)
and considering the effect on NSTEACS it is reasonable to continue
DAPT for 1 year for all ACS, including STEMI. In addition, most
patients will be treated with PCI and therefore the duration will depend
on the type of stent used as well as the risk of reinfarction (which will
be dependent on other factors such as diabetes and impaired left
ventricular function) that should be weighed up against the risk of
bleeding. Patients who receive a DES need to continue DAPT for at
least 1 year, as premature cessation is strongly associated with a risk
of stent thrombosis, which carries a high mortality. This was shown in
the PREMIER study where patients with DES who discontinued
clopidogrel experienced a nine-fold higher risk of mortalty (7.5 per cent
vs 0.7 per cent, p < 0.0001). Premature discontinuation in patients
managed medically may also lead to a higher risk of death and
reinfarction. Therefore, in any patients who are going to require
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non-cardiac surgery or who have a bleed, the cessation of antiplatelets
should be discussed with a cardiologist first.
Anticoagulants 
As previously discussed, heparin is required for 48 hours after 
thrombolysis with plasminogen activators. Heparin is not beneficial and 
is not recommended as routine therapy after streptokinase. UFH was used
in the initial trials of plasminogen activators, however more recently the 
EXTRACT-TIMI 25 trial showed that the use of LMWH post
thrombolysis resulted in a lower rate of reinfarction compared to UFH 
(9.9 per cent vs 12 per cent, p = 0.001) at a cost of increased major bleeding 
(2.1 per cent vs 1.4 per cent, p < 0.001). In meta-analyses, the use of
LMWH has been shown to be more effective than UFH in reducing 
reinfarction and ischaemia in NSTEACS treated medically with no 
increase in bleeding. In the SYNERGY trial, LMWH has also been shown 
to be as effective as UFH in patients undergoing an early invasive strategy
albeit at an increased risk of major bleeding (9.9 per cent vs 7.6 per cent).
The increased risk of bleeding in patients undergoing PCI may have been 
due to the addition of UFH while the previous dose of LMWH was still 
active. In the STACKENOX trial the addition of UFH to enoxaparin 
resulted in a considerable and prolonged increase in clotting parameters 
(anti-Xa and anti-IIa) but had no effect on the more routinely measured
activated clotting time (ACT). Additionally, LMWH alone during PCI in
the STEEPLE trial showed lower rates of mainly femoral access site 
complications. However, the use of UFH is still recommended during PCI 
procedures as it is rapidly effective with a measurable change in the ACT 
and it can be promptly reversed with protamine if necessary. 
Bivalirudin, a direct thrombin inhibitor, is also effective in STEMI and 
NSTEACS patients and can be continued during PCI. The main advantage 
of bivalirudin is the reduction in bleeding compared to the use of heparin 
and GpIIb/IIIa inhibitors. In NSTEACS, fondaparinux, a factor Xa 
inhibitor, when given subcutaneously at a dose of 2.5 mg, was shown to be
as effective as the LMWH enoxaparin in the OASIS-5 trial. Major bleeds 
were reduced by 48 per cent in the fondaparinux group, although it was 
noted that there was a higher incidence of catheter-related thrombus which 
did not impact on the primary end point. Therefore fondaparinux can be
recommended for NSTEACS, particularly for those at high risk of bleeding, 
when intervention is likely to be delayed, or when medical management is 
preferred. If patients on fondaparinux undergo PCI, it is recommeded that
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in STEMI in the OASIS-6 trial involving 12 092 patients either treated with
thrombolysis, primary PCI or without any reperfusion therapy. There was 
a significant reduction in the primary end point of death or reinfarction at
30 days when compared to UFH. (9.7 per cent vs 11.2 per cent, p = 0.008). 
This benefit was mainly observed among patients who were not treated 
with primary PCI. Even those that did not receive reperfusion therapy
without a conventional indication for UFH benefited from fondaparinux 
in reducing the incidence of the primary end point. The benefits were
onserved without an increase in bleeding and stroke.
Overall, anticoagulants are recommended in all patients with ACS, but 
the doses and agents used need to be carefully considered in relation to
patients’ bleeding risks. 
Glycoprotein IIB/IIIA inhibitors 
Background 
Because activation of the GpIIb/IIIa receptor is the final common pathway
of platelet aggregation through its ability to cross-link with other GpIIb/ 
IIIa receptors through fibrinogen or von Willebrand factor, different 
agents have been developed specifically to inhibit this process. These are 
the chimeric (murine–human) antibody fragment to the GpIIb/ IIIa 
receptor, abciximab (Reopro™), synthetic peptides such as eptifibatide 
(Integrelin™) and synthetic non-peptides such as tirofiban (Aggrastat™). 
Abciximab is a Fab antibody fragment of a human–murine (chimeric)
monoclonal antibody (c7E3) with a short plasma half-life but with a strong 
receptor affinity, persisting for weeks (although platelet aggregation 
returns to normal within 48 hours). Abciximab is relatively non-specific 
and also inhibits the vitronectin (α ) receptor which is on endothelialvβ3
cells and the MAC-1 receptor on leucocytes. By contrast, the synthetic 
(small molecule) GpIIb/IIIa inhibitors have half-lives of 2–3 hours and are 
more specific to the receptor. There is an increased risk of bleeding with
these agents, which is typically mucocutaneous or at access sites,
particularly at the site of a femoral artery sheath. 
Abciximab (ReoproTM) 
Abciximab has the most data among the GpIIb/IIIa inhibitors, in
particular when used after angiography. Analysis of pooled data from three
large trials (EPIC/EPILOG/EPISTENT) including 7290 patients with ACS 
receiving stenting has shown a 29 per cent reduction in late mortality 
when compared to placebo. Based on the experience of the EPIC trial, the 
EPILOG trial confirmed the need to reduce the bolus heparin dosing to
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70 U/kg during intervention to diminish this risk. More recent data from
the ISAR-REACT 2 study have shown the benefit for abciximab in
addition to loading with clopidogrel 600 mg in NSTEACS. At 30 days,
the composite end point of death/MI/urgent target vessel
revascularization was reduced in the abciximab group by 25 per cent, 
compared to placebo (8.9 per cent vs 11.9 per cent, p = 0.03). Subgroup
analysis had revealed that the benefits were isolated to those patients who 
had positive troponins. Interestingly, the 1-year follow-up of 
ISAR-REACT 2 has shown continued benefit in the primary end point
(23.3 per cent vs 28 per cent, p = 0.012), which now also extended to
troponin-negative patients. 
The use of abciximab up-front (prior to angiography) has been studied
in a meta-analysis of 29 570 patients. The benefit of abciximab was
only observed in patients who subsequently went on to have PCI.
Based on current evidence, abciximab should be considered in the
catheter laboratory for all troponin-positive NSTEACS requiring PCI.
Among STEMI patients, the use of abciximab has been shown to be of
benefit in a large meta-analysis with 27 115 patients. However, several
of the trials did not use stents, and none of the included studies used
the higher loading dose of clopidogrel, so these studies do not really
reflect contemporary practice. Indeed, a more recent study, BRAVE-3,
showed no additional benefit on infarct size (measured by single-
photon emission CT) with abciximab when 600 mg of clopidogrel
was used. Based on the evidence, the use of abciximab for STEMI is
recommended, but not mandated, and may be reserved for patients
at low bleeding risk, who have not received adequate loading with
clopidogrel, or those with a large thrombus burden. 
Tirofiban and eptifibatide 
The small molecues tirofiban and eptifibatide have also been shown to be
of benefit when used in NSTEACS.
In the PRISM study, treatment with tirofiban in addition to aspirin 
and UFH reduced death and non-fatal MI at 7 days (4.9 per cent vs 
8.3 per cent, p < 0.01) and 30 days (8.7 per cent vs 11.9 per cent, p < 0.01). 
Benefit was restricted to those patients who were troponin positive. In a 
concurrent trial, PRISM-PLUS, 1915 patients with NSTEACS received 
either tirofiban alone, tirofiban with heparin or heparin alone (all with 
aspirin) for a mean of 71 hours. The tirofiban-alone group had an excess 
of mortality and was discontinued. Angiography was done as clinically 
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lower 7-day and 6-month composite end points (death/MI/refractory
ischaemia) compared to heparin alone, 12.9 per cent vs 17.9 per cent 
(32 per cent reduction, p < 0.01) and 27.7 per cent vs 32.1 per cent 
(a 19 per cent reduction, p < 0.05), respectively. Tirofiban was compared to
abciximab in the TARGET study and was found to be inferior at
30 days with regards to the primary end point of death, MI and urgent
revascularization. However, there was no significant difference at
6 months and 1 year follow-up. 
Eptifibatide is a cyclic heptapeptide that contains the KGD (lysine-glycine­
aspartate) amino acid sequence. In the PURSUIT trial, 10 948 patients 
with NSTEACS received heparin, low dose, or high-dose eptifibatide
(Integrilin™) for 72 hours. At 30 days, the composite end point of death/ 
non-fatal MI was significantly lower in the eptifibatide group, driven by a
14.2 per cent vs 15.7 per cent (p < 0.05) in the eptifibatide and placebo group,
respectively. This occurred through a non-significant reduction in MI. The
ESPRIT study looked at patients undergoing PCI with a stent (46 per cent
with NSTEACS) and compared eptifibatide to placebo. The primary end
point was a composite of death, MI, urgent target vessel revascularization
and thrombotic bailout GpIIb/IIIa inhibitor therapy within 48 hours
after randomization. It showed a reduction in the eptifibatide arm from
10.5 per cent to 6.6 per cent (p = 0.0015) which was sustained to 6 months.
The up-front use of these two agents is recommended in NSTEACS. 
However, early angiography is becoming more widely available, and 
allows for PCI to relieve ischaemia. The use of GpIIb/IIIa inhibitors after 
angiography has the added advantage of selecting the patients likely to
benefit the most (i.e. those undergoing PCI), and avoids administration to
subjects requiring surgical revascularization, or to those at an increased risk 
of bleeding. This was shown to be the case in the EARLY-ACS trial where 
up-front eptifibatide was compared to delayed provisional use. There was 
no difference in the primary end point (death/MI/recurrent ischaemia 
requiring urgent revascularization/thrombotic bailout). However, there was 
a significant risk of major bleeding (2.5 per cent vs 1.8 per cent, p = 0.015). 
Compared with abciximab, there are fewer data supporting the use of the 
small molecules in STEMI. The EVA-AMI and MULTISTRATEGY studies 
compared abciximab with eptifibatide and tirofiban, respectively. Both 
trials showed similar benefits with the smaller molecules to abciximab.
However, as with abciximab, the benefit in addition to higher loading 
doses of clopidogrel has not been shown. In the ON-TARGET 2 trial, early 
tirofiban was used with 600 mg of clopidogrel and was not found to have
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any clinical benefit compared to placebo. Overall, the small molecules can 
be recommended for selective use in NSTEACS, but there is not enough 
data to recommend their routine use in STEMI. 
Beta-blockers 
Beta-blockers have antiarrhythmic, anti-ischaemic and antihypertensive 
properties. Small studies indicate that these beneficial effects reduce chest 
pain, myocardial wall stress and infarct size in patients with STEMI. An 
overview of almost 30 000 patients randomized to placebo or IV therapy 
in the pre-thrombolytic era indicated that they were well tolerated, 
preserved left ventricular function and reduced the incidence of 
arrhythmia and early mortality. 
The large COMMIT study compared the use of early IV then oral 
metoprolol with placebo in STEMI patients. The metoprolol group showed 
a modest reduction in reinfarction and ventricular fibrillation but no 
overall benefit on mortality. More importantly, the rate of cardiogenic 
shock was significantly higher in the metoprolol group. Therefore, routine 
use of intravenous beta-blockers cannot be recommended for all patients 
with STEMI. As maximum mortality benefit from beta-blocker therapy 
is obtained in higher-risk patients, whose infarctions are complicated 
by arrhythmias or heart failure; treatment should be directed to specific 
problems such as ongoing chest pain, poorly controlled hypertension and 
tachy-arrhythmia. However, patients should be carefully selected to avoid 
those at risk of developing shock (e.g. patients with large, un-reperfused 
anterior infarcts and patients with mechanical complications). 
Long-term oral beta-blockers, commenced in the convalescent phase of MI, 
have been evaluated in a large number of placebo-controlled trials. In a recent 
meta-analysis of 82 trials enrolling more than 54 000 patients, mortality 
was reduced by almost 25 per cent due to the prevention of reinfarction 
and sudden death. These benefits are apparent irrespective of age, site of 
infarction, and presence or absence of previous MI or complications. Serious 
side effects are rare. Benefit is still apparent after several years of therapy, and 
beta-blockers should therefore be continued indefinitely. 
On the basis of these trial data, all patients should be considered for long-
term oral beta-blocker after STEMI. Contraindications to beta-blocker 
therapy are present in around 15 per cent of patients, and consist of: 
• resting heart rate <55 bpm 
• second or third degree heart block 
• a history of asthma. 
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In should be remembered that many patients with COPD have fixed 
obstructive defects and beta-blockers should not be excluded from all 
patients labelled with COPD. Since side effects and compliance can be
problematic in some patients, cardioselective agents such as bisoprolol or
metoprolol are preferable. Where there is concern as to whether a patient 
will tolerate a beta-blocker, a low dose of a short-acting prepartion can be
used such as with metoprolol 25 mg bd as opposed to the usual dose of
50 mg bd. Treatment should be started on presentation for NSTEACS and 
once haemodynamically stable after STEMI. The dose of beta-blockers 
should be increased as necessary to obtain a resting heart rate of 50–60 bpm 
and continued indefinitely in STEMI patients.  
Calcium channel blockers 
Calcium channel blocking drugs have anti-ischaemic, vasodilating and
antihypertensive properties that may be beneficial in patients with acute MI.
A meta-analysis of more than 20 000 patients enrolled in placebo-controlled
randomized trials, however, showed no significant beneficial effect on
mortality. There is some evidence that the type of calcium antagonist used
may be important. Dihydropyridine calcium antagonists are powerful
vasodilators and may induce tachycardia, since they have no effect on the
cardiac conduction system. In almost 10 000 studied patients dihydropyridine
agents showed a trend towards increased mortality. Both diltiazem and
verapamil have effects on the cardiac conduction system, slowing heart rate,
potentially improving their efficacy in MI patients. In a series of trials
randomizing 9000 patients (DAVIT-1, DAVIT-2, MDPIT and INTERCEPT),
these drugs also had no significant beneficial effect on mortality, although the
incidence of reinfarction and recurrent ischaemia was reduced. Subgroup
analysis suggested that the overall neutral effect reflects an increase in
mortality in patients with ventricular dysfunction, and a reduction in
mortality in those with well-preserved ventricular function. 
These studies suggest that dihydropyridine calcium antagonists should be
avoided in MI patients. Rate-slowing calcium antagonists such as verapamil
and diltiazem should not be given to patients with significant left ventricular
dysfunction. For patients in whom a beta-blocker is contraindicated or poorly
tolerated, and left ventricular function is well preserved, a rate-slowing calcium
antagonist can be safely used for symptom control if required. 
ACE inhibitors 
Activation of the renin–angiotensin system is an early compensatory
response to an evolving MI. Activation of the renin–angiotensin system
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leads to vasoconstriction, increased heart rate and sympathetic 
activation. In the early phases of evolving MI these deleterious changes 
will increase ventricular wall stress, increase oxygen consumption and 
reduce electrical stability. In the longer term, persistent activation of 
the renin–angiotensin system potentiates adverse remodelling, leading 
to ventricular dilatation and heart failure. The adverse consequences 
of renin–angiotensin activation can be blocked by the use of ACE 
inhibitors with potentially beneficial effects on mortality. More than 
100 000 patients have been evaluated in a series of trials that reported in 
the 1990s (GISSI-3, ISIS-4, AIRE, SAVE, CCS-1 and TRACE). Trials of 
short-term non-selective ACE inhibitor therapy started early after MI 
demonstrated a small (approximately 6.5 per cent) reduction in 30-day 
mortality with treatment. Trials of long-term selective therapy in 
high-risk patients (with clinical evidence of heart failure or evidence of 
substantial left ventricular dysfunction) demonstrated a large 
(approximately 20 per cent) reduction in mortality, with particular 
benefit in diabetics (HOPE study). Both the HOPE and EUROPA study 
also showed benefit in patients with coronary disease irrespective of left 
ventricular function, thereby implying an additional antiatherogenic 
effect. On the basis of these trial data, ACE inhibitors should be 
prescribed early after ACS in patients who are clinically stable with an 
adequate blood pressure. If possible, treatment should be initiated 
within 24 hours of admission, titrated up to target doses. Current 
ACE inhibitors licensed post-MI are ramipril (target dose 5 mg bd or 
10 mg od) and perindopril (target dose 8 mg od). Renal function and 
electrolytes should be monitored to ensure there is no significant 
ACE inhibitor-induced deterioration in renal function (a 20 per cent 
reduction in eGFR on and ACE inhibitor is acceptable). In patients who 
are intolerant to ACE inhibitors, angiotensin-2 receptor blocker may be 
used instead. 
Statins 
Statin therapy has been evaluated in a series of large primary and 
secondary prevention trials enrolling more than 50 000 patients (CARE, 
4S, WOSCOPS, AFCAPS, LIPID and most recently the Heart Protection 
Study). These trials conclusively demonstrate that: 
• 	 statin therapy reduces mortality in patients with symptomatic 
ischaemic heart disease by around a third 
• 	 statin therapy is safe and well tolerated 
• 	 patients of all ages and either sex benefit 
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• 	patients with relatively normal cholesterol levels obtain similar 
benefit to those with substantial cholesterol elevation 
• 	 initiation of treatment in hospital helps to reduce the rate of early 
recurrent ischaemia and readmission. 
Overall, the benefit of statin therapy in the primary prevention of coronary 
heart disease and in the secondary prevention of further events in patients 
with angina, and previous unstable angina or infarction is well-established. 
There is also evidence to support their role as adjunctive therapy in ACS. 
The rationale for this is based on their pleiotropic effects such as a positive 
effect on endothelial function, a reduction in platelet aggregability and an 
anti-inflammatory effect, manifest as a reduction in the C-reactive protein 
level. The MIRACL trial recruited 3000 patients with NSTEACS who were 
randomized to either atorvastatin 80 mg or placebo within 63 hours of 
presentation, in addition to routine anti-ischaemic therapy. At 4-month 
follow-up, there was a significant reduction in the composite end point 
of death/MI/resuscitated cardiac arrest/re-hospitalization for worsening 
angina in the treatment group, from 17.4 per cent to 14.8 per cent 
(p = 0.048). In addition, re-hospitalization alone was reduced as a secondary 
outcome. The PROVE-IT trial compared pravastatin 40 mg to atorvastatin 
80 mg in both NSTEACS and STEMI. It showed a 16 per cent reduction 
in events (death, MI, unstable angina requiring re-hospitalization, 
revascularization or stroke) in those taking atorvastatin at 30 days. On the 
basis of these trial data, all patients with ACS should be commenced on a 
high dose of statin early in their hospital admission. 
Hypokalaemia 
Hypokalaemia is common in patients with acute infarction, and is related 
to prior treatment with diuretics or catecholamine effects on electrolyte 
handling. Hypokalaemia is associated with myocardial electrical instability 
(the incidence of ventricular fibrillation may be as high as 15 per cent in 
infarcts associated with a serum potassium of 3.0–3.5 mmol/L, and 5 per cent 
or less in infarcts associated with a potassium of 4.5–5.0 mmol/L) and 
should be corrected. If serum potassium is below 4.0 mmol/L in the absence 
of an important arrhythmia, then oral potassium supplements are given 
(e.g. slow K, three tablets three times daily, providing approximately 
72 mmol potassium daily) and potassium rechecked after 12–18 hours. If 
ventricular arrhythmias occur in association with a serum potassium of 
less than 4.0 mmol/L, intravenous potassium is given as detailed in 
Appendix A, rechecking serum levels after 3 hours to ensure that 
potassium levels have risen to greater than 4.0 mmol/L. 
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Magnesium therapy 
A number of small studies (including LIMIT-2) suggested that routine 
administration of magnesium may reduce mortality following acute 
infarction by beneficial effects on heart rate, contractility, electrical 
stability and platelet activity. The routine use of magnesium was therefore 
examined in almost 60 000 patients in the ISIS-4 study, and this showed
that treatment had no beneficial effect on mortality. Subgroup analysis
showed no benefit even when magnesium was given early, or to patients 
who did not receive thrombolytic therapy. These results were confirmed
in the recent MAGIC trial of over 6000 patients. There is therefore no 
good evidence to support the routine use of magnesium in patients with
evolving acute MI. Magnesium is, however, still indicated for the 
treatment of arrhythmias. 
Nitrate therapy 
Nitrates have a number of potentially beneficial effects (systemic 
vasodilatation and coronary artery dilatation), and small early studies 
suggested that their routine administration to patients with acute 
infarction may reduce mortality. The ISIS-4 and GISSI-3 trials investigated 
routine nitrate use in a total of almost 80 000 patients, and found no 
substantial beneficial effect on mortality. Although nitrates are safe and
effective in the treatment of post-infarction ischaemia or heart failure,
they should not routinely be administered to uncomplicated patients. 
Hyperglycaemia 
Patients with pre-existing diabetes have an increased risk of ischaemic
heart disease, and an unfavourable prognosis following acute MI. Patients 
who have no history of diabetes but an elevated glucose on admission also
have a poor prognosis. The high mortality may be related to the 
occurrence of autonomic neuropathy, pre-existing ventricular 
dysfunction or due to detrimental myocardial cellular changes induced by
diabetes. Additionally, sympathetic activation will induce insulin
resistance and hyperglycaemia in susceptible patients, increasing the 
release of non-esterified fatty acids, which augment myocardial oxygen 
consumption, depress contractility and increase the risk of heart failure.
A strategy of controlling elevated plasma glucose by insulin infusion 
followed by subcutaneous injections in hyperglycaemic patients with
acute MI could prevent these adverse metabolic effects, and was 
investigated in over 600 patients randomized in the DIGAMI trial.
Treatment with IV insulin infusion reduced mortality by around 
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who had not previously received insulin therapy, and were at low risk of 
death on the basis of clinical criteria. On the basis of these trial data, it is
recommended that all patients with an admission glucose >11 mmol/L
should be commenced on a sliding scale IV insulin infusion with
the infusion rate adjusted to maintain blood glucose in the range 
7–11 mmol/L, in combination with 500 mL of 5 per cent dextrose infused 
over 24 hours. Oral hypoglycaemic agents should be withdrawn. The
infusion should be continued for at least 24 hours, or until the patient is
clinically stable. However, it is less clear how to manage patients in the 
long term. The DIGAMI trial suggested that 3 months of tight glycaemic 
control with subcutaneous insulin may improve outcomes; however, this
was not confirmed in the DIGAMI-2 trial. Therefore, tight control with
conventional oral hypoglycaemics may be of benefit where possible, and 
may reduce the incidence of adverse effects due to insulin such as weight
gain and hypoglycaemia. 
Prophylactic antiarrhythmic therapy 
Ventricular tachyarrhythmias are an important cause of death early after 
the onset of MI. Class I antiarrhythmic drugs can suppress these 
arrhythmias, but this beneficial effect may be offset by adverse effects such 
as the induction of bradyarrhythmias, induction of tachyarrhythmias and 
depression of ventricular function. A meta-analysis of more than 200 000
patients treated with prophylactic class I drugs showed no beneficial
effects on mortality. On the basis of these trial data, routine prophylactic 
therapy with class I antiarrhythmic drugs early in the course of evolving 
MI is not recommended. 
Pre-existing drug therapy 
Patients admitted with evolving acute MI are often already on treatment 
with oral beta-blockers for pre-existing angina or hypertension. Given the 
beneficial effects of beta-blockers following infarction and the potential 
adverse effects associated with abrupt beta-blocker withdrawal, 
administration of these agents should continue uninterrupted unless 
important heart failure or a symptomatic bradyarrhythmia develops. 
Combined oral contraceptives and HRT are associated with an increased 
risk of thromboembolism and reinfarction, and should be withdrawn. 
Non-steroidal anti-inflammatories not only increase the risk of bleeding 
from the GI tract but also reduce the effectiveness of aspirin and are 
associated with higher rate of myocardial infarction and death. Similarly,
COX-2 inhibitors should be avoided in the post-infarct period. 
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COMPLICATIONS OF ACS 
Background 
Complications following ACS are more common following STEMI. 
Modern reperfusion including the increased use of PCI has resulted in
dramatic reductions of reinfarction and death over the last decade;
consequently, this has resulted in a reduction in the incidence of
post-ACS complications. In a SWISS registery of STEMI patients,
reinfarction decreased from 3.7 per cent to 0.9 per cent between the
years 2000 and 2007. This was linked with an increase in the use of PCI
from 43 per cent to 85 per cent over the same time period. However,
complications still occur and when they do arise are often related to
more extensive STEMI, where the infarct-related artery has not been
reperfused. This is more common in patients who present late, the
elderly (over 75) and those with diabetes. These patients often have
poorer left ventricular function and additionally may have extensive
coronary disease which is not easily amenable to revascularization. Left
ventricular dysfunction is directly associated with lower rates of
survival and those with extensive myocardial injury more commonly
have mechanical and arrythmic complications. In patients with severe
left ventricular dysfunction (EF <30 per cent) despite successful
revascularization for STEMI, the presence of pathological Q waves on
ECG and signs of heart failure are clinical markers of poor myocardial
recovery and prognosis. It is important to identify these patients early
so they can be monitored closely and to allow for prompt treatment
when necessary.
Left ventricular failure 
Background 
Left ventricular failure (LVF) is common after STEMI. In patients with
only a small area of infarction, catecholamine-mediated increase in heart
rate and contractility in the normally functioning non-infarcted segments
of  the left ventricle will prevent decompensation. In patients with more 
extensive infarction, those mechanisms are overwhelmed, left ventricular 
end diastolic pressure rises and pulmonary oedema occurs. In some 
patients, LVF is due to, or exacerbated by, complications such as
arrhythmia, severe mitral regurgitation or ventricular septal rupture.
The occurrence of LVF is an adverse prognostic feature, with a close 
correlation between the degree of failure and mortality (with in-hospital 
mortality rising from 6 per cent in patients free of signs of LVF, to 
38 per cent in those with extensive crepitations).
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Diagnosis and assessment 
Clinical diagnosis of LVF after ACS is often difficult. Clinical signs, 
symptoms and investigational features are highly variable, inconsistent 
and only loosely correlated together. For example, basal crepitations are 
common in patients with lung disease, irrespective of the presence of LVF, 
and pronounced radiological pulmonary congestion can be present in a 
patient whose chest is clear to auscultation. LVF should be suspected in 
any patient with ACS and extensive ventricular dysfunction (due to a large 
degree of infarction, or a smaller infarction occurring in a patient with 
previous ischaemic ventricular damage) who develops breathlessness in 
association with a third heart sound and crepitations. Physical signs can 
change rapidly, and the heart and lungs should be auscultated at regular 
intervals during the early phase of evolving MI. The chest x-ray may show 
abnormalities including cardiomegaly, upper lobe diversion and perihilar 
alveolar shadowing. If signs of LVF develop, a careful clinical assessment 
is required (including echocardiography if possible) to exclude a 
mechanical complication, such as severe acute mitral regurgitation or 
ventricular septal rupture. 
Treatment 
Treatment of LVF consists of measures to relieve distress, reduce cardiac 
filling pressures (by vasodilatation) and decrease intraventricular fluid 
volume (by induction of diuresis), leading to a fall in left ventricular end 
diastolic pressure with resolution of pulmonary oedema. Chronic drug 
therapy aims to prevent the recurrence of symptoms and can reduce 
mortality in the case of eplerenone. This aldosterone antagonist has been 
shown to reduce mortality in patients with signs of post-MI heart failure 
and left ventricular ejection fraction of ≤ 40 per cent. This may be due to 
beneficial effects on reducing myocardial fibrosis or by reducing the 
incidence of hypokalaemia that may be an important contributing factor 
to fatal arrhythmias. In addition, in some patients left ventricular 
function will improve with resolution of myocardial stunning, helping to 
prevent recurrence of symptoms after the acute event. Treatment of acute 
LVF consists of: 
• 	 sitting the patient in an upright posture and giving oxygen. This 
helps to diminish venous return and improve oxygenation 
• 	 giving diamorphine by slow IV injection in 2.0 mg boluses, along 
with an antiemetic such as metoclopramide 10 mg. Diamorphine 
acts as a sedative to relieve distress, and as a vasodilator to improve 
pulmonary oedema 
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• 	 giving a loop diuretic such as frusemide 80–160 mg as a slow 
intravenous injection. Intravenous loop diuretics induce 
vasodilatation followed by diuresis, improving LVF by a dual 
mechanism of action 
• 	 if blood pressure is adequate (>100 mmHg), commencing an IV 
nitrate infusion as detailed in Appendix A. Nitrate-induced 
vasodilatation helps to reduce venous return, leading to a fall in left 
ventricular end diastolic pressure and an improvement in 
pulmonary oedema. The nitrate infusion should commence at a 
low dose and be increased periodically 
• 	monitor urine output accurately to ensure adequate renal perfusion 
and to assess response to diuretics. 
If these measures fail to control the situation, a further IV bolus of 
frusemide should be given and a senior colleague consulted. If a surgically 
treatable infarct-related complication can be identified, such as acute 
severe mitral regurgitation or ventricular septal rupture, insertion of an 
intra-aortic balloon pump or assisted ventilation (which can be instituted 
non-invasively using mask-based systems) may help to stabilize the patient 
for long enough to allow corrective surgery. In the absence of a treatable 
complication, the prognosis of severe LVF that does not respond to 
diamorphine, diuretics and nitrates is poor. 
Cardiogenic shock 
Background 
Cardiogenic shock occurs in a small proportion of patients who 
present with extensive infarction and is responsible for the majority of 
in-hospital deaths. The GRACE registery data and a large Swiss registery 
have shown that the incidence has recently decreased as the use of 
reperfusion and in particular primary PCI has increased. This is likely 
to be as a result of reducing recurrent ischaemia with use of stents and 
antiplatelets, in addition to smaller infarct sizes due to accessibility of 
early primary PCI and thrombolysis. Cardiogenic shock complicating 
an ACS can be due to: 
• 	 infarction or ischaemia of >40 per cent of the left ventricular 
myocardium leading to pump failure (85 per cent of cases) 
• 	 a potentially reversible complication leading to severe 
decompensation, such as acute mitral regurgitation, ventricular 
septal rupture or right ventricular infarction (15 per cent of 
cases). 
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The factors associated with an increased risk of developing cardiogenic 
shock are: 
• 	 extensive Q-wave anterior MI, STEMI associated with left bundle 
branch block or failure of reperfusion 
• 	MI occurring in patients with previous infarction or CABG 
• 	 increasing age or female sex 
• 	hypertension 
• 	 diabetes. 
In patients who present with an extensive infarction, cardiogenic shock 
usually develops early (within 24 hours of admission). If cardiogenic 
shock develops later, a careful assessment of the patient is required. In t  his 
situation cardiogenic shock is often associated with recurrent ischaemia 
leading to infarct extension and further impairment of left ventricular 
function, or to a mechanical complication, which may be amenable to 
surgical correction. Data from registry studies of cardiogenic shock 
treated by medical therapy suggest that mortality remains around 
80–90 per cent. Treatment in cardiogenic shock is designed to improve 
myocardial perfusion by the use of intra-aortic balloon counterpulsation 
and emergency revascularization. Data derived from case series, registry 
studies and retrospective analysis of thrombolysis trial databases 
suggest that early aggressive supportive therapy combined with cardiac 
catheterization and revascularization may favourably influence mortality. 
Stabilization and revascularization may be beneficial by aiding recovery 
of stunned myocardium around the edge of the infarct zone, allowing 
some recovery and improvement in myocardial function. These studies 
are compromised by their non-randomized trial design, and the potential 
confounding effect of patient selection bias, which may skew the results 
in favour of revascularization (since the fittest youngest patients who 
are most likely to survive are the cases most likely to undergo intensive 
treatment and revascularization). Randomized trials have been 
difficult to organize, but some information is now available. The Swiss 
Multicentre trial of Angioplasty for Shock (SMASH) demonstrated that 
revascularization was associated with a non-significant trend to reduced 
mortality although the small size of the study (55 patients) did not allow a 
statistically reliable conclusion to be reached. The SHould we emergently 
revascularize Occluded Coronaries for shocK (SHOCK) trial randomized 
302 patients to receive either early revascularization or medical therapy. 
Survival was non-significantly improved at 30 days, and significantly 
improved at 6 months (50.3 per cent mortality in the revascularization 
group compared with 63.1 per cent mortality with medical therapy). 
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Subgroup analysis suggested a larger benefit for younger (<75 years of age) 
patients treated early (within 6 hours of diagnosis). Taken together, this 
body of non-randomized and randomized trial data suggests that selected 
patients with cardiogenic shock may benefit from intensive supportive 
therapy combined with revascularization. 
Diagnosis 
A diagnosis of cardiogenic shock due to left ventricular dysfunction can 
be confidently made in patients with evidence of extensive ischaemic 
myocardial damage who present within 24 hours of the onset of an acute 
STEMI with features of: 
• 	 hypotension (systolic BP persistently <90 mmHg) 
• 	 clinical signs of a low output sate (urine output <30 mL/h, poor 
peripheral perfusion or impaired cerebration) 
• 	 evidence of raised cardiac filling pressures (the presence of clinical 
or radiological pulmonary oedema implies that pulmonary artery 
wedge pressure is >15 mmHg). 
If there are atypical features to the clinical presentation, careful evaluation is 
required to exclude treatable complications of MI. In particular, if there is: 
• 	 late onset of cardiogenic shock or an associated new murmur, the 
cardiogenic shock may be due to a mechanical complication 
• 	 low blood pressure in the absence of pulmonary oedema in a 
patient with inferior or posterior infarction or a negative fluid 
balance, when hypotension may be due to right ventricular 
infarction or hypovolaemia. 
If any doubt exists as to the cause of the cardiogenic shock, 
echocardiography and pulmonary artery catheterization are required. In 
patients with cardiogenic shock due to severe left ventricular dysfunction 
there will be extensive left ventricular hypokinesia at echocardiography in 
association with a raised (>15 mmHg) pulmonary wedge pressure and a 
low (<2.2 L/min/m2) cardiac index. 
Management of cardiogenic shock due to severe ischaemic left 
ventricular dysfunction 
In treating these patients, the priorities are to stabilize the haemodynamic 
situation, and identify patients who are likely to benefit from aggressive 
intervention. Stabilizing the haemodynamic state requires: 
• 	 treatment of arrhythmias 
• 	 giving oxygen for hypoxia 
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• 	 treating pulmonary oedema with intravenous frusemide 
• 	 early percutaneous revascularization with use of intra-aortic 
balloon pump. 
In a patient less than 75 years of age who has presented early after an 
infarct, cardiac catheterization and (if possible) angioplasty should be 
considered. Patients unsuitable for revascularization, especially those 
with significant co-morbidity including pre-exisiting renal impairment 
have a very poor prognosis and are not likely to survive. If an underlying 
mechanical complication such as ventricular septal rupture or acute 
severe mitral regurgitation is present, and surgical correction is possible, 
insertion of an intra-aortic balloon pump or ventilation should be 
considered to help stabilize the patient. 
Management of hypotension associated with right ventricular 
infarction or hypovolaemia 
Right ventricular infarction commonly occurs in association with an 
extensive infero-posterior STEMI due to proximal occlusion of a large 
right coronary artery. Ischaemic damage leads to a rise in right ventricular 
end diastolic pressure and reduction in right ventricular stroke volume. 
The infarcted dilated right ventricle impairs left ventricular filling. These 
two mechanisms lead to a fall in cardiac output and systemic hypotension. 
AF and complete heart block occur in about a third of patients with right 
ventricular infarction. These arrhythmias cause further haemodynamic 
deterioration due to loss of atrial transport in a situation where ventricular 
filling is already compromised. Right ventricular infarction should be 
suspected in any patient with inferior STEMI who develops hypotension. 
The diagnosis can be confirmed by: 
• 	 the presence of hypotension in association with a raised jugular 
venous pressure (JVP) and clear lung fields 
• 	 ST elevation in a V4R lead 
• 	 insertion of a pulmonary artery catheter and echocardiography. 
Patients with right ventricular infarction as the cause of their hypotension 
have a characteristic haemodynamic profile, with a low or normal wedge 
pressure in association with a raised right ventricular diastolic and 
right atrial pressure. Echocardiography is required to ensure that the 
hypotension is not due to a ventricular septal rupture or acute severe 
mitral regurgitation. 
Improving outcome in patients with right ventricular infarction depends 
on increasing right ventricular preload by fluid loading and avoiding 
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vasodilator drugs, correcting arrhythmias and using inotropes only when 
fluid balance has been optimized. Treatment therefore consists of: 
• 	 insertion of a pulmonary artery catheter to confirm diagnosis and 
guide treatment 
• 	 avoiding treatment with diuretics or vasodilators, which will 
exacerbate the haemodynamic problem by reducing preload 
• 	 fluid loading with 200 mL of physiological saline over 10 minutes, 
followed by 1–2 litres over 2–4 hours, followed by 200 mL/h. The 
infusion rate should be carefully titrated to maintain an optimal 
wedge pressure of 15 mmHg 
• 	 if hypotension persists despite an optimal wedge pressure, treating 
with intravenous inotropes 
• 	 if complete heart block occurs, restoring AV synchrony with 
temporary dual chamber pacing 
• 	 if AF occurs, restoring AV synchrony with cardioversion. 
With aggressive treatment, mortality in hypotensive patients with right 
ventricular infarction can be reduced to 20–30 per cent. 
If fluid intake is poor or aggressive diuretic therapy has been employed, 
hypotension can occur in the absence of major left or right ventricular 
dysfunction due to intravascular volume depletion. These patients will 
have hypotension, clear lung fields and a normal venous pressure. A 
V4R recording will normally show no ST elevation. It can be difficult 
to confidently differentiate this from right ventricular infarction, and a 
pulmonary artery catheter will be required to clarify the diagnosis and 
guide therapy. In patients with intravascular volume depletion, wedge 
pressure, right ventricular and right atrial pressures will be low. Treatment 
consists of withholding diuretics and vasodilators and expanding 
intravascular volume with intravenous fluids. 
Ventricular free wall rupture 
Rupture of the free wall of the left ventricle occurs in up to 3 per cent of all 
hospitalized patients with STEMI, accounting for 20 per cent of hospital 
deaths. Risk factors for free wall rupture are: 
• 	 increasing age 
• 	 female sex 
• 	 first infarct 
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• 	hypertension 
• 	marked/persistent ST elevation. 
In addition, the incidence of free wall rupture may be increased by 
thrombolytic therapy, particularly if it is given late in the course of the 
infarct. Intravenous beta-blocker therapy reduces the risk of free wall 
rupture. Free wall ruptures present within a few days of the onset of 
STEMI. The usual presentation is with a sudden acute rupture presenting 
as collapse with electromechanical dissociation which does not respond to 
resuscitation. In 25 per cent of cases a subacute rupture occurs, with a slower 
leak of blood into the pericardial space which may produce tamponade. 
Echocardiography confirms the presence of fluid in the pericardial space. 
Immediate surgery should be considered, as there is a high risk of major 
rupture and death occurring unpredictably. 
Ventricular septal rupture 
Ventricular septal rupture occurs in up to 2 per cent of hospitalized 
patients with STEMI, with most cases occurring within the first 
post-infarct week. With anterior infarction, the defect is usually apical 
and involves one direct perforation. With inferior infarction, the defect is 
often a complex serpiginous or fenestrated lesion involving the posterior 
or basal septum; these complex defects are more technically difficult to 
surgically repair. Patients present with signs and symptoms of heart 
failure in association with a new pansystolic murmur, maximal at the 
lower left sternal edge. The clinical presentation may be confusing, with 
progression to cardiogenic shock and a minimal murmur. The diagnosis 
can be confirmed by echocardiography or right heart catheterization. The 
diagnostic features are: 
• 	 visible defect in intraventricular septum with jet crossing from left 
to right ventricle on echocardiography 
• 	 an increase in oxygen saturation from right atrium to right 
ventricle of >10 per cent due to oxygenated blood crossing the 
septum via the defect. A large increase in saturation implies the 
presence of a large defect. 
When the diagnosis has been established, supportive therapy with diuretics, 
nitrates, inotropes and an intra-aortic balloon pump may help to stabilize 
the haemodynamic status. Without corrective surgery, 90 per cent of 
patients die, usually within days of diagnosis. Even with surgery, mortality 
is 25–50 per cent (with mortality risk increased in older patients, those 
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with major haemodynamic compromise, and when the defect complicates 
inferior infarction). Surgery should probably be carried out as early as 
possible, since most patients will develop progressive haemodynamic 
compromise with multi-organ failure if the operation is delayed, and this 
decreases the chance of surviving an operation. Percutaneous closure, of
post-MI VSDs, with occluder devices has been successfully carried out. 
This is not recommended at present for routine use and patients require 
careful selection with regards to the position of the defect. 
Acute mitral regurgitation 
A mild degree of mitral regurgitation occurs in 40 per cent of patients
with STEMI. This mild regurgitation is related to ventricular dilatation
and shape change (which distort mitral annulus geometry) or papillary
muscle dysfunction (which interferes with mitral leaflet function).
The postero-medial papillary muscle is more vulnerable to ischaemia
since its blood supply is derived solely from the circumflex artery,
whereas the antero-lateral papillary muscle has a dual vascular supply
(from the circumflex and left anterior descending). This mild degree
of mitral regurgitation is usually well tolerated, and detectable only by
the presence of a mitral pansystolic murmur. The mitral regurgitant
murmur may be transitory, disappearing as reperfusion or recovery of
left ventricular function restores mitral annulus geometry or papillary
muscle function. 
Severe acute mitral regurgitation complicates around 1 per cent of patients 
with STEMI, usually early in the first post-infarct week. The mechanism 
is usually rupture of the postero-medial papillary muscle complicating
an inferior STEMI, leading to a flail posterior mitral leaflet. Severe acute 
mitral regurgitation can occur as a consequence of a small localized 
subendocardial infarct in a patient with well-preserved left ventricular 
function if the area of infarction involves the postero-medial papillary
muscle. Patients present with severe heart failure, which may progress to
cardiogenic shock. There may be a new loud pansystolic murmur, maximal 
at the apex and radiating to the axilla. If the pressure gradient between 
the left ventricle and left atrium is minimal (due to pressure equalization 
between the two chambers when the regurgitation is severe), the murmur 
may be minimal or absent. Even in the absence of a characteristic murmur, 
acute severe mitral regurgitation should be looked for in any patient who 
develops severe heart failure, particularly if the onset is delayed or the 
deterioration occurs in a patient with inferior infarction with preserved left 
ventricular function. 
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Patients with suspected acute severe mitral regurgitation require urgent 
evaluation with a view to emergency surgery. The diagnosis can be 
confirmed by: 
• 	 echocardiography; this may show a f lail leaf let and Doppler 
evidence of severe mitral regurgitation. The left atrium is often 
not enlarged 
• 	 right heart catheterization and oximetry; oximetry shows no shunt, 
and prominent V waves may be visible in the pulmonary artery 
wedge pressure trace. 
Treatment with diuretics, vasodilators and an intra-aortic balloon pump 
may help to stabilize the patient initially, but mortality without operation 
is >90 per cent. Urgent mitral valve surgery is required for all suitable 
patients. Perioperative mortality is 30 per cent and patients who survive to 
discharge have a good long-term prognosis. 
Left ventricular thrombus, aneurysm formation and 
thromboembolism 
The incidence of left ventricular thrombus (LVT) detected on 
echocardiography post-MI is around 5 per cent in the modern, 
reperfusion era. It is associated with poor left ventricular function and 
mitral regurgitation. Patients with a small degree of infarction, 
particularly if the site is inferior or lateral, are at lower risk. All patients 
with extensive anterior MI should have an early echocardiogram. If a 
thrombus is visualized (particularly if it is large, irregularly shaped or has 
frond-like appendages), there is a substantially increased risk of an early 
systemic embolus often leading to stroke. From observational studies, 
anticoagulation with warfarin has been shown to reduce the incidence of 
cerebral emboli in patients with LVT. However, the duration of 
anticoagulation has not been well established and the use of DAPT has not 
been investigated. Many patients require DAPT following ACS and the 
addition of warfarin has been shown to significantly increase the risk of 
major bleeding. Therefore warfarin and DAPT should only be used in 
patients with LVT at highest risk of thromboembolism such as those with 
AF and poor left ventricular function. Ideally the treatment should be 
switched to warfarin alone or with a single antiplatelet agent as soon as 
reasonably possible, which usually depends on the type of stent used at 
revascularization. 
Left ventricular aneurysm (LVA) develops in a large proportion of 
patients with complicated extensive infarcts and is often associated 
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with LVT and heart failure. The clinical features that increase the risk of 
LVA formation are: 
• 	 extensive anterior STEMI 
• 	 persistent ST elevation in the infarct zone 
• 	heart failure. 
Patients with confirmed LVA should be considered for anticoagulation to 
reduce thromboembolism. In view of their concomitant left ventricular 
dysfunction they should also receive adequate drug therapy, including 
ACE inhibitors and aldosterone antagonists. They are at high risk of 
ventricular arrhythmia and should be evaluated for an implantable 
cardioverter defibrillator (ICD). If they remain symptomatic with heart 
failure or develop worsening mitral regurgitation, due to negative left 
ventricular remodelling, they should be considered for coronary artery 
bypass surgery and aneurysmectomy. 
Clinically significant deep venous thrombosis and pulmonary embolism 
are now rare following uncomplicated ACS. The risks are increased in 
patients with extensive complicated STEMI, particularly if prolonged bed 
rest or heart failure occur. In high-risk patients, prophylactic low-dose 
subcutaneous LMWH should be instituted and continued until the patient 
is clinically stable and mobile. 
Pericarditis 
Pericarditis is an early complication associated with extensive STEMI, 
usually within the first week. The clinical features of pericarditis 
complicating anterior STEMI are: 
• 	 sharp central chest pain, worse with respiration, relieved by sitting 
up or leaning forward but not relieved by glyceryl trinitrate (GTN) 
• 	 an associated friction rub. 
In inferior STEMI a friction rub is rare, and the pain may be atypical 
or radiate to the left shoulder. Progression of pericarditis to a clinically 
significant effusion is rare. Treatment consists of: 
• 	 reassuring the patient about the cause of the symptoms 
• 	 pain relief with simple analgesics such as dihydrocodeine, with 
non-steroidal anti-inflammatory agents reserved for patients with 
persistent symptoms 
• 	 avoiding administration of anticoagulants if possible, as they may 
increase the risk of progression to haemorrhagic pericardial 
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Patients who present later (between 2 weeks and 3 months post-MI)
with pericardial pain and friction rub, fever and an elevated erythrocyte 
sedimentation rate (ESR) may have Dressler’s syndrome. This is thought to be
an immunological syndrome triggered by myocardial necrosis. Patients may
have associated pleurisy and, rarely, pulmonary infiltrates. Dressler’s syndrome
is now rare after MI, and is seen most commonly after cardiac surgery. 
EARLY PERI -INFARCTION ARRHYTHMIAS 
Background 
Peri-infarction arrhythmias (occurring within 48 hours) are very common
in patients with STEMI, and are an important cause of death. Acute 
myocardial ischaemia induces a wide range of detrimental changes in
myocyte metabolism (intracellular acidosis, raised cAMP, raised sodium,
magnesium and calcium). These occur in association with adverse
changes in systemic biochemical and physiological function induced by 
the evolving infarct (systemic acidosis, abnormal potassium, lactate, 
adenosine, CO2 and lysophosphoglycerides along with catecholamine 
release and autonomic disturbance). These factors interact to destabilize 
myocardial electrical function, leading to the induction of peri-infarction 
arrhythmias. Even a small area of ischaemia or infarction can develop 
electrical instability, leading to the induction of potentially lethal
arrhythmias. These local and systemic proarrhythmic disturbances are 
maximal early after the onset of the ACS, resolving within 48 hours,
thereby reducing the risk of late arrhythmia recurrence due to these 
mechanisms. Since these early peri-infarction arrhythmias are not related
to infarct size and have a low recurrence rate, they are not invariably 
associated with a poor long-term prognosis.
Infarct site has an important influence on the type of peri-infarction 
arrhythmias that occur. In patients with anterior infarction there is a relative 
excess of sympathetic activation, promoting the induction of tachyarrhythmias 
in areas of enhanced automaticity. There is a high density of vagal receptors
in the infero-posterior wall of the left ventricle, which are activated during
inferior infarction. The resultant increase in vagal activity, acting in
conjunction with infarct-related disturbance of function in the conduction
system, increases the incidence of bradyarrhythmias. 
Supraventricular and ventricular ectopic beats 
Frequent ectopic beats occur in the majority of patients with ACS.
Supraventricular ectopic beats are due to enhanced automaticity in the 
EARLY PERI-INFARCTION ARRHYTHMIAS 65 
 66 EARLY PERI-INFARCTION ARRHYTHMIAS 
ACUTE CORONARY SYNDROMES 
atria or AV junction. Since ventricular activation occurs via the normal 
conduction system, supraventricular ectopics are characterized by a QRS 
complex of normal morphology, which occurs prematurely and may be 
preceded by an abnormal P wave. Ventricular ectopics arise due to enhanced 
automaticity in the ventricular myocardium. Since depolarization occurs 
outside the normal conduction system, the resultant QRS complex has a 
broad configuration. Ectopic beats are usually asymptomatic, and are not 
associated with an adverse prognosis, regardless of their frequency and 
complexity. When frequent ectopics occur: 
• 	 pain relief should be adequate – if continuing ischaemic pain is 
present, use of IV beta-blockade or further diamorphine should be 
considered 
• 	heart failure should be looked for and treated if present 
• 	 electrolytes should be checked and oral supplements given if 
potassium is <4.0 mmol/L 
• 	 giving IV magnesium should be considered if the patient has been 
on long-term diuretic therapy prior to admission. 
There is no evidence that suppression of ectopics with antiarrhythmic drugs 
prevents the occurrence of life-threatening arrhythmias or improves prognosis. 
Sinus tachycardia 
Sinus tachycardia is common after an ACS, and is often associated 
with extensive anterior STEMI, sympathetic activation and an adverse 
prognosis. In sinus tachycardia, each QRS complex is preceded by a 
normal P wave, the QRS complexes are of normal morphology, and the 
rate is normally less than 140 bpm. If sinus tachycardia is persistent and 
excessive, it may cause extension of myocardial necrosis b  y increasing 
oxygen consumption. If sinus tachycardia is persistent: 
• 	 adequate analgesia should be ensured 
• 	heart failure should be looked for and treated 




Prolonged sinus tachycardia is most likely to occur in a patient with 
extensive infarction and major left ventricular impairment. 
Atrial tachyarrhythmias 
Peri-infarction AF occurs in 10–20 per cent of STEMI patients. Atrial 
electrical instability or stretch leads to the development of multiple micro 
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re-entry circuits within the atrium leading to chaotic atrial electrical activity 
which is intermittently conducted via the AV node to erratically depolarize 
the ventricles. The rapid ventricular rate and loss of AV synchrony results in 
a significant reduction in cardiac output and an increase in ischaemia. 
Characteristic ECG features of AF are an irregular baseline due to 
fibrillation waves (often best seen in V1) with completely irregular 
ventricular activity. The incidence of AF is increased in patients with: 
• 	 large infarctions 
• 	 increased age 
• 	 pericarditis 
• 	 right ventricular infarction 
• 	 diabetes 
• 	 hypertension 
• 	 inotrope use. 
The development of early (<24 hours) AF is usually associated with 
inferior STEMI, whilst later (>24 hours) AF is usually associated with 
anterior STEMI and heart failure. Mortality is more than doubled in ACS 
patients who develop AF. 
The treatment of ACS-related AF depends on the ventricular rate and 
associated clinical features: 
• 	 If the ventricular rate is rapid (>200 bpm), systolic BP is low 
(<90 mmHg) or the arrhythmia is associated with chest pain, 
heart failure or impaired consciousness, immediate direct current 
cardioversion (DCC) is the treatment of choice. 
• 	Many episodes of ACS-related AF are short-lived (50 per cent last 
less than 30 minutes) and well tolerated. If AF occurs with a rate of 
<110 bpm, systolic blood pressure is maintained above 90 mmHg 
and there are no associated symptoms, no treatment is necessary 
initially. 
• 	 If AF persists for more than 30 minutes, has a rate consistently 
>110 bpm, is associated with a fall in systolic BP or with rate-related 
symptoms, drug treatment is indicated. 
A variety of drugs can be used to treat patients with peri-infarction AF. In 
patients with coexistent symptomatic left ventricular dysfunction, digoxin 
(0.25–0.5 mg IV every 6–8 hours up to a maximum of 1 mg/24 hours) 
helps to slow ventricular rate and its inotropic properties may improve 
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cardiac function. Digoxin slows ventricular rate by an indirect effect on AV
nodal conduction, mediated by an increase in parasympathetic activity. In
patients with acute infarction who have extensive sympathetic activation 
and vagal inhibition, this mechanism may be relatively ineffective. In
patients who have no signs of heart failure (or other contraindication), IV 
atenolol is effective for rapid ventricular rate control. If a central venous 
line is in place, intravenous amiodarone is useful. This can be administered 
to patients regardless of left ventricular function. In addition to achieving 
rapid ventricular rate control (due to a beta-blocking effect) amiodarone 
also has a beneficial effect on atrial electrical stability. This helps to restore 
sinus rhythm in up to 75 per cent of treated patients within 4 hours. 
All patients with AF should be anticoagulated with heparin. If the 
arrhythmia persists for more than 24 hours, restoration of sinus rhythm by
electrical cardioversion should be considered to reduce the long-term risk 
of arrhythmia-associated thromboembolism. Atrial flutter is less common 
than AF, but presents and is managed in a similar fashion. 
Idioventricular rhythm 
Idioventricular rhythm is very common in STEMI patients, presenting
as a regular broad complex tachycardia with a stable QRS configuration
and a rate of less than 120 bpm. It is due to enhanced automaticity in a
ventricular focus, and is often associated with spontaneous or
therapeutic reperfusion. Idioventricular rhythm is rarely associated
with haemodynamic compromise and has no adverse effect on
mortality. Since the arrhythmia is usually well tolerated, no specific
treatment is required. 
Ventricular tachycardia 
Non-sustained VT (three or more consecutive ventricular beats at a rate 
>120 bpm, lasting for less than 30 seconds) occurs in up to 7 per cent of 
STEMI patients. When it occurs in patients with previous MI or has a
rapid rate, it may be a marker of an adverse prognosis. In most patients it is
asymptomatic, and antiarrhythmic therapy (with the exception of
beta-blockers) should be avoided. As for other non-sustained 
peri-infarction arrhythmias, treatment should be directed towards 
control of pain, ongoing cardiac ischaemia, heart failure and correction of
electrolyte disturbance. If episodes of non-sustained VT are frequent,
prolonged or symptomatic, and do not respond to the above measures or 
beta-blockers and magnesium then amiodarone can be considered if the 
corrected QT interval is normal. 
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Sustained VT (lasting for >30 seconds) is relatively uncommon, occurring 
in up to 2 per cent of STEMI patients. The occurrence of sustained VT is 
associated with extensive ventricular dysfunction and recurrent ischaemia, 
and is therefore a marker of increased hospital mortality. Monomorphic 
VT presents as a regular broad complex tachycardia with a rate >120 bpm. 
Polymorphic VT presents as a broad complex tachycardia with variable 
morphology. Polymorphic VT is usually rapid and poorly tolerated. 
Sustained VT has important adverse effects in post-infarct patients, 
leading to: 
• 	 hypotension and heart failure if the ventricular rate is rapid and left 
ventricular function poor 
• 	 ischaemia and infarct extension due to increased myocardial 
oxygen consumption 
• 	 further electrical instability (exacerbated by the above 

mechanisms) leading to VF.
 
The onset of sustained VT is therefore a medical emergency. Treatment 
selection depends on the degree of haemodynamic compromise and the 
underlying cause: 
• 	 If systolic BP <90 mmHg or the patient has chest pain, a reduced 
conscious level or heart failure related to the tachycardia, DCC is 
the treatment of choice. If consciousness is lost with the onset of 
VT, the shock should be administered immediately. If the patient 
remains conscious, despite haemodynamic compromise, sedation 
with 2–10 mg IV midazolam is given prior to cardioversion. 
• 	Patients with ischaemic substrate for VT should be considered for 
intra-aortic balloon pump and revascularization if VT is refractory 
to other treatment. 
• 	 If systolic BP >90 mmHg and the patient is not distressed or poorly 
perfused, initial treatment should be with amiodarone 300 mg IV 
over 1 hour, followed by an infusion of 900 mg over 24 hours. If VT 
persists and the patient deteriorates haemodynamically during 
amiodarone administration, immediate DCC should be 
performed. 
• 	Torsade de Pointes, where the QT interval may be prolonged, 
should be treated with correction of the underlying cause (i.e. drug 
toxicity or hypokalaemia) as well as giving IV magnesium. If 
refractory to treatment, then temporary pacing either via the right 
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atrium or right ventricle should be considered with the aim of 
increasing the heart rate to >90bpm. 
• 	Temporary overdrive pacing may also be effective in terminating 
episodes of resistant VT. A pacing lead should be inserted into the 
right ventricle. When VT occurs, pacing therapy should be
instituted at a rate 20 per cent faster than the VT for 10 seconds,
then abruptly discontinued. If the pacing therapy is successful, 
sinus rhythm will return. The ECG should be checked and pacing 
instituted if the QT interval is prolonged. Rapid VT or VF may be
precipitated by overdrive pacing, requiring immediate 
cardioversion. The addition of high-dose beta-blockade, and 
haemodynamic support with a balloon pump, may also help to 
suppress the arrhythmia. 
Since these arrhythmias are often associated with left ventricular 
impairment or recurrent ischaemia, treatment with diuretics, nitrates 
and anti-ischaemic agents should be optimized, and early cardiac 
catheterization considered. 
Ventricular fibrillation 
Ventricular fibrillation is characterized by rapid disorganized multiple
re-entrant wavelets in the ventricle, resulting in loss of co-ordinated
ventricular myocyte activity with loss of output and cardiac arrest.
Untreated, the arrhythmia is fatal, and is responsible for most
pre-hospital deaths in patients with STEMI. Most episodes occur early,
with 80 per cent occurring within 12 hours of symptom onset. If
defibrillation is performed rapidly, most episodes of VF can be
reversed, but success rate declines rapidly with time. When VF occurs
early in patients with good left ventricular function, long-term survival
is not compromised; when VF occurs late in patients with heart failure,
it is often a terminal event. The protocol for treatment of VF is detailed
in Chapter 2. 
Sinus bradycardia 
Sinus bradycardia (<60 bpm) is common early after ACS, particularly in
patients with inferior STEMI and vagal activation. If the heart rate is
persistently below 45 bpm or there are rate-related symptoms, a bolus of
atropine 0.6 mg IV (repeated as necessary) will increase the sinus rate. If
sinus bradycardia persists despite repeated boluses of atropine, temporary
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Conduction disturbances in relation to infarct site 
A variety of conduction disturbances can occur in patients with evolving 
STEMI. Although early reperfusion has shortened the duration of 
symptomatic episodes and reduced the need for temporary pacing, the 
incidence of AV block has remained relatively constant. When a 
conduction disturbance occurs in a patient with inferior STEMI, it is
usually due to vagal activation, AV nodal ischaemia, or both. If complete 
heart block develops, it is usually well tolerated. Since there is no damage 
to the conduction system in the ventricles, a secondary pacemaker in the 
bundle of His takes over ventricular activation, producing a stable reliable 
rhythm with a rate of >40 bpm, which is usually sufficient to maintain the 
circulation with no compromise. This escape rhythm is conducted via the 
normal ventricular activation pathways, and therefore will have a narrow
QRS configuration. Normal AV nodal function recovers within hours or 
days, with a return to normal sinus rhythm. 
By contrast, when AV block develops in a patient with anterior STEMI, it
is often poorly tolerated and is associated with a high risk of early death. 
For AV block to occur in anterior STEMI, extensive and widespread 
damage to the left ventricular myocardium and the interventricular
septum must occur, and the patients often die from heart failure. In these 
patients, the conduction disturbance is related to infarction of the bundle 
of His within the interventricular septum. The secondary pacemaker 
that is responsible for ventricular activation will be situated outside the 
specialized conduction system in the surviving ventricular myocardium. 
The escape rhythm generated by this type of secondary pacemaker will 
often have an unreliable rate of <40 bpm (since the inherent automaticity 
of cells outside the specialized conduction system is usually low), and 
will have a broad QRS configuration as ventricular activation will be
slow. This slow rate will be poorly tolerated in a patient with extensive
ventricular damage, and episodes of unpredictable ventricular asystole 
often occur. When AV block occurs following acute anterior STEMI, 
temporary pacing is usually required. If the patient survives the acute 
episode, the AV block is often persistent or recurrent, and a permanent 
pacemaker may be required. 
In extensive anterior STEMI with involvement of the septum, ischaemic
damage to the bundle of His may lead to left or right bundle branch
block on the surface EGG. The development of left bundle branch block
usually indicates that extensive myocardial necrosis has occurred, with
associated significant left ventricular dysfunction and a poor prognosis.
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Right bundle branch block can occur with less extensive infarction, as
can involvement of only the anterior fascicle of the left bundle, leading
to left axis deviation. Patients who develop left bundle branch block
in combination with a long PR interval, or the combination of right
bundle branch block, left axis deviation and a long PR interval, have
suffered extensive damage to their conduction system; such patients
should be discussed with a senior colleague, as prophylactic temporary
pacing may be indicated to avert the need for pacemaker insertion in a
compromised patient if sudden complete heart block with a slow escape
rhythm develops. 
First degree heart block 
First degree AV block manifests with prolongation of the PR interval 
(Figure 1.8). It is the most common conduction disturbance, occurring in
up to 15 per cent of patients, usually associated with inferior STEMI.
Progression to self-terminating and well-tolerated episodes of high-grade 
AV block is common. No specific treatment is required, other than
withholding drugs (such as beta-blockers or digoxin), which impair AV
nodal conduction, and closely monitoring the patient. 
Mobitz type 1 (Wenckebach) heart block 
Mobitz type 1 block is common after inferior STEMI. It often occurs in
patients who progress from first degree, through Mobitz type 1 to well
tolerated complete block with a narrow complex escape rhythm. The
ECG shows a progressive increase in PR interval culminating in a
complete failure of conduction and a dropped beat. Apart from avoiding
AV nodal blocking drugs, no treatment other than close observation is
required. 
Mobitz type 2 second degree block 
Mobitz type 2 block is less common, and manifests itself as sudden
unpredictable failure of AV nodal conduction, resulting in a dropped
beat with no preceding change in the PR interval. Mobitz type 2 block is
usually associated with septal involvement in extensive anterior STEMI,
leading to ischaemic damage to the bundle of His, and often coexists
with bundle branch block. Mobitz type 2 block frequently progresses to
poorly tolerated complete heart block with a slow and unreliable broad
complex escape rhythm. Patients with anterior STEMI who develop
Mobitz type 2 block have a poor prognosis. When Mobitz type 2 block
occurs, a senior colleague should be consulted, as prophylactic
temporary pacing may be indicated to avert the need for pacemaker
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insertion in a compromised patient if sudden complete heart block with a 
slow escape rhythm develops. 
Third degree (complete) heart block 
Complete heart block occurs in up to 6 per cent of STEMI, and presents 
with complete dissociation between atrial and ventricular activity 
(Figure 1.9). The pathophysiology and recommended treatment depend 
on the site of infarction associated with the heart block. 
In inferior STEMI, patients usually progress through first degree and 
Wenckebach block to well-tolerated complete heart block with a narrow 
complex escape rhythm. If the blood pressure is well maintained and the 
patient is asymptomatic, no treatment is necessary. If the ventricular rate 
falls below 40 bpm, pauses of >3 seconds occur, the systolic BP falls below 
90 mmHg or rate-related symptoms develop: 
• 	 atropine 0.6 mg should be given IV, repeated as necessary 
• 	 if symptomatic complete heart block persists despite atropine, a 
temporary pacing wire should be inserted. 
Normal AV nodal conduction usually returns within 48 hours, a 
permanent pacemaker is not required, and prognosis after discharge from 
hospital is good. 
In patients with anterior STEMI, complete heart block often occurs 
suddenly, particularly in patients who develop left bundle branch block or 
have a period of Mobitz type 2 block. The escape rhythm is broad, complex 
and slow, often associated with severe haemodynamic compromise in a 
patient with extensive infarction and major left ventricular impairment. 
Temporary pacing is always required to maintain an adequate rate. 
High-grade AV block often persists, necessitating permanent pacemaker 
implantation. A large proportion of patients who develop complete heart 
block following anterior STEMI die, often from pump failure due to 
ventricular damage. 
Permanent cardiac pacing after STEMI 
In patients with inferior STEMI, high-degree AV block is usually 
self-limiting, but can persist for up to 2 weeks. Patients with high-degree 
block that persists beyond this point will require a permanent pacing 
system. In patients with anterior STEMI and high-degree block, even if 
transient, there is a high risk of subsequent asystole and a permanent 
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LATE POST -INFARCTION ARRHYTHMIAS 
Background 
Arrhythmias that develop more than 48 hours after the onset of STEMI
have a different pathophysiology and therapeutic approach. Many of the
arrhythmias are related to the formation of fibrosis in the infarct zone.
Myocardial fibrosis slows and disturbs conduction, resulting in the
development of re-entry circuits that are electrically unstable and generate
ventricular tachyarrhythmias. Since these late arrhythmias have a chronic
substrate, they are likely to be recurrent. Because of this, they are a common
cause of post-infarction mortality, and are a marker of a poor prognosis. 
Frequent ventricular ectopic beats 
The presence of frequent ventricular ectopic beats in the post-infarction 
period (>10/h) is strongly associated with an adverse prognosis. More than
100 000 patients have been studied in randomized trials investigating the 
use of class I and class III antiarrhythmic drugs to suppress ventricular 
ectopics in the hope of preventing subsequent malignant arrhythmias.
None of the large well-conducted trials has shown a mortality benefit (and 
some have shown an adverse pro-arrhythmic effect). In patients with
frequent ventricular ectopics, secondary preventative therapy with ACE 
inhibitors and beta-blockers should be optimized and revascularization 
performed if there is ongoing ischaemia; antiarrhythmic drug therapy 
should not be prescribed. 
Ventricular tachycardia 
Ventricular tachycardia occurring after the first 48 hours, even if
asymptomatic or non-sustained, is an important risk factor for early 
sudden death, particularly when it occurs in association with significant
left ventricular dysfunction (ejection fraction <35 per cent). Trials of class 
I antiarrhythmic drugs have been uniformly disappointing, with no 
beneficial effect, and some evidence of an adverse pro-arrhythmic effect. 
In the late 1990s, five important trials (EMIAT, CAMIAT, MADIT,
MADIT-2 and MUST) reported, and provide some guidelines for an
evidence-based approach to management of these patients. Current 
guidelines state that patients who have syncopal VT or VF without a
treatable cause (i.e. not related to their index presentation) should be
considered for an ICD for secondary prevention. Patients who are over 
1 month from their index event qualify for an ICD on primary grounds if
they have an ejection fraction (EF) of <30 per cent and QRS duration of
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monitor and inducible VT on electrophysiological testing. Therefore, all 
patients with impaired left ventricular function should be carefully
evaluated to assess who will require further investigation. 
RECOVERY AND REHABILITATION 
The in-hospital recovery period 
Following admission with ACS, all patients should remain on bed rest
with continuous rhythm monitoring and close supervision in a CCU 
environment for at least 24 hours. This is the period of time when the risk
of a potentially fatal but reversible arrhythmia is high. In addition, 
multiple therapeutic interventions designed to reduce infarct size, 
stabilize the patient and improve prognosis are required. Management 
after this first 24-hour period will depend on clinical stability and risk
profile. Patients who have a small ACS (localized ECG changes and small 
enzyme rise) who are clinically stable with no complications after 
24 hours generally have a good prognosis. These uncomplicated patients 
can begin to mobilize and undertake self-care after 24 hours, and be
transferred out of the CCU to a less intensively monitored ward
environment. Hospital stay should be limited to 2–3 days for 
uncomplicated patients who have been successfully treated by either PCI 
or with thrombolysis and subsequent PCI. Those that have been managed
conservatively without coronary angiography should remain in hospital
for 5–7 days and should be considered for other means of risk
stratification if appropriate. By discharge, patients should be walking
200 metres on the level and up a flight of stairs without symptoms. The 
occurrence of any ischaemia, heart failure, dysrhythmia or other 
complications during the mobilization phase indicates the need for 
careful reassessment with a view to determining the need for further 
investigation prior to discharge. 
Patients who have extensive myocardial injury (widespread ECG changes 
and large enzyme rise) are at increased risk of early complications, and 
remain unstable for a more prolonged period of time. These complicated 
patients need to stay on CCU for intensive treatment and monitoring, 
with a large proportion requiring cardiac catheterization, PCI, cardiac 
surgery or arrhythmia intervention prior to hospital discharge. High-
risk patients who are stabilized should be transferred out of CCU with a 
view to discharge after slow mobilization. Patients and relatives should be
provided with verbal and written information about their condition, and 
referred to a rehabilitation programme. 
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Rehabilitation 
After ACS, cardiac rehabilitation aims to restore patients to their optimal 
physical, psychosocial, emotional and vocational status using a 
multidisciplinary and multifactorial programme. Each patient needs a 
programme tailored to meet individual needs. As a minimum, sessions of 
medical assessment and review, education and counselling should be 
offered to all patients. Patients who make a good recovery from their ACS 
and have a satisfactory negative exercise test should enter a supervised 
exercise programme. In patients with extensive infarction or a positive 
exercise test, exercise rehabilitation should be deferred until investigation 
and further treatment are completed. Patients who have important 
co-morbidity may not be suitable for an exercise programme. Patients 
who complete a multifactorial rehabilitation programme benefit from: 
• reduced anxiety and depression 
• increased chance of returning to active employment 
• improved cardiovascular function and exercise capacity
 
• optimized risk factor management.
 
These beneficial effects combine to improve prognosis, with meta-analysis 
of over 2000 patients enrolled in randomized studies suggesting that 
rehabilitation programmes reduce readmission rates and improve 
mortality by about 25 per cent over 3 years. 
Lifestyle modification and general advice 
Smoking cessation after ACS reduces the rate of progression of coronary 
disease. Cardiac event rates are reduced by 50 per cent. Access to 
specialized smoking cessation clinics should be available for all smokers. 
Reducing the number of cigarettes smoked, or changing to cigars or a 
pipe, is not an effective way of reducing risk. Even consumption of one 
cigarette a day doubles the risk of further ACS. Passive smoking has a 
similar adverse effect as smoking one cigarette daily, and partners of ACS 
survivors should be encouraged to stop. A diet low in saturated fat and 
calories but high in carbohydrates, fruit, vegetables, fibre and fish has 
favourable effects on lipid profile, blood pressure and haemostatic risk 
factors, and is recommended after ACS. An active lifestyle with regular 
exercise and stress management techniques improves quality of life and 
may have beneficial effects on survival. Although consumption of low 
levels of alcohol may be cardioprotective, high levels of alcohol 
consumption (more than three units per day) are associated with 
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The Driver and Vehicle Licensing Agency (DVLA) does not require 
that patients inform them after an uncomplicated ACS, although
patients are not allowed to drive for up 4 weeks unless successfully treated 
with primary PCI and the EF is ≥40 per cent, in which case driving 
can commence after 1 week. After a complicated ACS the DVLA may 
impose a large period of restriction, and patients should be advised to
contact the authority directly for advice. The requirements of insurance 
companies are variable. Patients should seek advice from their own 
insurer before recommencing driving after ACS. Patients who hold 
a vocational licence to drive an HGV or public service vehicle must 
contact the DVLA after an ACS. These licences will be automatically 
withdrawn, but may be returned if the DVLA is satisfied with a medical 
report and the results of a post-ACS exercise test (currently patients are 
required to exercise for 9 minutes of the Bruce protocol, off medical 
therapy, with no symptoms or ECG changes). Air travel should be
avoided for 6 weeks after an uncomplicated ACS or longer in patients 
with complications. Sexual activity should be avoided early after ACS. 
Patients who have a satisfactory exercise test result can be reassured that
the cardiovascular demands of intercourse are normally less than of the 
exercise test, and be encouraged to return to normal activity. Patients 
with significant post-MI exercise symptoms may need more specialized 
psychosexual counselling. 
KEY POINTS 
• 	ACS are very common. Although modern treatment has improved
outcome in younger patients, ageing of the population results in a 
continuing high prevalence of morbidity and mortality. 
• 	Most deaths occur shortly after the onset of symptoms. 
• 	Almost all episodes of ACS are caused by thrombotic occlusion or 
partial occlusion of a coronary artery related to an unstable 
atherosclerotic lesion. 
• 	Plaque instability (reflecting enhanced inflammatory activity within
an atherosclerotic lesion) may be triggered by multiple factors. 
• 	 Initial categorization of an ACS is based on clinical evaluation
combined with analysis of the ECG. 
• 	 Cardiac troponins are highly sensitive and specific biomarkers, with
elevation confirming that irreversible myocardial necrosis has occurred. 
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• 	Emergency treatment requires analgesia, antiplatelet drugs, treatment
of hypokalaemia and hyperglycaemia and appropriate reperfusion 
therapy. 
• 	Where available, primary PCI is superior to thrombolysis. 
• 	Beta-blockers, ACE inhibitors and statins should be instituted in all 
suitable patients. 
• 	Heart failure and hypotension require careful evaluation. 
• 	Mechanical complications are relatively rare but associated with high
rates of morbidity and mortality. 
• 	Many arrhythmias are transient and self-terminating. 
• 	Active rehabilitation after MI improves long-term outcome. 
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BACKGROUND 
Epidemiology and physiology 
Cardiovascular disease is the leading cause of death in the UK, with more 
than 300 000 victims each year. Sudden cardiac death represents
approximately 25–30 per cent of all cardiovascular death, claiming an
estimated 70 000–90 000 lives each year. 
Although the causes of cardiac arrest are numerous (Table 2.1), most
events in adults occur as a result of ischaemic heart disease. A number of
studies have shown a circadian pattern of cardiac arrest with the majority
of events occurring in the morning hours (6 a.m. to 12 noon) and a low 
Table 2.1 Causes of VF/pulseless VT, asystole and pulseless electrical 
activity (PEA) 
Causes of ventricular fibrillation 
Reversible triggers 
Acute myocardial infarction/ischaemia 
Electrolyte disturbances (hypokalaemia, hyperkalaemia, 
hypocalcaemia, hypomagnesaemia, metabolic acidosis, etc.) 
Drugs (antiarrhythmics, phenothiazines, tricyclic antidepressants, 
digoxin toxicity, etc.) 
Illicit drug use, e.g. cocaine, amphetamines, ecstasy (see Chapter 8) 
Commotio cordis (see Chapter 10, cardiac trauma) 
Electric shock 
 
    
      
 
RESUSCITATION 
Structural heart disease 
Coronary artery disease 
• Atherosclerotic 
• Non-atherosclerotic (Prinzmetal angina, anomalous origin of
coronary artery, etc.) 
Cardiomyopathies 
Valvular heart disease 
Myocarditis 
Congenital heart disease 
Arrhythmogenic right ventricular dysplasia 
Primary pulmonary hypertension 
Infiltrative heart disease (amyloidosis, sarcoidosis, tumour) 
Structurally normal heart 
Wolff–Parkinson–White syndrome 
Long QT syndromes 
Brugada syndrome 
Idiopathic VT/VF 




Drugs (antiarrhythmics, beta-blockers, verapamil) especially with
pre-existing sinus node disease 
Causes of pulseless electrical activity 
‘4 Hs and 4 Ts’ 
Hypoxia 
Hypovolaemia 
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to minimize brain 
damage 
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incidence at night. Some data also suggest a late afternoon peak between 
4 p.m. and 7 p.m. A seasonal variation in cardiac arrest is also recognized
with an increased number of cases occurring during the winter months. 
Resuscitation after cardiopulmonary arrest is effective in only one in five
patients with about a third of long-term survivors having apparent motor 
or cognitive deficits. 
By far the most commonly encountered rhythm is ventricular fibrillation
(VF) or pulseless ventricular tachycardia (VT) occurring in more than
50 per cent of cases. With time, VF deteriorates from coarse VF to fine VF
and eventually to asystole. The prognosis is less favourable for non-VF/VT 
rhythms. Independent predictors of mortality during follow-up include 
increased age (>65 years), the presence of heart failure and cardiac arrest
not related to an acute coronary syndrome (ACS). 
After a cardiac arrest, the only interventions that have been proven to 
improve long-term survival are basic life support and early defibrillation
[immediate commencement of cardiopulmonary resuscitation (CPR)
confers a 2.7-fold increase in the rate of survival]. Therefore, the key to a 
successful outcome is dependent on initiation of a rapid sequence of
events with minimal delay (Figure 2.1). Ideally, the goal of in-hospital 
defibrillation should be a collapse–shock interval of less than 3 minutes.
Although data from randomized controlled trials are limited, techniques
for CPR have been standardized in recent years, and the guidelines in this
chapter are based on those published by the Resuscitation Council (UK) 
and the European Resuscitation Council (ERC). 
The major role of CPR is to provide some blood flow to both the
myocardium and central nervous system to allow for successful
defibrillation and resuscitation, and to preserve long-term organ function.
Although a number of theories have been proposed, the mechanism by
Figure 2.1 The key to a successful resuscitation outcome is dependent on a 






























which external chest compression provides an artificial circulation is not
fully known. Even when performed optimally, chest compression does not
achieve more than 30 per cent of the normal cardiac output. One of the most
important concepts in understanding the physiology of CPR is that of
coronary perfusion pressure. Coronary perfusion pressure is defined as the
difference between the aortic diastolic pressure and the right atrial pressure
(the venous return of myocardial flow is through the great cardiac vein,
coronary sinus and eventually the right atrium; therefore, an increase in
right atrial pressure may impede venous run-off from the myocardial
capillary bed). The majority of coronary flow occurs during artificial
diastole or the chest relaxation phase of CPR, and is dependent on the
coronary perfusion pressure. Experimental studies have shown that the
larger the coronary perfusion pressure, the greater the coronary blood flow,
and the greater the chance for a successful outcome. The coronary perfusion
pressure can be optimized by increasing the peripheral vascular tone using
vasoconstrictors such as adrenaline, or by increasing the number of chest
compressions per minute. A compression rate of 100 per minute is currently
recommended by the ERC, partly due to concerns that higher rates may be
physically too exhausting for members of the arrest team. 
During cardiac arrest and CPR, a severe mixed acidosis can develop. A 
reduction in alveolar gaseous exchange because of an increase in dead
space and a decrease in lung compliance (due to pulmonary oedema) can 
lead to respiratory acidosis. The combination of circulatory collapse and 
poor tissue perfusion can result in marked metabolic acidosis. Severe 
acidosis is negatively inotropic, causes electrolyte disturbances and can
cause intractable arrhythmias and a poor resuscitation outcome. 
THE ABC OF RESUSCITATION AND SPECIFIC INTERVENTIONS 
The ABC of resuscitation begins with basic life support and the
establishment of an adequate airway (A), breathing (B) and circulation (C).
The purpose of basic life support is to maintain adequate ventilation and
circulation until advanced techniques can be applied to reverse the
underlying cause of the arrest. It is assumed that a sound knowledge in basic
life support already exists, and therefore this chapter concentrates mainly
on management issues and interventions during advanced life support. 
Airway 
A quick inspection of the oropharynx should be performed, and any 
obstructions such as food or loose dentures should be removed. Tight-
fitting dentures should be left as it helps support the soft palate. Manoeuvres
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such as the head tilt, chin lift and jaw thrust can be used to ensure that the 
tongue and soft tissues do not obstruct the airway. A variety of airway
adjuncts are now available on most resuscitation trolleys and include 
facial masks, Guedel airways (an estimate of the size may be obtained by
selecting an airway with a length corresponding to the vertical distance
between the incisor tooth and the angle of the jaw) and nasopharyngeal
tubes (the diameter size in adults is usually 6–7 mm or the diameter of the
little finger). The tip of a nasopharyngeal tube should be visible in the 
pharynx behind the tongue. For more skilled and experienced staff, the 
insertion of a laryngeal mask or, ideally, an endotracheal tube can be
attempted. 
Breathing 
It is important to look, listen and feel for breath sounds and chest 
movements. In any patient in whom breathing is inadequate or absent, 
artificial ventilation must be commenced as soon as possible.
Oxygenation of the patient is the primary objective and the highest 
concentration of oxygen available should be administered. This can be
achieved by using a mask with a reservoir bag, which can deliver inspired
oxygen concentrations of 85 per cent at flow rates of 10–15 L/min. Tidal
volumes of 400–600 mL are adequate to make the chest rise and are less
likely to cause gastric insufflation and aspiration. Between 1.5 and 
2 seconds should be spent in the inspiratory phase. 
Circulation 
Until now, previous resuscitation guidelines have required the absence of 
a carotid pulse to diagnose cardiac arrest and start CPR. However, times 
in excess of 30 seconds are required to achieve an accuracy of 95 per cent. 
As a consequence, current guidelines have de-emphasized the carotid
pulse as the sole criterion for starting CPR, and include the search for 
signs of a circulation such as chest wall movement and breathing. If there 
is no circulation, then chest compressions should be commenced. The heel
of one hand should be placed in the middle of the lower half of the
sternum, the fingers should be off the chest and the other hand is brought 
down to rest on the back of the hand with the fingers interlocked. Vertical
downward pressure is applied to depress the sternum 4–5 cm and then the 
pressure is released. A compression rate of 100 per minute using a 
compression to ventilation ratio of 30:2 is now recommended for single 
and multiple rescuers when ventilating non-invasively (bag and mask).
Once intubated, ventilation should continue at approximately 



























ventilation. Uninterrupted chest compression results in substantially 
higher mean coronary perfusion pressure. 
Defibrillation 
The only definitive treatment for VF or pulseless VT is defibrillation. 
Although these rhythms are initially readily treatable, the chances of
successful defibrillation diminish rapidly with time and decline by
7–10 per cent per minute. In the case of a witnessed arrest especially when 
a shockable rhythm has been identified, it is reasonable to attempt a 
precordial thump. The thump delivers a small amount of kinetic energy,
which may be adequate to convert a fibrillating myocardium. All reported
cases of successful precordial thump occurred within 10 seconds of
VF/VT. If precordial thump is not successful or if VF/VT is more
prolonged then electrical cardioversion is required. Often, patients are not 
monitored and the duration of VF/VT is unknown, in this case chest 
compressions should be initiated first until the rhythm is determined.
Experimental studies have shown that interruption in chest compressions
is associated with a lower chance of survival. In addition, interruptions in
chest compression reduce the chance of successfully converting VF to 
another rhythm. Therefore, unless the patient is monitored and 
defibrillation can be achieved immediately after collapse, chest 
compressions should be started and maintained until defibrillation is
possible. Following defibrillation chest compressions should be continued 
as delay in checking for a pulse may further compromise the myocardium
if a perfusing rhythm has not been restored. 
Shocks are initially started at between 150 J and 360 J with a biphasic device.
Biphasic shocks involve the polarity of the current being reversed part way
through the delivery of a shock, as a result the defibrillation threshold is
lowered and the shock energy required for successful defibrillation is
reduced. Monophasic defibrillators are being phased out as they are less
efficient at terminating VF/VT. If they are used they should be set to
360 J from the outset. The paddles should be applied firmly to the chest wall
with water-based gel pads between them and the skin. The pressure applied
should be approximately 8 kg of force and the correct positions are shown
in Figure 2.2a. The use of hands-free self-adhesive pads allows for safer
operation by allowing the operator to discharge the device without leaning
over the patient. They also allow for quick identification of rhythm
and therefore quicker defibrillation than using standard electrodes. If
defibrillation is unsuccessful in the anterolateral position, then further 
attempts in the anteroposterior position (Figure 2.2b) and/or a different



































































































































































































































































































































































































































































defibrillator are worth trying. The positions of the positive and negative
paddles do not matter when defibrillating. 
In patients with permanent pacemakers, defibrillation in the
anteroposterior position is preferable, even though modern pacemakers 
are fitted with protection circuits. When defibrillation is attempted, ensure
that the electrodes are placed at least 12–15 cm from the pacemaker unit. 
Pacing 
Pacing can often be life saving, especially in situations where bradycardia
preceded the cardiac arrest or where bradycardia is associated with
haemodynamic intolerance following successful resuscitation. Pacing can 
be attempted non-invasively or invasively, depending on the equipment 
available and/or the experience of the operator. 
Non-invasive (transcutaneous) pacing 
Transcutaneous pacing can be easily applied, requires minimum training
and avoids the risks of central venous cannulation. Many defibrillators are 
now equipped with external pacing facilities and it is important for those 
involved in managing cardiac arrest to familiarize themselves with this
option. Pacing is usually carried out through self-adhesive gel pads which 
can also be used for defibrillation if necessary. When used for pacing, the 
device often additionally requires a 3-lead ECG (electrocardiogram) to be
attached. The ECG gain is adjusted to ensure sensing of any intrinsic QRS 
complexes. The demand mode is selected and the pacing rate set to 
60–90 bpm. The pacing current is set at the lowest setting and the 
pacemaker turned on. The current is then slowly increased, observing the 
patient, and monitored until electrical capture is seen. As the current 
increases, the skeletal muscles contract and a pacing spike is seen on the 
monitor. Electrical capture is recognized by wide QRS complex and a 
broad T wave. A current range of 50–100 mA is usually sufficient (Figure 
2.3). The presence of a palpable pulse ensures electrical capture results in
mechanical capture (myocardial contraction). Failure to achieve 
mechanical capture in the presence of good electrical capture indicates 
non-functional myocardium. Patients often require sedation with an IV
benzodiazepine (Diazemuls) as the procedure can be painful.
Transcutaneous pacing is only a temporary measure until transvenous
pacing can be instituted. 
Transvenous pacing (box 2.1) 
The resuscitation trolley should always be present and venous access
available. Bradycardia, asystole and ventricular tachyarrhythmias are 







































































































































































































  Box 2.1 Indications for temporary transvenous
cardiac pacing 
RESUSCITATION 
often induced during the procedure, and therefore atropine, isoprenaline 
and lidocaine should be readily at hand. The commonest route for placing 
a temporary wire is usually the right subclavian vein (the left side is then 
available for a permanent implant if required). The risk of vascular access
site complications can be reduced by using the femoral vein, with the 
additional advantages that haemostasis can easily be secured by pressure 
if bleeding occurs, and the requirement for wire manipulation during 
placement is usually minimal. 
Emergency/acute 
Acute myocardial infarction 
• Asystole 
• Symptomatic bradycardia (sinus bradycardia with hypotension 
and Mobitz type 1 second degree AV block with hypotension not 
responsive to atropine) 
• Bilateral bundle branch block (alternating BBB or RBBB with
alternating LAHB/LPHB) 
• New or indeterminate age bifascicular block with first degree AV 
block (trifascicular block) 
• Mobitz type 2 second degree AV block 
• Overdrive suppression of tachyarrhythmias 
Bradycardia not associated with acute myocardial infarction 
• Asystole 
• Second or third degree AV block with haemodynamic
compromise or syncope at rest 
• Ventricular tachyarrhythmias secondary to bradycardia 
Elective 
• Support for procedures that may promote bradycardia 
• General anaesthesia with: 
– second or third degree AV block 
– intermittent AV block 
– first degree AV block with bifascicular block 
– first degree AV block and LBBB 
• Cardiac surgery 
– aortic surgery 
– tricuspid surgery 
– ventricular septal defect closure 
– ostium primum repair 
BBB, bundle branch block; LAHB, left anterior hemiblock; LPHB, left 
posterior hemiblock; RBBB, right bundle branch block. 
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A sheath with a non-return valve should be placed in the vein using a 
Seldinger technique, to allow easy manipulation of the wire. A size 5F 
bipolar pacing wire is appropriate in most cases. A working pacing box 
(pulse generator) must be ready before inserting the wire. When using the 
subclavian approach (with a standard 20–30° curve on the wire tip), the 
wire is advanced into the right atrium under fluoroscopic control and 
rotated until it points downwards and to the patient’s left. Advancing 
across the tricuspid valve will often induce ventricular ectopics, which 
usually settle rapidly and require no treatment. If difficulty is
encountered in crossing the tricuspid valve, changing the curve at the 
wire tip usually helps. If this fails, fashioning the electrode into a loop in
the right atrium by pointing the lead tip to the right cardiac border may 
be successful. The electrode is twisted clockwise or anticlockwise until 
the tip lies near the tricuspid valve. Slight withdrawal of the electrode at 
this stage will allow the tip to flick through the valve into the right 
ventricle. The electrode should never be advanced if resistance is
encountered: rather, the electrode should be withdrawn slightly, rotated
and then carefully advanced again. When using the femoral approach, the 
curve on the wire tip should be directed towards the midline as the wire 
enters the right atrium. As the wire is subsequently advanced it usually 
easily crosses the tricuspid valve. 
The best position for the pacing wire is usually with the tip in the right 
ventricular apex, to the left of the midline and with the tip of the wire 
pointing inferiorly on screening (if the wire is directed to the left, towards 
the left shoulder, it may be in the coronary sinus and often will not capture 
at an acceptable threshold). There should be enough slack in the loop of 
the electrode to allow for changes in posture and deep inspiration, but not 
so much as to allow the tip to displace either in the right atrium or the 
pulmonary artery. The wire is then attached to the connecting leads and 
pacing box. 
To test the threshold, the pacing box is first set to the demand mode, then 
the pacing rate set at 5–10 bpm faster than the patient’s intrinsic rate. The 
output is set at 3 V; this should result in a paced rhythm. The amplitude of
the voltage is slowly turned down until capture is lost. Acceptable 
stimulation thresholds are below 1 V, although higher levels may be
acceptable if the patient is elderly, has had an inferior infarct, or if several 
sites have been tried, all with relatively high thresholds. The stability of
the pacing wire is checked during deep breathing, coughing and sniffing. 

















threshold has been ascertained, the output voltage should be set at three 
times the threshold or 3 V, whichever is higher. This compensates for 
subsequent threshold elevations due to inflammation and oedema at the 
electrode–tissue interface. If in sinus rhythm, a back-up rate of 50/min is
set. If there is heart block or bradycardia, the rate is normally set at 
70–80/min. 
The wire is sutured firmly with a loop formed externally to minimize the 
chance of inadvertent lead displacement. Finally, a chest x-ray is obtained
to exclude any complications. 
Temporary venous pacemakers should be checked at least once daily for 
pacing threshold, evidence of infections around venous access sites,
integrity of connections, and battery status of the external generator. 
Underlying rhythm should also be assessed and recorded at these checks.
Pacing thresholds are checked by increasing the pacing rate to obtain
continuous pacing, then progressively decreasing the output voltage until 
capture is lost. A sudden increase in the threshold usually indicates the 
need for repositioning. 
ARRHYTHMIA ALGORITHMS 
Shockable rhythms (VF/pulseless VT) 
This is recognized on the cardiac monitor by the presence of chaotic 
fibrillation waves, due to wandering cardiac electrical activity along 
continuously changing pathways (Figure 2.4a, Box 2.1) or a broad complex 
tachycardia (Figure 2.4b). Defibrillation with a biphasic shock is the 
definitive treatment for VF (Figure 2.5). The likelihood of survival
decreases 10 per cent for each minute of time after the onset of
uncorrected VF. Defibrillation should be performed as soon as the 
diagnosis of VF is considered, with an initial shock of 150 J to 360 J,
followed by chest compressions. If pulseless electrical activity develops, 
the non-shockable algorithm is followed. If VF persists, CPR is
maintained for 2 minutes, followed by assessment of rhythm and further 
shocks if indicated (Figure 2.5). During CPR, an adequate airway and
oxygenation (intubating the patient only if trained or experienced) are 
ensured, intravenous access obtained, and adrenaline 1 mg administered 
every 3–5 minutes. Adrenaline works principally as a vasoconstrictor
(α-agonist effect) to increase the efficiency of basic life support, not as an
adjuvant to defibrillation. Adrenaline 2–3 mg (made up to a volume of
10 mL using sterile water) can be given via the tracheal tube. This should 

























































































Look for signs of life 
CPR 30:2 





(VF / pulseless VT) 
Non-shockable 
(PEA / Asystole) 
During CPR: 
• Correct reversible
 causes (see below) 
1 Shock 
150–360 J biphasic 
or 360 J monophasic 
Immediately resume 
CPR 30:2 




 position and contact 
• Attempt / verify:




• Give adrenaline every
3–5 minutes 
• Consider: amiodarone,









Hyopthermia Thrombosis (coronary or pulmonary)
 
RESUSCITATION 
Figure 2.5 Cardiac arrest algorithm based on the European Resuscitation 
Council and the Resuscitation Council (UK). 
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then be followed by at least five ventilations to disperse the drug into the 
peripheral bronchial tree and aid absorption. 
Recent studies suggest that amiodarone may be superior to lidocaine in
cardioverting shock-resistant VF. In addtion there is evidence that 
amiodarone increases the chance of survival to hospital for shock-
resistant VF. Therefore, it is now recommended that amiodarone be used
as the first-choice antifibrillatory agent. A dose of 300 mg IV should be
administered if VF/VT persists after three shocks. Lidocaine can be used
if amiodarone is not available though it should not be given if amiodarone
has already been used due to potential pro-arrhythmic effects of multiple 
drugs. Drug doses and infusion regimens are discussed in Appendix A. 
Non-shockable rhythms 
These rhythms usually have a poor outcome unless a reversible cause can 
be found and rapidly treated. The right side of the resuscitation algorithm 
(Figure 2.5) should be followed. 
Asystole 
This is recognized by the total absence of any ventricular electrical activity
on the cardiac monitor. Causes are summarized in Box 2.1. The gain setting
on the monitor is set to 1 mV and the leads and electrical connections are
secured. Where possible, an additional lead should be viewed so as to avoid
missing a potentially reversible arrhythmia (fine ventricular fibrillation). If
in doubt, treatment is with defibrillation as in VF/pulseless VT. Basic life
support should be commenced for 2 minutes, during which time advanced
airway and ventilation techniques are performed, intravenous access gained
and adrenaline 1 mg given. Atropine 3 mg IV or 6 mg via the tracheal tube
(made up to a volume of at least 10 mL of sterile water) is administered. The
monitor should be closely inspected for the presence of atrial activity (P
waves), which may suggest complete heart block with ventricular asystole.
This may respond to external (transcutaneous) or transvenous pacing
depending on the skills and equipment available. If asystole persists, CPR is
continued with the administration of adrenaline 1 mg every 3–5 minutes.
The administration of higher-dose adrenaline as a single bolus is no longer
recommended. 
Pulseless electrical activity 
This is recognized by the presence of an ECG rhythm compatible with a
cardiac output in the setting of a cardiac arrest. The commonest cause of
sudden, unexpected development of pulseless electrical activity (PEA)







resuscitation in this situation is very rare. Other important causes to consider
are summarized in Box 2.1. The best chance of survival is the early diagnosis
and treatment of the conditions detailed in Box 2.1. Having instituted basic
and advanced life support, and administered any specific therapy for the
above conditions, IV adrenaline 1 mg is given every 3–5 minutes. 
EARLY POST -RESUSCITATION CARE 
Immediately after an arrest, blood gases, electrolytes, cardiac-specific 
enzymes, full blood count and ECG are checked, and any problems 
treated. For instance: 
• 	Hypoxia is usually present, so high concentrations of oxygen 
should be given. Oxygen saturation is monitored with pulse 
oximetry, ensuring a saturation of >93 per cent. 
• 	 Serum potassium is maintained above 4 mmol/L and magnesium 
above 2 mmol/L. If potassium is above 6 mmol/L, 10 mL of 10 per 
cent calcium chloride is given IV over 5 minutes, followed by 50 mL 
of 50 per cent dextrose and 10 units of Actrapid (insulin) to 
stabilize the myocardium and correct hyperkalaemia. 
• 	 If the pH is less than 7.1 or the base excess ≤10 mmol/L, giving 
bicarbonate (8.4 per cent) in 25-mL boluses should be considered to 
maintain a pH of 7.3–7.5. 
• 	Consider the need for antiarrhythmic drug therapy to limit the risk 
of further arrhythmia. 
• 	Hyperglycaemia should be controlled with an insulin sliding-scale 
regimen. 
• 	Hypoglycaemia should be treated with a bolus of 20 mL of
  
50 per cent dextrose or glucose solution IV.
 
• 	 Persistent cardiac ischaemia that may have precipitated the cardiac arrest 
should be looked for and treated. In particular VT/VF that is ischaemia 
driven may respond to the use of an intra-aortic balloon pump. 
• 	A portable chest x-ray should be arranged and any pneumothorax 
treated. 
• 	Left ventricular failure and hypotension should be treated, if 
present. If hypotension persists consider a pulmonary artery 
catheter to guide optimal fluid and inotropic therapy. 
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• 	The patient should be catheterized and urine output monitored. 
• 	The nervous system should be examined and neurological function 
documented using the Glasgow Coma Scale. 
• 	The patient should be examined to ensure that there is no other 
medical or surgical intervention requiring immediate management. 
• 	A comprehensive history should be obtained, including a family 
history from available witnesses. The possibility of overdoses and 
other non-primary cardiac disease (such as hypothermia, 
cerebrovascular accidents, subarachnoid haemorrhages, etc., see 
Box 2.1) should be excluded. 
There are no definitive data as to when to discontinue intravenous 
antiarrhythmic drug infusions. It is common clinical practice to continue 
the infusion for a minimal of 24–48 hours and to discontinue the infusion 
provided there is no arrhythmic recurrence. For patients with refractory 
ventricular arrhythmias, high-dose beta-blockade coupled with atrial or 
dual chamber pacemaker therapy, and light anaesthesia together with 
muscle relaxation and artificial ventilation, may be life saving. Urgent 
referral for coronary revascularization or electrophysiological testing 
should be considered. 
Following a successful resuscitation, most patients will regain 
consciousness rapidly. Hypoxia must be avoided after resuscitation, and 
assisted ventilation should be used if there is a reasonable chance of 
recovery. The patient who remains unconscious and dependent on 
assisted ventilation should be transferred to the intensive care unit after 
close liaison with the anaesthetist. The decision to withdraw ventilatory 
support should be made by the most senior member of the medical/ 
anaesthetic team. The opinions of other members of the medical and 
nursing team, the patient (if previously known) and their relatives should 
be taken into consideration before making a final decision. 
If asystole or PEA persists after 25 minutes of resuscitation in a 
normothermic adult without drug toxicity, then success is unlikely and 
the attempt should probably be abandoned. If VF persists at this point, the 
situation is still potentially reversible, and it may be worth persisting with 
attempts at resuscitation. Pupillary dilatation should not be used as a 
reason for discontinuing resuscitation, as this can be drug induced. When 
hypothermia is present, attempts to revive the patient should be continued 























and potassium are normal. It is well documented that full recovery can 
occur with resuscitation attempts of up to 9 hours. 
LATE POST -RESUSCITATION CARE 
Following a cardiac arrest, patients should be thoroughly investigated and 
appropriate therapy directed to minimize the risk of recurrence (Box 2.1). 
Reversible triggers such as ACS, electrolyte disturbances, drugs (both 
prescribed and illicit) should be excluded. These can usually be diagnosed 
from the history, biochemical tests (including toxicology screens and 
cardiac enzymes) and serial ECGs. Structural heart disease can be
excluded with echocardiograms, left and right heart cardiac 
catheterization (including right ventriculogram and myocardial biopsy)
and magnetic resonance imaging (MRI). Patients with structurally 
normal hearts should be investigated with a 24–48-hour Holter monitor,
exercise stress testing and possible programmed electrophysiological
stimulation. Particular attention should be paid to the response of the QT 
interval during Holter monitoring and stress testing. If no triggering
events can be identified, then patients should be considered for an
implantable cardioverter defibrillator. 
Where there is a family history of sudden cardiac death, the patient’s
family should be screened with an ECG, Holter monitor, echocardiogram
and stress testing. Genetic screening for some of the inherited syndromes 
can also be carried out in some centres. 
NEW DEVELOPMENTS 
Alternative techniques to standard manual CPR have been developed to
improve perfusion during CPR. Active compression–decompression CPR
(ACD-CPR) is performed with a portable device equipped with suction cup
to actively lift the anterior chest during decompression. This decreases
intrathoracic pressure, enhancing venous return for the next compression.
Randomized studies have shown equivocal benefit using this technique,
and therefore it is not recommended for routine use at present. However,
these devices may be advantageous in situations where delivering adequate
chest compressions is difficult, such as during transport. They have also
been used in several cases that allowed patients to undergo CT scanning or
even coronary angiography without interrupting CPR. 
The major determinant of survival in patients with VF and pulseless VT is
the time taken for defibrillation. Consequently, there has been a natural













progression to make defibrillators more available. The development and 
easy applicability of automatic external defibrillators have strengthened 
this view. Once a cardiac arrest has been diagnosed, the electrodes of the 
system are attached to the chest using the standard positions. The device
is able to recognize VF and deliver defibrillatory shocks if required. 
Instructions are provided automatically on the screen and some models 
reinforce these instructions with synthesized voice messages. An override 
facility is available if one wants to use it as a manual defibrillator. These 
devices can be used by the public and require minimal training. 
Consequently, in some countries, these devices are now deployed in public 
locations such as airports, commercial aircraft, train stations and casinos. 
Recently, the US Food and Drug Administration has approved a vest-like 
defibrillator device that can be worn under clothing, rather than being 
implanted in the chest. The vest contains an electrode belt that is applied
to the chest and monitors the heart rhythm. If an abnormal
life-threatening heart rhythm is detected, and the patient loses 
consciousness, the device administers an electrical shock. 
KEY POINTS 
• 	CPR is a dynamic subject and therefore all health care staff involved in
patient care should be trained and kept up to date with advanced life
support protocols. 
• 	The most commonly encountered rhythm during a cardiac arrest is VF
or pulseless VT. 
• 	The prognosis is less favourable for non-shockable rhythms unless a 
reversible cause is present. 
• 	The only interventions that have been shown to improve long-term 
survival are basic life support and early defibrillation. 
• 	Careful post-resuscitation care is essential to maximize the chances of 
a full recovery. 
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BACKGROUND 
The management of cardiac arrhythmias complicating acute coronary 
syndrome (ACS) is dealt with in Chapter 1. This chapter deals with the 
management of arrhythmias that occur as a complication of other cardiac 
and medical disorders. Optimal treatment of these arrhythmias depends 
on two principles: 
• 	 inspecting the electrocardiogram (ECG) and reviewing the 
clinical presentation to establish the diagnosis. This provides 
information about arrhythmia mechanism and guides treatment 
selection. 
• 	 assessing the effect of the arrhythmia. Patients with good cardiac 
function will often tolerate arrhythmias without major 
haemodynamic compromise. Patients with coexistent cardiac 
impairment may be severely compromised by an arrhythmia. 
Tachyarrhythmias associated with major haemodynamic 
compromise usually require urgent cardioversion. 
Bradyarrhythmias associated with major haemodynamic 
compromise often require pacing. Patients with better tolerated 
arrhythmias can be treated with drug therapy. 
If there is any doubt about diagnosis or treatment, a senior colleague 
should be consulted for advice. 
The symptoms produced by the onset of an arrhythmia are highly 
variable. In an individual with no cardiac disease, an arrhythmia may be 
asymptomatic. A rapid tachyarrhythmia often produces palpitations. In 
 
ARRHYTHMIAS 
patients with cardiac disease, arrhythmia-related reduction in cardiac 
output and coronary perfusion may lead to ischaemic chest pain, heart 
failure and disturbed consciousness. 
It is useful to classify tachycardias according to whether the ECG QRS 
complexes are narrow or broad. 
Narrow-complex tachyarrhythmias usually arise from above the level of 
the bundle of His. In most cases, ventricular activation occurs via the 
normal conduction system, hence the narrow QRS configuration. This 
group can itself be subdivided into two groups, depending on whether 
they arise from the atrial myocardium (atrial fibrillation [AF], atrial 
flutter and atrial tachycardia) or a mechanism involving the 
atrioventricular (AV) node (atrioventricular nodal re-entry tachycardia 
[AVNRT] and atrioventricular re-entry tachycardia [AVRT] accessory 
pathways). The commonest narrow-complex tachyarrhythmias are AF, 
atrial flutter and AVNRT. 
Broad-complex tachyarrhythmias usually arise from the ventricles, 
although some ventricular tachyarrhythmias arise high in the bundle of 
His and can be relatively narrow. In a minority of cases, tachyarrhythmias 
arising from above the bundle of His can be associated with a broad QRS 
complex: abnormal slow ventricular activation occurs in those with 
pre-existing or rate-related bundle branch block, and in some patients 
with an accessory pathway. Because of this overlap, QRS duration is not a 
totally reliable guide to the site of origin of an arrhythmia, and additional 
information obtained from careful inspection of all features of the ECG, 
previous ECGs and ECGs in sinus rhythm is required before a diagnosis 
can be reached. 
Antiarrhythmic drug therapy has important limitations. The available 
agents are of limited efficacy, and a drug prescribed in the correct dose for 
an appropriate indication may fail to work. The available drugs may 
themselves be pro-arrhythmic, and may also have many unwanted side 
effects, including causing impairment of myocardial contractility, 
gastrointestinal and central nervous system disturbances. The available 
drugs can be categorized using the Vaughan–Williams classification, 
which provides information on the drugs’ electrophysiological effects: 
• 	 CLASS I: these agents have membrane-stabilizing properties, 
slowing sodium transport during myocyte depolarization, and can 
act on the atria, ventricles or conduction tissue. 
• 	 CLASS II: these agents block cardiac beta-receptors and act 
predominantly on the sinus and AV nodes (although there is 
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also some membrane-stabilizing effect in the atria and 
ventricles). 
• 	 CLASS III: these agents act on myocyte potassium channels, 
prolong the duration of the action potential and can act on the 
atria, ventricles or conduction system. 
• 	 CLASS IV: these agents block calcium channels, and act 

predominantly on the sinus and AV nodes.
 
Some drugs have more than one class of action, and others such as 
adenosine and digoxin cannot be classified using this simple system. 
Because of the complex nature of these drugs and the potential to induce a 
wide range of adverse effects, it is important to become familiar with the 
use of a small number of front-line drugs. Polypharmacy should be 
avoided; if the first-line therapy fails, a senior colleague should be 
contacted for advice before using a second drug. The onset of an 
arrhythmia is often associated with problems such as heart failure, 
pulmonary infection or embolism, thyroid disturbance, hypoxia, 
electrolyte imbalance or drug administration. It is important to look for 




AF is the most common cardiac arrhythmia (Figure 3.1). The incidence 
and prevalence of AF increases with age: the prevalence is approximately 
9 per cent in patients in their ninth decade. 
The development of AF is associated with atrial electrical instability or 
atrial distension induced by: 
• 	 hypertension 
• 	 congestive heart failure 
• 	 valvular heart disease 
• 	 ischaemic heart disease 
• 	 pulmonary infection or embolism. 
Other less common causes of AF are cardiac trauma (including iatrogenic 
trauma associated with cardiac surgery), metabolic abnormalities, exposure 
to toxins (such as alcohol), pericardial disease or systemic infection. In some 
patients, AF can arise in an otherwise entirely normal heart. This lone AF 
may be due to small localized areas of electrical instability in the atrium 
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ARRHYTHMIAS 
(usually close to the pulmonary vein orifices), or increased susceptibility to 
fluctuations in autonomic neural stimuli to the heart. 
Diagnosis and assessment 
Regardless of the underlying aetiology, patients with AF develop multiple 
random wavelets of depolarization in the atrial myocardium. This rapid 
erratic electrical activity is intermittently conducted to the ventricles via the 
AV node, producing a rapid, irregularly irregular ventricular rhythm. The 
onset of AF is often associated with symptoms due to a reduction in cardiac 
output or the rapid irregular ventricular rhythm causing a sensation of 
palpitation. The mean resting rate in patients with new onset AF is usually 
between 110 and 130 bpm. A rate in excess of 150 bpm should raise the 
suspicion of a hyperadrenergic state (thyrotoxicosis, or fever) or acute 
blood loss. A very rapid (rate 250 bpm) broad-complex AF is suggestive of 
the presence of a rapidly anterogradely conducting accessory pathway 
(Wolff–Parkinson–White syndrome [WPW]). 
When AF persists for more than 48 hours, stasis of blood in the fibrillating 
atrium may lead to clot formation and systemic embolization. The risk of 
thromboembolism is low in patients with recent-onset (up to 48 hours’ 
duration) AF. In some patients (particularly if cardiac function is normal), the 
AF will be well tolerated and asymptomatic. The 12-lead ECG of patients with 
AF will show an absence of P waves, rapid erratic fibrillation activity visible in 
the baseline between ventricular complexes, and an irregularly irregular 
ventricular rhythm which usually has a narrow complex QRS configuration. 
Initially, episodes of AF may be short lived and self-terminating (paroxysmal 
AF). Repeated episodes, however, lead to adverse changes in atrial 
electrophysiological and mechanical function, which decrease electrical 
stability and eventually lead to the development of sustained AF. Episodes of 
AF that persist for several days rarely terminate spontaneously. 
In patient assessment, careful history taking and clinical examination are 
important. If there is time, a chest x-ray and echocardiogram will also 
help. Particular importance should be paid to: 
• 	 the duration of AF 
• 	 the presence of coexistent cardiac disease (such as hypertension, 
ischaemic heart disease, valvular heart disease or left ventricular 
dysfunction) 
• 	 the effects of AF on patient symptoms, ventricular rate, blood 
pressure (BP) and cardiac function. 
These important features help to guide the selection of appropriate therapy. 
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Treatment of recent-onset poorly tolerated AF 
The onset of AF may be poorly tolerated, producing major symptoms and 
haemodynamic compromise. Patients with coexistent structural 
abnormalities (such as valvular heart disease, left ventricular hypertrophy, 
coronary artery disease or left ventricular dysfunction) or an accessory 
pathway capable of rapid anterograde conduction are intolerant 
of AF. When AF is poorly tolerated, many antiarrhythmic drugs are 
contraindicated or have an unpredictable response. If AF is associated with 
• angina or heart failure, or 
• rate > 200 bpm, or 
• systolic BP < 90 mmHg, 
• an accessory pathway 
urgent restoration of sinus rhythm by direct current cardioversion (DCC) 
is the treatment of choice irrespective of the duration of AF. Emergency 
treatment in this context should not be delayed by the administration of 
anticoagulants. As long as the AF is of <48 hours’ duration, the risk of 
procedure-related thromboembolism is low. Ideally, if there are no 
contraindications, heparin should be commenced upon presentation if 
patients have not been previous anticoagulated to a therapeutic level. Oral 
anticoagulation should be started if sinus rhythm is not re-established, or 
for those felt to be at risk of recurrent episodes of AF, or for those at high 
risk of stroke. 
Among patients with permanent AF in whom haemodynamic 
compromise has recently occurred due to an uncontrolled ventricular 
response, treatment should focus on rate control. 
Treatment of recent-onset well-tolerated AF 
In patients with recent-onset (< 48 hours) AF who do not have major 
symptoms or haemodynamic instability, ideally, electrical cardioversion 
should be performed. If there is likely to be a delay in performing DCC, 
AF can be treated with antiarrhythmic drugs. Drugs that act 
predominantly on the AV node (such as digoxin, beta-blockers and 
calcium antagonists) are not effective at restoring sinus rhythm. In 
particular, these agents should not be used for patients with WPW 
syndrome, as they may enhance anterograde conduction via the accessory 
pathway, potentially resulting in very rapid ventricular rates, hypotension 
and ventricular fibrillation. Class I or class III drugs that act on the atrial 
myocardium can restore sinus rhythm in most patients if the drugs are 
administered early in adequate doses, with the highest success rates 
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achieved by class Ic drugs. If the patient has a structurally normal heart 
(no significant valve disease, ischaemic heart disease or left ventricular 
dysfunction) intravenous (IV) flecainide 2 mg/kg (to a maximum of
150 mg) restores sinus rhythm in 90 per cent  of patients within 1 hour. 
The use of flecainide should be avoided if there is any pre-existing 
structural heart disease, as this will increase the risk of major adverse
effects. In a patient with associated structural heart disease, an IV
loading dose of amiodarone 300 mg followed by an infusion of 900 mg
over 24 hours is safe (see Appendix A), produces rapid slowing of the 
ventricular rate (due to its beta-blocking effects) and is moderately 
effective for cardioversion. If pharmacological cardioversion fails, DCC 
should be performed. Thromboembolism is just as likely to occur
following pharmacological, as opposed to electrical, cardioversion.
As above, heparin should be commenced immediately the diagnosis is
made, followed by warfarin as appropriate.
Treatment of well-tolerated AF of long or unknown duration 
If the AF has been present for more than 48 hours (or for an unknown
duration), there is a significant thromboembolic risk associated with
cardioversion. In these patients, one option is to consider using a strategy
of anticoagulation and ventricular rate control, particularly for older
patients, those with intolerance to antiarrhythmic agents, and those
deemed unsuitable for cardioversion.  Anticoagulation may be instituted
with heparin followed by warfarin but often warfarin alone is used in the
outpatient setting. Digoxin takes several hours to slow the ventricular rate
(acting indirectly on the AV node via the autonomic nervous system) and its
efficacy is reduced in a hyperadrenergic patient. Intravenous beta-blockers
produce rapid rate control regardless of the level of sympathetic tone
(e.g. metoprolol or atenolol 5–10 mg according to need and tolerability by
slow IV injection is effective in most patients). Intravenous therapy
should be followed by adequate oral doses. Where beta-blockers are
contraindicated, rate-limiting calcium blockers such as diltiazem or
verapamil can be used. If there is coexistent ventricular dysfunction,
digoxin (0.125–0.5 mg) is often favoured but gradual introduction of
beta-blockers should also be considered for long-term rate control.
Among younger patients, first-time presenters, or those with unacceptable 
symptoms or with coexistent heart failure, a strategy of rhythm control 
may be preferred initially. Usually, after a month’s anticoagulation, 
electrical cardioversion can be considered. In certain cases, e.g. where 

















facilities and expertise allow, cardioversion can be performed earlier, 
guided by transoesophageal echocardiography (to exclude the presence of 
intracardiac thrombus). 
Contemporary practice has been influenced following publication of
studies (AFFIRM, RACE, and others) that have shown no superiority of
rhythm over rate control among older subjects with persistent AF. Indeed, 
rhythm control was associated with higher rates of embolic stroke, likely 
related to discontinuation of anticoagulation after regaining sinus rhythm. 
Treatment of post-operative AF 
Post-operative AF is common, particularly among those undergoing 
cardiac surgery: it is estimated to occur in up to one-third of patients 
undergoing coronary artery bypass graft surgery, and is more frequent
when valve surgery is undertaken. Older patients, and those with previous
episodes of AF, are more likely to develop post-operative AF. 
Post-operative AF has important implications for morbidity and 
mortality, and can contribute to lengthening admissions. Episodes may 
relate to electrolyte disturbances, hypoxia or infections, and treatment 
should focus on these precipitants. Otherwise, episodes should be
managed as for other cases of acute-onset AF. Ideally, rhythm
management should be used for AF complicating cardiac surgery. 
ATRIAL FLUTTER 
In atrial flutter (Figure 3.2), the electrophysiological mechanism is
different from that of AF. In most patients with atrial flutter a re-entry
circuit in the right atrium depolarizes at a rate of 300/min in a circular
anticlockwise direction, down the lateral border of the right atrium, 
through an area of slowed conduction near the tricuspid valve annulus 
and back up the atrial septum. The normal AV node cannot conduct at 
this rate, and commonly 2:1 AV block occurs. The electrocardiogram
shows a regular narrow complex tachycardia (in the absence of bundle 
branch block) at a rate of 150 bpm. This rate may be slower in a patient
with impaired AV nodal function, or faster if sympathetic nervous system 
activation is present. Atrial activity may be visible on the ECG, seen as
saw-tooth flutter waves with a rate of 300/min, best visualized in V1. The 
flutter waves may only be visible during a temporary increase in the 
degree of AV block induced by vagal manoeuvres or intravenous
adenosine. It is important and useful to have documentation of the 
presence of flutter waves, and these procedures should be performed with
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printable ECG monitoring. Atrial flutter may degenerate into AF, or the 
rhythm may alternate between flutter and fibrillation. 
The onset of atrial flutter may be associated with symptoms of 
haemodynamic compromise due to the rapid ventricular rate and loss of 
effective atrial mechanical activity. As with AF, there is a risk of intra­
atrial clot formation in atrial flutter, leading to systemic embolization, and 
these patients require appropriate antithrombotic therapy as well as 
arrhythmia treatment. Attempts to slow the ventricular rate using drugs 
are often unsuccessful, and the aim of treatment should be to restore sinus 
rhythm. Treatment depends on the clinical circumstances: 
• 	 If the arrhythmia is associated with significant haemodynamic 
compromise (systolic BP <90 mmHg), or symptoms of angina, 
impaired conscious level or heart failure, urgent DCC is the 
treatment of choice. 
• 	 If the arrhythmia is well tolerated, an attempt can be made to 
restore sinus rhythm with drug therapy, although atrial flutter is 
often resistant to treatment with drugs. Class Ic antiarrhythmic 
drugs may terminate atrial flutter, but can also cause a poorly 
tolerated increase in ventricular rate (by slowing the flutter rate to 
less than 300/min and therefore facilitating 1:1 atrioventricular 
conduction at a rate greater than 150 bpm). Amiodarone has 
beneficial effects on atrial electrical stability, and may terminate the 
arrhythmia. In addition, amiodarone impairs atrioventricular 
conduction, and this property will help to slow the ventricular rate. 
We therefore recommend IV amiodarone for the treatment of atrial 
flutter, using the regimen detailed in Appendix A. If amiodarone is 
ineffective, the ventricular rate can be slowed with IV atenolol 
5–10 mg. Anticoagulation and cardioversion can then be performed 
following the same guidelines as for AF. Overdrive pacing is an 
alternative treatment that is effective in restoring sinus rhythm in 
70 per cent of patients. If facilities are available, a temporary pacing 
wire is positioned against the lateral wall of the right atrium. A 
burst of rapid atrial pacing at a rate of 400 bpm for several seconds 
will usually restore sinus rhythm. Occasionally AF will be 
precipitated, and this will often spontaneously revert to sinus 
rhythm. If it persists, it is easier to treat than atrial flutter. 
• 	 If atrial flutter persists despite 24 hours of intravenous amiodarone, 
or is resistant to overdrive pacing, DCC (often at very low energies) 
has a high success rate in restoring sinus rhythm. 
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Chronic drug therapy of atrial flutter has only limited efficacy.
Radiofrequency ablation (with targeted lesions around the tricuspid annulus 
designed to interrupt the macro re-entry circuit) has much better success 
rates (up to 97 per cent in some cases) and is preferable for suitable patients. 
ATRIOVENTRICULAR NODAL RE -ENTRY TACHYCARDIA 
Background 
Atrioventricular nodal re-entry is the mechanism responsible for most
(70 per cent) episodes of symptomatic paroxysmal regular narrow complex
tachycardia. This is a common arrhythmia, associated with recurrent
attacks of palpitation throughout life, usually with an onset between 30 and
50 years of age. It is more common in women than men. In most patients
there is no associated valvular, myocardial or coronary artery disease.
Tachycardia onset is associated with sudden onset of rapid palpitation,
which may be associated with dizziness, syncope and polyuria. The
arrhythmia is usually well tolerated haemodynamically, because the heart is
structurally normal. In patients with the common form of AVNRT, the AV
node has two functionally and anatomically distinct pathways. These two
pathways are joined into a final common pathway through the lower part of
the AV node. One pathway is capable of fast conduction, and conducts
electrical activity from atria to ventricles in normal sinus rhythm. The other
pathway is slow conducting and is redundant during normal sinus rhythm.
This slow pathway, however, has a short refractory period, and recovers its
ability to conduct before the fast pathway. An appropriately timed atrial
ectopic can be conducted down the slow pathway and back up the fast
pathway, setting up a regular continuously reciprocating mechanism
responsible for the sudden onset of a tachycardia. This re-entry in the AV
node depolarizes atria and ventricles simultaneously, and resultant P waves
are usually not visible because they are superimposed on the QRS complex.
The ECG therefore shows a rapid regular narrow complex tachycardia (in
the absence of bundle branch block) with a rate between 130 and 250 bpm
and no visible P waves. (Occasionally, P waves may be visible as pseudo-R
waves, particularly in lead V1 and the inferior leads.) The heart rate varies
with activity of the autonomic nervous system, increasing in association
with sympathetic activation (for example, standing up increases
sympathetic activation, speeding up AV nodal conduction and increasing
the tachycardia rate). The tachycardia can induce ST segment and T-wave
changes that persist for some time after termination of the arrhythmia, but




Most episodes of AVNRT can be terminated by vagal manoeuvres or 
intravenous drug therapy. Stimulating the vagus by a Valsalva manoeuvre, 
carotid sinus massage (after excluding the presence of carotid bruits) or 
activation of the diving reflex (by application of a cold stimulus to the 
face) will temporarily slow AV nodal conduction and interrupt the 
tachycardia circuit, terminating the arrhythmia in some patients. Some of 
these techniques can be used by the patient to try to terminate an attack at 
home, avoiding the need to attend hospital. Adenosine has a very short 
half-life (as short as 1.5 seconds) and no significant haemodynamic side 
effects. It works by transiently blocking conduction at the AV node and is 
very effective at terminating AVNRT. Adenosine is given as a rapid bolus 
at 3–6 mg into a proximal peripheral vein, often the cubital vein, and 
immediately flushed through with 10 mL of saline. If this fails, 
incremental doses of up to 18 mg can be administered. The patient should 
be warned that transient facial flushing, dyspnoea and chest pain are 
common, but last for less than 20 seconds. 
Adenosine can induce bronchospasm and is contraindicated in patients 
with asthma or AV block. It should also be used with caution in patients 
with chronic obstructive pulmonary disease (COPD) because of the 
potential to induce or exacerbate bronchospasm. If drug-induced 
bronchospasm occurs, further drug administration should be avoided 
and, if necessary, treatment with nebulized bronchodilators commenced. 
Dipyridamole potentiates the effects of adenosine, and dosage should be 
reduced to an initial 1 mg, increasing to a maximum of 4 mg if required. 
Theophyllines antagonize the action of adenosine, which may render the 
drug ineffective in these patients. 
If adenosine is contraindicated or ineffective, verapamil is an effective 
alternative agent, given as 5–10 mg over 30–60 seconds. Verapamil should 
be avoided if: 
• 	 systolic BP is <100 mmHg 
• 	 left ventricular function is known to be impaired 
• 	QRS complex is >120 ms (three small squares) 
• 	 patient is receiving concurrent treatment with beta-blockers 
• 	 patient is known to have an anterogradely conducting accessory 
pathway. 
If both adenosine and verapamil are contraindicated, a senior 
colleague should be consulted; the options would be to use a class Ic 
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antiarrhythmic drug, or pace termination. To terminate AVNRT by 
pacing: 
• 	A temporary pacing wire is placed in contact with the atrial 
endocardium and pacing instituted at 100 bpm. If a pacing spike 
occurs at an appropriate time point it will induce a critical 
refractory period in the circuit and terminate the arrhythmia. 
• 	 If underdrive pacing fails, the atria is paced 20 per cent faster than 
the tachycardia rate for 30 seconds, then the pacing abruptly 
terminated. This will often terminate the arrhythmia by a similar 
mechanism to underdrive pacing. There is a small risk of 
precipitating AF, which is usually short lived and reverts to sinus 
rhythm. 
If all these measures fail, DCC can be used to restore sinus rhythm. 
ACCESSORY PATHWAY TACHYCARDIAS 
Background 
In the normal heart the atria and ventricles become electrically isolated 
during fetal development. The only route by which atrial electrical activity
can be conducted to the ventricles is via the AV node. Incomplete 
separation of the atria and ventricles during fetal development leads to the 
persistence of a connection that is capable of abnormally conducting 
electrical activity between atria and ventricles. These abnormal
connections are called accessory pathways, and they can be responsible 
for a variety of ECG abnormalities and tachyarrhythmias. Accessory 
pathways are the mechanism responsible for around 20 per cent  of 
paroxysmal regular supraventricular tachyarrhythmias. The pathways 
can arise in a variety of different sites around the AV rings, and connect to 
various areas of the ventricles or conduction system. The most common
position for an accessory pathway is in the left lateral free wall of the heart.
Less commonly, pathways can be situated close to the septum, in the right 
free wall, or, rarely, can be multiple. The appearance of the surface ECG 
and the type of arrhythmias that occur depend on the precise anatomy
and conduction characteristics of the accessory pathway. Accessory 
pathway tachycardias are more common in males than females. The 
commonest arrhythmia in these patients arises when electrical activity
repeatedly circulates between the atria and ventricles via the AV node and 
accessory pathway, producing an atrioventricular re-entry tachycardia 




























arrhythmia (if AF occurs in a patient with a pathway that is capable of
rapid anterograde conduction from atria to ventricles, rapid activation of
the ventricles can result in VF and sudden cardiac death). 
Diagnosis from the ECG during sinus rhythm 
In many patients with an accessory pathway, the resting ECG will be
abnormal. If the pathway is capable of anterograde conduction from atria to
ventricles, initial slow ventricular activation will occur via the pathway during
normal sinus rhythm. This produces a short PR interval and delta wave
(Figure 3.3). This type of accessory pathway is present in up to 3 per 1000 of
the population (although many of these patients never have symptoms). The
occurrence of arrhythmias in association with this type of pathway and
abnormal ECG is termed WPW syndrome. The common left-sided pathways
produce a predominantly positive QRS complex in V1. The less common
right-sided pathways produce a predominantly negative QRS complex in V1.
In some patients the accessory pathway is only capable of retrograde
conduction from ventricles to atria. In these patients ventricular activation
occurs normally via the AV node, there is no pre-excitation, and the surface
ECG during sinus rhythm is completely normal. This ‘concealed’ accessory
pathway is, however, still capable of conducting retrogradely, thereby
participating in the re-entry circuit of an AVRT. The presence of a concealed
accessory pathway is occasionally suggested by the characteristics of the ECG
during tachycardia, indicating AV re-entry as a possible tachycardia
mechanism. In most cases, however, it is difficult to distinguish AVRT from
AVNRT based on the tachycardia ECG. 
Atrioventricular re-entry tachycardia 
Because the AV node and accessory pathway have different refractory
periods, an appropriately timed ectopic can initiate a repetitive cycle of 
depolarization involving the AV node and accessory pathway. In the 
common type of AVRT, electrical activity passes to the ventricles via the 
AV node, then back via the accessory pathway to depolarize the atria and 
reinitiate the cycle (orthodromic tachycardia). Since ventricular 
depolarization occurs via the normal conduction system, the ECG will
show a rapid regular narrow complex tachycardia (with no pre-excitation).
Since atrial depolarization occurs after ventricular depolarization, an
inverted P wave may be visible within the ST-T wave segments, roughly 
halfway between QRS complexes. Rarely, activation passes from atria to 
ventricles via an antegradely conducting pathway, then back to the atria 
via the AV node. Since ventricular depolarization is initiated via the 
pathway, the tachycardia will have a broad QRS morphology (antidromic 
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tachycardia). This type of rare AVRT is difficult to differentiate from 
ventricular tachycardia (VT) without the aid of an electrophysiological
study (EPS). 
Patients presenting with AVRT are generally similar to those with
AVNRT (relatively young, no structural heart disease apparent), although
AVRT is less likely to present in middle age than AVNRT. 
Atrial fibrillation 
AF is less common in patients with accessory pathways, but can be life
threatening. The atria depolarize rapidly (350–600 impulses per minute) 
during AF. In a normal individual, the AV node protects the ventricles
from this rapid erratic electrical activity. If AF occurs in a patient with an
accessory pathway that is capable of rapid anterograde conduction, rapid 
atrial electrical activity can be conducted directly to the ventricles, 
resulting in a very fast ventricular response that can lead to 
haemodynamic collapse, or degenerate to VF. The ECG will show an
irregularly irregular rhythm with a variable QRS morphology (due to 
most complexes being conducted via the pathway, leading to a broad QRS 
morphology, with a minority conducted via the AV node leading to a 
narrow QRS morphology). 
Treatment 
In patients with WPW sydrome who present with the common form of
narrow complex orthodromic tachycardia and who are not 
haemodynamically compromised, initial drug therapy is appropriate. As a
general principle, drugs that predominantly block AV nodal conduction
should be avoided in patients known to have an accessory pathway. In
certain circumstances, AV nodal blocking drugs can cause tachycardia 
acceleration (for instance, in patients with AF and a pathway capable of
rapid anterograde conduction). It is therefore preferable to use a drug that 
acts predominantly to slow accessory pathway conduction. Intravenous
flecainide 2 mg/kg (maximum 150 mg) has a good safety profile in a 
patient with an accessory pathway, and will terminate more than 80 per 
cent of episodes. If flecainide fails, consult a senior colleague before 
administering another drug. If the patient is haemodynamically 
compromised with the tachycardia, DCC is the treatment of choice. 
When AF occurs in a patient with a pathway capable of rapid anterograde 
conduction, the ventricular rate can exceed 250 bpm. These rapid 
ventricular rates are often associated with haemodynamic compromise or
heart failure, and urgent DC cardioversion is required. If the AF is slower 
































and well tolerated, a drug that slows accessory pathway conduction (such 
as flecainide 2 mg/kg IV) can be used to slow the ventricular rate and 
restore sinus rhythm. 
Because of the inherent risk of sudden death, all patients with an
accessory pathway should be reviewed by an electrophysiologist to plan
an optimal investigation and treatment strategy. The most dangerous
pathways are those that are capable of rapid antegrade conduction from
atria to ventricles. Concealed pathways and pathways that show
intermittent pre-excitation or pre-excitation that disappears with
exercise are unlikely to be capable of rapid antegrade conduction, but
electrophysiological characterization of the conduction characteristics of 
the pathway is more reliable than inspection of the surface ECG.
Ablation is highly successful and low risk, and should be considered for
all patients with an accessory pathway (the risks of long-term
antiarrhythmic drug therapy are probably greater than the procedure-
related risks of EPS and ablation). 
ATRIAL TACHYCARDIA 
Atrial tachycardia is relatively rare. Unifocal atrial tachycardia arises
from a single repetitively discharging area of micro re-entry or
enhanced automaticity. During the arrhythmia the ECG will usually
show a regular narrow complex tachycardia with a rate of 120–240 bpm
(Figure 3.4). Each QRS complex will be preceded by a morphologically
abnormal P wave, usually best seen in V1. An upright P wave in V1
indicates the tachycardia is due to a left atrial focus, a positive P wave in
AVL indicates a right atrial origin. The arrhythmia can arise in patients
with structural heart disease leading to atrial dilatation or dysfunction,
particularly in patients with cardiorespiratory co-morbidities, but
commonly no cause is found. Atrial tachycardia is often resistant to
drug therapy. Nodal blocking drugs will not terminate the arrhythmia,
but may slow the ventricular rate. Antiarrhythmic drugs that stabilize
atrial electrical activity (such as sotalol, f lecainide and amiodarone) may
terminate the arrhythmia. If drug therapy fails, overdrive pacing or
cardioversion should be considered.  Unifocal atrial tachycardias are
readily treated by ablation in suitable patients who have recurrent
symptoms. 
Unifocal atrial tachycardia may arise as a complication of digoxin
toxicity. In this case, digoxin induces a variable degree of
atrioventricular block as well as triggering the discharge of an atrial











































































ectopic focus. The atrial rate is generally 150–200 bpm, and the degree of 
atrioventricular block may f luctuate, producing an irregular ventricular 
rhythm. When atrial tachycardia with variable block complicates 
digoxin therapy: 
• 	 further digoxin therapy should be withheld until the arrhythmia 
resolves 
• 	 beta-blockers should be given (if necessary) to slow the ventricular 
rate 
• 	 potassium should be maintained above 4.0 mmol/L 
• 	Digibind (see Chapter 8) should be considered. 
DCC should be avoided, as it may induce intractable arrhythmias in a 
patient with digoxin toxicity. 
Multifocal atrial tachycardia most commonly arises as a complication 
of r  espiratory disease in acutely ill elderly patients, and is characterized 
by  multiple atrial foci producing constant variation in the P-wave 
morphology and a variable atrial rate (Figure 3.5). Therapy consists of 
ensuring that the potassium level is adequate, treating the underlying 




A tachycardia with broad QRS complexes can be due to: 
• 	VT 
• 	 supraventricular tachycardia in a patient with pre-existing or 
rate-related bundle branch block 
• 	 supraventricular tachycardia in a patient with an accessory 

pathway that is capable of anterograde conduction.
 
A series of clinical and ECG guidelines can be used to determine the 
site of tachycardia origin. The patient’s general clinical state is no guide 
to the site of tachycardia origin. The degree of haemodynamic 
compromise that occurs depends on the ventricular rate and left 
ventricular function. A rapid supraventricular tachycardia in a patient 
with left ventricular dysfunction may cause major haemodynamic 
collapse, whilst a slow VT may be well tolerated in a patient with good 
left ventricular function. If the patient is not severely compromised, 
clinical assessment, a 12-lead ECG or the use of IV adenosine helps to
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identify the site of origin of a broad complex tachycardia. The useful 
features are: 
• 	A totally irregular broad complex tachycardia is likely to be AF 
with bundle branch block or an accessory pathway. 
• 	Capture or fusion beats, independent P waves that are dissociated 
from ventricular activity or clinical evidence of AV dissociation 
(cannon waves or variable intensity S1) confirm that the 
tachycardia is VT. 
• 	A broad QRS (>140 ms), marked axis deviation, ventricular 
concordance, a deep S wave in V6 or an RSr pattern in V1 suggest a 
ventricular origin (Figure 3.6). 
• 	 If an IV adenosine bolus has no effect on the tachycardia, it is 
probably VT. If the arrhythmia terminates, it is probably of 
supraventricular origin. The transient period of AV block 
associated with adenosine administration may allow visualization 
of atrial fibrillation, flutter or tachycardia activity. 
It is important to remember that the vast majority of broad complex 
tachycardias are due to VT, particularly if the patient is known to have 
structural heart disease. Intravenous verapamil should never be given to 
a patient with a broad complex tachycardia as it may cause severe and 
intractable haemodynamic depression if the tachycardia is VT. If doubt 
as to the diagnosis remains after clinical assessment, inspection of the 
ECG and administration of adenosine, then the arrhythmia should be 
treated as VT. 
Monomorphic VT 
The commonest cause of monomorphic VT is ischaemic heart disease. 
Monomorphic VT occurring early in the course of an ACS is usually due to 
enhanced automaticity in an infarcting segment of myocardium. 
Monomorphic VT occurring late after an ACS is usually associated with 
re-entry in scar tissue. Less common causes include cardiomyopathy, 
myocarditis, arrhythmogenic right ventricular dysplasia, valvular heart 
disease, or scarring associated with cardiac surgery. Occasionally, 
monomorphic VT can arise in an entirely normal heart. The occurrence of 
monomorphic VT with a left bundle and right axis configuration in a patient 
with a normal heart indicates that the arrhythmia is arising from the right 
ventricular outflow tract. A relatively narrow QRS duration suggests that the 
origin of the tachycardia lies close to the bundle of His (fascicular VT). Both
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these tachycardias can be terminated by adenosine and are amenable to 
radiofrequency ablation. If the resting ECG shows T-wave inversion in 
V1–V3 and there is a family history of palpitations or sudden death, 
arrhythmogenic right ventricular dysplasia is a possibility. If the arrhythmia 
is exercise induced in a structurally normal heart, right ventricular outflow 
tachycardia is a possibility.  If there is evidence of conduction tissue disease 
then bundle branch re-entry tachycardia should be considered. 
Monomorphic VT consists of a rapid succession of ventricular ectopic 
beats occurring at a rate >120 bpm. The rhythm will be predominantly 
regular and each successive ventricular complex will have a uniform 
appearance. The regularity and morphology of the tachycardia may be 
intermittently altered by the occurrence of capture of fusion beats. 
Monomorphic VT that lasts for less than 30 seconds is defined as 
non-sustained. A right bundle branch block configuration indicates a left 
ventricular origin for the tachycardia, whilst a left bundle branch block 
configuration indicates a right ventricular origin. Treatment of sustained 
monomorphic VT is detailed in Chapter 1. If the monomorphic VT is not 
clearly related to an ACS, there is a high risk of recurrence, and expert 
investigation is required to determine the underlying cause. The 
investigations to consider are: 
• 	 coronary angiography to evaluate the presence and extent of 
coronary artery disease in patients with ischaemic heart disease 
• 	 cardiac imaging with echocardiography or MRI to evaluate cardiac 
structure and function in patients with cardiomyopathy 
• 	 stress testing to look for exercise-induced ischaemia or VT. 
If an identifiable precipitating factor such as cardiac ischaemia can be 
identified, this should be treated before using antiarrhythmic drugs. If 
there is no clear treatable factor, drug therapy or implantation of an 
implantable cardioverter defibrillator (ICD) should be considered. An 
ICD is preferable if the VT was associated with cardiac arrest, major 
haemodynamic compromise, the patient has an ejection fraction of 
<35 per cent or an abnormality such as cardiomyopathy is present. If the 
patient is not suitable for ICD implantation, drug therapy is an inferior 
alternative. The most effective drugs to prevent recurrence of VT are 
beta-blockers, sotalol and amiodarone. 
Polymorphic VT 
Polymorphic VT is characterized by repeated progressive changes in QRS 
morphology and orientation, producing an appearance of twisting







around the baseline (Figure 3.7). Polymorphic VT in the absence of 
QT prolongation is mainly associated with ACS, and is dealt with 
in C  hapter 1. Polymorphic VT occurring in association with QT 
prolongation is termed Torsade de Pointes tachycardia. This type of 
VT occurs when abnormal ventricular repolarization with resultant QT 
prolongation occurs due to bradycardia, hypokalaemia, hypomagnesaemia 
or drugs. The common drugs associated with QT prolongation are 
antiarrhythmics, antibiotics, antihistamines and antipsychotics. Rarely, 
QT prolongation may be congenital, when it is due to inherited or 
sporadic genetic defects of myocyte potassium and sodium channels. 
Treatment consists of: 
• 	withdrawal of any implicated drugs 
• 	 treatment of sustained episodes with DCC if associated with 
haemodynamic collapse 
• 	 pacing at 100 bpm to shorten the QT interval 
• 	 giving IV magnesium 8 mmol stat then 2.5 mmol/h infusion for 
24 hours. 
In patients with congenital QT prolongation, beta-blockade (excluding 
sotalol), sympathectomy or an ICD may be required. 
Ventricular fibrillation 
The commonest cause of VF is ischaemic heart disease, and it is 
responsible for 90 per cent  of deaths related to ACS. The emergency 
management of VF is dealt with in Chapters 1 and 2. If VF occurs in the 
absence of evidence of an ACS, careful investigation is required as 
described for VT. All patients who survive an episode of VF not associated 
with ACS should be considered for an ICD, as this is prognostically more 
effective than drug therapy. 
BRADYARRHYTHMIAS 
Background 
Bradyarrhythmias arising as a complication of ACS (particularly inferior
STEMI) are dealt with in Chapter 1. Bradyarrhythmias that are not related
to an ACS are most commonly due to idiopathic fibrosis of the conduction
system (which is more common in the elderly), although a wide range of
other cardiac conditions can occasionally be responsible. These 


































































First degree heart block (prolongation of the PR interval to >200 msec) 
signifies slow conduction of electrical activity from atria to ventricles
(Figure 3.8). First degree block does not cause symptoms, and can occur 
in young people in association with high vagal tone. In older individuals 
it may indicate the presence of underlying fibrosis in the conduction
system with a risk of progression to higher grade AV block. In second 
degree block there is intermittent failure of conduction of atrial impulses
to the ventricles, manifest as a P wave not followed by a QRS complex. In
Mobitz type 1 (Wenckebach) second degree AV block, a progressive
increase in impaired conduction in the AV node occurs with each
successive sinus beat. This leads to a progressive prolongation in the PR
interval until an atrial impulse fails to be conducted, resulting in a 
dropped beat. After the dropped beat, AV conduction recovers and the 
sequence is repeated. Mobitz type 1 block can be a benign phenomenon 
occurring in normal individuals with high vagal tone, particularly 
during sleep. In the absence of high vagal tone in a younger individual, 
Mobitz type 1 block is associated with a significant risk of progression to 
high degree AV block with symptoms. In Mobitz type 2 second degree
AV block, impaired conduction in the bundle of His or bundle branches
leads to intermittent failure of conduction of atrial impulses to the 
ventricles without preceding lengthening of the PR interval. These 
patients often have associated bundle branch block and axis deviation 
(bifascicular block), occasionally with associated PR interval
prolongation, reflecting extensive disease in the bundle of His. Patients 
with Mobitz type 2 block have extensive conduction system disease and 
are at increased risk of Stokes–Adams attacks, slow ventricular rates and 
sudden death. Complete heart block occurs when there is total failure of
conduction of electrical activity from atria to ventricles (Figure 3.9).
Complete heart block can be due to disease at nodal or bundle of His 
level. If the block is at nodal level, the escape rhythm that results will be
narrow complex, stable and usually fast enough to support an adequate 
circulation. In patients with extensive disease in the bundle of His, the
subsidiary pacemaker will be low in the conduction system, producing a 
slow, unreliable broad complex escape rhythm, with an increased risk of 
major symptoms. 
Sino-atrial node disease 
When fibrosis predominantly affects the sinus node and atria, sino-atrial
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ARRHYTHMIAS 
by a variety of often intermittent tachy- or bradyarrhythmias. The 
common rhythm disturbances are: 
• 	 sinus bradycardia 
• 	 sinus arrest 
• 	 atrial flutter or fibrillation. 
In up to one-third of these patients the fibrotic process extends into the 
AV node and heart block coexists. 
Clinical features and management 
The electrocardiographic features of heart block are discussed in Chapter 1. 
In SAN disease the ECG shows sinus bradycardia, sinus arrest, atrial 
fibrillation or flutter and sometimes AV block (these features may only be 
evident with prolonged rhythm monitoring). First degree and Mobitz type 1 
AV block do not cause symptoms. If the conduction disturbance is not clearly 
associated with high vagal tone, close monitoring is required as higher grade 
AV block may develop. In patients with bifascicular block, there is a small 
risk of progression to complete heart block, but pacing in the absence of 
symptoms is not required. If general anaesthesia is required for non-cardiac 
surgery in a patient with bifascicular block and prolongation of the 
PR interval (trifasicular block), many authorities recommend prophylactic 
temporary pacing to guard against sudden complete heart block. 
In Mobitz type 2 and complete heart block a slow ventricular rate may cause 
tiredness, dyspnoea or heart failure. If the escape rhythm is unreliable or 
intermittently fails, syncope or sudden death may occur. Patients with SAN 
disease have bradyarrhythmia-related syncope or dizziness which may be 
associated with palpitations due to tachyarrhythmias. 
Patients who present with symptomatic bradyarrhythmias due to chronic 
conduction system disease may require short-term support to maintain an 
adequate heart rate. If there is a history of dizziness or syncope associated 
with a ventricular rate of <40 bpm (particularly if the escape rhythm is 
broad complex), or pauses of >3 seconds, then treatment is required. The 
options are: 
• 	 to commence an isoprenaline infusion (Appendix A) to increase 
the ventricular rate 
• 	 to apply an external pacing system for temporary rate support 
• 	 to insert a temporary pacing wire. 
The complication rate for temporary pacing is high for inexperienced 















appropriately skilled operator, and are discussed in more detail in 
Chapter 2. If temporary pacing is used, the femoral vein provides a good
access site that minimizes the risk of access site complications and also 
reduces the amount of pacing lead manipulation required. If the patient has 
a rate of >40 bpm with a narrow complex escape rhythm and no long
pauses, it is appropriate to monitor the rhythm in a coronary care unit 
environment, avoiding rhythm support initially. All patients with
symptomatic chronic bradyarrhythmias should be considered for 
permanent pacing. 
KEY POINTS 
• 	 Selecting the best treatment depends on the mechanism and effect
of an arrhythmia. 
• 	QRS duration is not a totally reliable guide to the site of origin of an
arrhythmia. 
• 	Antiarrhythmic drug therapy has many limitations (due to poor 
efficacy and side effects). 
• 	AF is common – treatment depends on the duration of the 
arrhythmia and its haemodynamic effects. Atrial flutter is
relatively uncommon, and is treated in a similar fashion to AF. 
• 	The commonest cause of recurrent narrow complex tachycardia is
AV nodal re-entry (which usually can be terminated by adenosine). 
• 	Accessory pathways are not always associated with an abnormal
resting ECG. The commonest associated arrhythmia is a regular 
narrow complex tachycardia with P waves visible between QRS 
complexes; AF is rare but can be dangerous. 
• 	A broad complex tachycardia can be due to VT, bundle branch
block or an accessory pathway. Most of these tachycardias are VT. 
• 	Many bradyarrhythmias are well tolerated and emergency pacing 
should be avoided if possible. 
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BACKGROUND 
Epidemiology 
In a small proportion of patients with hypertension, an accelerated phase of
the disease may develop into malignant hypertension. This presents 
clinically as a hypertensive emergency with marked elevation of blood
pressure accompanied by end-organ damage. The frequency of
hypertensive emergencies is declining due to widespread early treatment of
less severe hypertension, with contemporary incidence rates of around 
1 per cent in hypertensive subjects. A hypertensive crisis is commonest in 
the young black male population. 
This accelerated phase may present us a medical emergency in which
the blood pressure should be reduced immediately to avoid irreversible
target organ damage. The urgent need for blood pressure control is
most acute where life-threatening complications such as an aortic
dissection or encephalopathy occur. Any hypertensive condition can
develop into a crisis, although it is commoner in secondary forms of the
disease such as with phaeochromocytoma and in renovascular
hypertension. Prior to the introduction of effective antihypertensive
therapy, less than 25 per cent of patients with malignant hypertension
survived 1 year, with a 1 per cent 5-year survival. In the current era with
renal dialysis support, 1- and 5-year survival is 90 per cent and 80 per
cent, respectively. In severe hypertension, early death is usually due to
stroke or acute renal failure. In the longer term, coronary artery disease
becomes the commonest cause of death. 
Hypertensive emergencies are most common in patients with
long-standing, poorly controlled chronic hypertension, often following an
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abrupt cessation in antihypertensive therapy. In these patients, chronic 
vascular changes provide a degree of protection to the end organs. In
previously normotensive patients who develop an acute rise in blood
pressure (for example, as a complication of acute renal failure or
pregnancy) there are no chronic vascular adaptive changes to limit the 
adverse effects of the hypertension, and severe end-organ damage can 
occur at lower pressures. 
Pathophysiology 
Any cause of hypertension can lead to a hypertensive emergency
(Table 4.1).  The likelihood of severe adverse effects is highest in
patients who develop a rapid increase in systemic blood pressure: the 
vascular adaptation to chronic hypertension reduces the likelihood
of end-organ damage, with the corollary that in the absence of 
pre-existing hypertension, a hypertensive emergency can occur at a lower 
pressure. A hypertensive emergency occurs when sustained diastolic 
blood pressure is above 130 mmHg leading to a risk of end-organ
damage. 
The exact initiating step in a hypertensive crisis is not well understood.
There is a cascade of physiological decompensation initiated by a
critical degree of hypertension, which occurs both systemically and
locally in vascular beds. An increase in vasoreactivity occurs. The
renin-angiotensin-aldosterone system is crucial in the development of
this hyper-reactivity. Angiotensin II is a potent vasoconstrictor and
also has direct cytotoxic effects on endothelium through activation of
gene expression or pro-inflammatory cytokines such as interleukin-6
(IL-6) and the transcription factor, NF-κb. Inhibition of tissue
angiotensin converting enzyme (ACE) can prevent malignant
hypertension in transgenic mice. Systemically, there is activation of the
sympathetic nervous system, the renin-angiotensin-aldosterone system
and increased release of antidiuretic hormone. This leads to systemic
vasoconstriction and a rise in vascular resistance, as well as an increase
in circulating blood volume. Paradoxically, the baroreceptor response
to this is overwhelmed with a further increase in circulating
vasopressor hormones. Locally, free radical production and endothelin
release is associated with further endothelial dysfunction, growth
factor release and vascular smooth muscle cell proliferation
diminishing local vascular autoregulation. Progressive endothelial
dysfunction through pro-inf lammatory cytokines with up-regulation
of endothelial adhesion molecules (such as E- and P-selectin) promotes






Table 4.1  Causes of hypertensive emergencies 
Essential hypertension 
Renal parenchymal disease 
• acute glomerulonephritis 
• renal vasculitis 
• haemolytic uraemic syndrome 






• hypheradrenalism (Cushing’s syndrome) 
• renin-secreting tumours 
Drugs 
• cocaine abuse 
• sympathomimetic abuse 
• erythropoietin in haemodialysis patients 
• cyclosporin A 
• interactions with monoamine oxidase inhibitors (tyramine ingestion) 
Autonomic hyper-reactivity 
• Guillain–Barré syndrome 
• acute intermittent porphyria 
Neurological disease 
• head injury 
• cerebrovascular accident 
• brain tumours 
local inf lammation. An increase in vascular permeability and
activation of the coagulation cascade is the consequence of this,
promoting further vasoconstriction. The end result of these adverse
changes in neuroendocrine and vascular function is an acute rise in
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blood pressure, with diastolic pressures consistently exceeding 
130 mmHg. The severe elevation in blood pressure leads to widespread 
fibrinoid necrosis in small arteries and arterioles. Thrombotic 
occlusion of these damaged vessels is common, leading to infarction in 
end organs. These damaged vessels also exhibit increased permeability 
leading to tissue oedema. 
There are several important vascular beds which are at risk during a 
hypertensive emergency: 
• 	  Cerebrovascular: hypertensive encephalopathy is an acute medical 
emergency characterized by headache, irritability, an altered 
conscious level, seizures and coma. The acute diffuse neurological 
effects of malignant hypertension are reversed by prompt reduction 
in the blood pressure. Other potential complications of a 
hypertensive crisis are intracerebral or subarachnoid haemorrhage, 
and thrombotic infarction in individuals with predisposing 
atherosclerotic cerebrovascular disease. 
• 	  Cardiovascular: acute left ventricular failure (LVF) or an acute 
coronary syndrome may occur due to the inability of a stiffened, 
hypertrophied left ventricle to cope with a sudden rise in systemic 
vascular resistance. Acute aortic dissection is a potential 
complication of a hypertensive crisis, particularly in patients with 
cystic medical necrosis of the thoracic aorta. 
• 	  Renal: haematuria and progressive renal failure can occur. 
The commonest clinical manifestations are of cerebral infarction (25 per 
cent), pulmonary oedema (23 per cent), encephalopathy (16 per cent) and 
congestive cardiac failure (12 per cent). 
Clinical features 
Malignant hypertension is associated with a persistent diastolic pressure 
of greater that 130 mmHg. Other diagnostic clinical features of malignant 
hypertensive crisis include: 
• 	 hypertensive retinopathy 
– haemorrhage, exudates and papilloedema (grades 3 and 4 
hypertensive retinopathy) 
• 	hypertensive encephalopathy 
– headache, confusion, altered consciousness, leading to seizure 
activity and coma 
 
HYPERTENSIVE EMERGENCIES 
• acute renal failure 
– protein and red blood cells noted on urinalysis 
– hypokalaemia from secondary hyperaldosteronism 
– oliguria may ensue 
• microangiopathic haemolytic anaemia 
When any of these features are present, immediate treatment to lower 
blood pressure is required. 
Miscellaneous situations 
In certain other hypertensive crises, an immediate reduction in blood 
pressure is required: 
• phaeochromocytoma 
• food or drug interactions with monoamine oxidase inhibitors 
• head injury 
• post-operative bleeding 
• severe, uncontrollable epistaxis 
There are other clinical situations where a quick rather than immediate 
reduction of blood pressure is required: 
• malignant hypertension with no end-organ compromise 
• rebound hypertension after drug withdrawal 
• severe hypertension post-surgery 
• severe widespread burn injury 
CLINICAL EVALUATION 
History 
An accurate history of the duration and severity of any pre-existing 
hypertension must be established. It is equally important to establish the 
presence of end-organ damage, such as hypertensive renal disease and 
cerebrovascular disease. Symptoms of target organ injury may be present: 
• anterior chest pain:  myocardial ischaemia, acute aortic dissection; 
• posterior chest pain: aortic dissection; 
• dyspnoea: acute pulmonary oedema, acute heart failure; 
• altered consciousness/seizures:  encephalopathy. 
It is important to take a complete drug history to establish both any 
pre-existing therapy and the possibility of recent drug withdrawal or 
non-compliance. The recreational abuse of cocaine or other 
sympathomimetic drugs should be considered. 
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• 	Blood pressure measurement – in both arms, erect and supine 
• 	Cardiovascular examination – presence of heart failure (raised 
jugular venous pressure (JVP), third heart sound, pulmonary 
crepitations) 
• 	Neurological examination – conscious level, visual fields, focal 
pyramidal signs 
• 	 Fundoscopy – new haemorrhages, exudates and papilloedema 
indicate a hypertensive emergency. 
Investigations 
Initial investigations: 
• 	Biochemistry – urea, creatinine and electrolytes 
• 	Haemotology – full blood count, including a blood film for 
evidence of haemolysis 
• 	 12-lead ECG – to exclude/confirm ischaemia, to indicate left 
ventricular hypertrophy 
• 	Chest x-ray – look for evidence of heart failure or dissection 
• 	Urinalysis – red blood cells, protein. 
Additional investigations should include: 
• 	 echocardiography 
• 	 renal ultrasound scan 
• 	 computed tomography of thorax and abdomen, and 
• 	magnetic resonance renovascular and neuro-imaging (see below). 
MANAGEMENT 
The treatment of a hypertensive crisis is based on consensus rather than
on randomized controlled trials. The first principle of care is that a
hypertensive emergency patient is managed in a high-dependency
environment with withdrawal of any potential treatments that may be
exacerbating the situation. This allows for accurate and continuous
blood pressure monitoring with an arterial line. Treatment should be
initiated by the intravenous route and titrated against the
antihypertensive response. Combination therapy is preferred to achieve
an additive effect and may be tailored towards any compromise in a
particular end organ. In aortic dissection, a combination of intravenous
beta-blockade (labetalol, which is a mixed alpha- and beta-blocker)
given first followed by sodium nitroprusside is the preferred therapy. In














    













with beta-blockade gives maximum anti-ischaemic effect, albeit with a
diminishing antihypertensive effect over time. In aortic dissection, a
relatively rapid reduction in systolic blood pressure (SBP) to <110 mmHg
should be aimed for. In hypertensive encephalopathy, centrally acting
drugs should be avoided, and the aim should be to reduce mean arterial
pressure (MAP) by 25 per cent over 8 hours. Where cerebral infarction
has occurred, rapid reductions in blood pressure should be avoided to
avoid cerebral hypoperfusion in the context of impaired autoregulation,
and care must be taken if fibrinolytic therapy is being considered. In
cases of intracerebral haemorrhage, blood pressure lowering should also
be performed gradually. When  associated with signs of increased
intracranial pressure (ICP), MAP should be maintained just below
130 mmHg (or SBP <180 mmHg) for the first 24 hours. For those without
increased ICP, a MAP <110 mmHg (or SBP <160 mmHg) should be
maintained for the first 24 hours.
SPECIFIC DRUG THERAPY 
Sodium nitroprusside 
This short-acting arterial and venous dilator is first-line therapy for 
a hypertensive emergency. It has an immediate effect and its dose
may be titrated against its efficacy. This will allow the simultaneous
administration of oral antihypertensive agents, facilitating
discontinuation of the nitroprusside infusion before the risk of 
thiocyanate toxicity. It is given in a dose of 0.25–10 μg/kg/min. 
Labetalol 
This mixed alpha- and beta-adrenergic blocker is the other mainstay
of therapy in a hypertensive emergency. Although its beta-blocking
effect is weaker than conventional beta-blockers, it can be given in bolus
form at a dose of 20–80 mg in addition to an intravenous infusion of
2 mg/min. 
ACE inhibition 
These drugs are effective in lowering blood pressure within 15 minutes of
an intravenous bolus such as enalaprilat (1.25–5 mg), with an effect lasting 
at least 4 hours. However, precipitous falls may occur in patients with
hypovolaemia or significant renovascular disease. In accelerated
hypertension, a pressure-induced natriuresis may occur, leading to the 
confounding physiological situation of hypovolaemia in the setting of 
hypertension. 
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This drug is approved for use in hypertensive emergencies. It is a
peripheral dopamine-1 receptor agonist, which peripherally vasodilates 
with an additional potent vasodilating effect on renal arteries. It has a
quick onset (5 minutes) and is used at a dose of 0.1–0.6 μg/kg/min. In one 
study compared with sodium nitroprusside, fenoldopam improved renal 
dysfunction in severely hypertensive patients with renal impairment. 
Glyceryl trinitrate 
Intravenous GTN (5–100 μg/min) is of particular use where significant
coronary artery disease coexists with a hypertensive emergency. Although
not a potent therapy for hypertension itself, the restoration of the 
imbalance between myocardial demand and supply through reduction in
intramyocardial wall tension, preload reduction and improved collateral
blood supply is of benefit, particularly when used in conjunction with
beta-blockade. Like sodium nitroprusside, afterload reduction is of
benefit in the presence of LVF. 
A recent systematic review of 15 randomized controlled trials was unable to
find evidence that antihypertensive drugs reduced mortality or morbidity
in patients with hypertensive emergencies (there were no randomized
studies specifically addressing this issue). Further, there was insufficient
evidence to determine which drug or drug class was most effective in
reducing mortality and morbidity. Whilst there were some small differences
in degree of blood pressure lowering among classes, the clinical significance
was unclear. The review demonstrated evidence of blood pressure lowering
efficacy for nitrates, ACE inhibitors, diuretics, alpha-adrenergic
antagonists, calcium channel blockers and dopamine agonists. Nitrates
(including nitroprusside) were the most studied group, making this class of
drug a reasonable choice of therapy in hypertensive emergencies. 
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Hypertensive encephalopathy 
There are both functional and structural processes which occur in the 
brain when there is an acute sustained increase in systemic blood pressure. 
The functional response to an excessive perfusion pressure is cerebral
arteriolar vasodilatation (rather than vasoconstriction as expected) and a 
loss of microcirculatory autoregulation, leading to the leakage of fluid into 
the perivascular space and cerebral oedema. With acute endothelial injury, 









permeability independent of the renin-angiotensin-aldosterone system. 
This leads to disruption of the blood–brain barrier, cerebral oedema and 
micro-haemorrhage. The normal range over which vital organs such as the 
brain and the heart autoregulate blood flow in the face of varying 
perfusion pressure (MAP) is between 60 and 120 mmHg. In patients with
pre-existing hypertension, this autoregulatory range is increased to 
between 110 and 180 mmHg through an increase in the intimal area of the 
larger resistive vessels (pre-arterioles) that deliver perfusion to the smaller 
resistive vessels (arterioles). These former vessels are influenced by the 
perfusion pressure and cerebral blood flow, and by myogenic tone. 
Conversely, in patients with no previous hypertension, signs of
encephalopathy can occur at a pressure as low as 160/100 mmHg. Thus, the 
clinical response is largely dependent on whether the patient develops the 
hypertensive crisis in the context of a previously normal blood pressure. 
Hypertensive encephalopathy is characterized by the acute onset of
lethargy, confusion, headache, visual disturbance and focal or generalized
seizures. If untreated, coma, cerebral haemorrhage and death may ensue. 
Intracerebral haemorrhage is particularly likely in thrombotic 
thrombocytopenic purpura and in pre-eclampsia where haemolysis 
occurs with acute liver injury and thrombocytopenia occurs. Magnetic 
resonance imaging with T2-weighting may confirm a posterior 
leucoencephalopathy affecting predominantly the white matter of the 
parieto-occipital regions (largely bilateral). The cerebellum and brainstem 
may also be affected, and occasionally the cerebral cortex. The posterior 
cerebral predilection occurs through a reduction in sympathetic 
innervation accompanying the basilar artery and its branches. 
Hypertensive encephalopathy is reversible, leading to the specific term 
hypertensive reversible posterior leucoencephalopathy syndrome (PLS). It
has been described in both children and adults and may also occur in
non-hypertensive situations such as through drug toxicity (cyclosporin
and tacrolimus [often an acute cause of hypertension], cisplatin and 
interferon-α therapy), acquired immunodeficiency syndrome (AIDS), 
thrombotic thrombocytopenic purpura and after blood transfusion. 
Although the aim of treatment is to bring the diastolic pressure down to 
around 100 mmHg within the first hour, it is important to be aware that 
patients with pre-existing hypertension and elderly patients are at 
particular risk of a watershed infarct with aggressive blood pressure 
reduction. In patients with seizure activity, anticonvulsant therapy using 
intravenous phenytoin or benzodiazepines should be given additionally. 
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Phaeochromocytoma arise from sympathetic ganglia derived from the 
primitive neural crest with 90 per cent  arising from the adrenal medulla,
10 per cent  bilateral and 10 per cent  malignant rather than benign. They
account for up to 0.2 per cent of hypertensive patients. These ‘tumours’,
which are essentially extreme nodular hyperplasia, may occur as part of
the familial multiple endocrine neoplasia (MEN-2) syndrome. They create 
extreme fluctuations in systemic blood pressure with associated
symptoms, although the hypertension becomes persistent in half of
patients. With adrenaline as the predominant catecholamine secreted
(mainly from adrenal medullary tumours), symptoms of an increased 
cardiac output with systolic hypertension, sinus tachycardia, sweating, 
flushing and apprehension occur. Noradrenaline is usually the 
predominant hormone (adrenal and most extra-adrenal tumours), and 
there is an increased peripheral vasoconstriction with diastolic as well as
systolic hypertension with less tachycardia or palpitations. In 45 per cent, 
the hypertension is paroxysmal, and often occurs in response to 
anaesthesia, parturition or pharmacological stress from histamine,
caffeine, beta-blockade or glucocorticoids. Attacks have a variable 
frequency, and the majority (80 per cent) last for less than an hour. Less
commonly, patients with familial tumours are normotensive. 
A direct relationship between high levels of catecholamines and
myocardial injury exists with the potential for myocarditis and acute LVF.
Diagnosis is made simply through a 24-hour urine collection for urinary 
metanephrines. To improve the specificity of this test, patients should 
have monoamine oxidase inhibitors and mixed alpha- and beta-blockers 
(labetalol, carvedilol) discontinued beforehand. The tumour may be
localized by CT scanning with the occasional need for radioisotope 
localization with MIBG. Where possible, phaeochromocytoma should be
resected with careful pre- and peri-operative alpha-adrenoceptor 
blockade (with intravenous phentolamine at 5–10 μg/min) to diminish
vasoconstriction and to allow intravascular volume expansion. 
Hypertensive emergencies in pregnancy 
The term gestational hypertension now covers the clinical syndrome of 
new-onset hypertension in the last trimester of pregnancy. The term 
eclampsia refers to the development of convulsions as a consequence of
acute gestational hypertension (pre-eclampsia). Gestational hypertension 

















differences between parents. Predisposing variables include older 
maternal age, black race, multiple gestations, concomitant renal disease 
and pre-existing hypertension. It is a self-limiting condition with
resolution after delivery and is characterized by sudden weight gain and 
oedema, retinal oedema, proteinuria and an increased plasma urate. An
increased susceptibility to hypertensive encephalopathy exists due to the 
lack of previous hypertension in the mother and thus a breakthrough of
increased cerebral blood flow from autoregulation which may lead to 
cerebral oedema and seizures. 
The unifying cause of gestational hypertension is a reduction in utero­
placental perfusion and subsequent decrease in prostaglandin production, 
and prostacyclin in particular. Although there was a vogue for the use of
low-dose aspirin (<100 mg) to inhibit thromboxane production and 
prevent the development of gestational hypertension, this approach 
remains controversial given the increased risk of excessive bleeding 
during delivery. 
The traditional approach to management has been bed rest and drug
therapy with methyldopa, given its long-term safety profile in pregnancy,
with the use of intravenous hydralazine around the time of delivery.
However, beta-blockers, the alpha-blocker prazosin, labetalol and 
nifedipine have also been used with success. Furthermore, intravenous
magnesium should be given in pre-eclampsia to prevent the development 
of seizure activity. A concern with the use of drugs, particularly 
beta-blockade, in mild gestational hypertension is the risk of intrauterine
growth retardation with little effect on blood pressure control compared
to simple bed rest alone. Should eclampsia supervene, patients should 
receive intravenous diazepam immediately to control seizure activity. 
Haemodynamic monitoring is recommended given the need to optimize 
intravascular volume status in the presence of oliguria (fluid challenge) or
increased loading conditions (vasodilatation). 
Hypertensive emergencies in critical illness 
In critical illness, there are many factors which can increase
catecholamine production and increase vasoconstriction leading to an
acute elevation of blood pressure. Post-anaesthetic sympathomimetic 
stimulation, fluid overload and hypothermia are common causes of 
hypertension in critically ill patients. Hypertensive crises may occur in up 
to 5 per cent  of intensive care unit patients. These may be treated by
non-pharmacological means in the first instance over a period of 
15 minutes, although these measures are likely to be effective only in a 




















minority of patients. Such treatments include the relief of anxiety, pain or
both; correction of hypoxia; patient instrumentation adjustment such as
of mechanical ventilation and nasogastric tubes or urinary catheters; and 
correction of circulating blood volume and electrolyte imbalance. Where 
this proves to be ineffective, sublingual nifedipine 10 mg may be given as
an initial treatment before intravenous therapy is considered.
KEY POINTS 
• 	 In about 1 per cent of patients with hypertension, an accelerated phase 
may occur as part of the progression of the disease and is commonest 
in the young black male population. It is commoner in secondary 
forms of the disease such as with phaeochromocytoma and in
renovascular hypertension. 
• 	Prior to established antihypertensive therapy, less than 25 per cent  of
patients with malignant hypertension survived 1 year, with a 1 per cent
5-year survival. In the current era with renal dialysis support, 1- and 
5-year survival is 90 per cent  and 80 per cent, respectively. Early death 
tends to occur due to stroke or acute renal failure. 
• 	Malignant hypertension is the clinical syndrome where a sudden 
increased systemic blood pressure is likely to result in acute end-organ
injury. The likelihood of this may vary according to pre-existing levels
and to the rate of the acute rise, although it is accepted that a persistent 
diastolic blood pressure of greater than 130 mmHg is likely to result in
vascular injury. 
• 	The clinical features of a hypertensive crisis comprise a diastolic blood
pressure greater than 130–140 mmHg, hypertensive retinopathy, 
hypertensive encephalopathy, acute renal failure and microangiopathic 
haemolytic anaemia (Table 4.2). 
• 	Hypertensive encephalopathy is an acute medical emergency
characterized by headache, irritability and an altered conscious level.
Other potential complications of a hypertensive crisis are an
intracerebral or subarachnoid haemorrhage and a thrombotic 
infarction in an individual with predisposing atherosclerotic
cerebrovascular disease. 
• 	Acute LVF is a common cardiovascular manifestation of a hypertensive 
crisis. Acute aortic dissection and acute coronary syndrome may also
occur.










• a diastolic blood pressure greater than 130 mmHg 
• hypertensive retinopathy 
– haemorrhage, exudates and papilloedema (grades 3 and 
4 hypertensive retinopathy) 
• hypertensive encephalopathy 
–  headache, confusion, altered consciousness, leading to seizure
activity and coma 
• acute renal failure 
– protein and red blood cells noted on urinalysis 
– hypokalaemia from secondary hyperaldosteronism 
– oliguria may ensue 
• microangiopathic haemolytic anaemia 
HYPERTENSIVE EMERGENCIES 
Table 4.2 Clinical manifestations of hypertensive crisis 
• 	A hypertensive emergency patient should be managed in a 
high-dependency environment with withdrawal of any potential
treatments which may be exacerbating the situation. Treatment 
should be initiated by the intravenous route and titrated against
antihypertensive response. Combination drug therapy is preferred to 
achieve an additive effect and may be tailored towards any compromise
in a particular end-organ. 
• 	 Sodium nitroprusside (a short-acting arterial and venous dilator)
is a first-line therapy for a hypertensive emergency. It has an
immediate effect and its dose may be titrated against its efficacy and 
allow the administration of oral antihypertensive agents to 
allow discontinuation before the risk of thiocyanate toxicity. 
• 	 Labetalol (a mixed alpha- and beta-adrenergic blocker) is the other 
mainstay of therapy in a hypertensive emergency given as bolus and 
intravenous infusion. 
• 	Gestational hypertension is the clinical syndrome of new-onset 
hypertension in the last trimester of pregnancy. It is more common in
primigravida and in situations where there are racial differences 
between parents. Predisposing variables include older maternal age,
black race, multiple gestations, concomitant renal disease and 
pre-existing hypertension. It is self-limiting with resolution after 
delivery and is characterized by sudden weight gain and oedema,
retinal oedema and proteinuria. 
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BACKGROUND 
Epidemiology 
Dissection of the thoracic aorta is one of the most dramatic acute medical 
emergencies with serious adverse consequences if not diagnosed and treated 
promptly and appropriately. It has been estimated that there are around 
3 cases per 100 000 population per year, most commonly occurring in men 
aged between 50 and 70 years, and more often in the black population. On 
average, left untreated, 50 per cent of patients die within 48 hours (estimated 
at a 1–2 per cent mortality per hour from presentation) with 70 per cent 
dead at 1 week and 90 per cent dead at 3 months. Frequency peaks in the 
morning, possibly related to the circadian variation in blood pressure. 
The International Registry of Acute Aortic Dissection (IRAD), 
established in 1996, has reported trends in the management and outcome 
of the condition. 
Definition and classification 
Thoracic aortic dissection has been classified on anatomical grounds with 
regard to the origin and extent of the dissection and this has major 
implications in the treatment of the condition. The thoracic aorta is most 
likely to dissect at either the ascending aorta or in the descending aorta 
just below the left subclavian artery. The original classification by 
DeBakey described three different types: 
• 	 type I – dissection in the ascending thoracic aorta extending round 
the arch into the descending aorta and into the abdomen; 
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• 	 type II – dissection in the ascending thoracic aorta only with no 
distal extension past the innominate artery; 
• 	 type III – dissection in the descending thoracic aorta distal to the 
left subclavian artery. Retrograde extension may occasionally occur 
back into the thoracic aortic arch and ascending aorta. In one 
follow-up study of aortic dissection, this subtype was subclassified 
into IIIa (limited to thoracic aorta) and IIIb (extension into the 
abdominal aorta). 
The natural history of types I and II are similar and have led to the simpler 
Stanford classification of: 
• 	 type A, where dissection arises in the ascending aorta irrespective 
of its extension; and 
• 	 type B, equivalent to DeBakey type III, but excluding dissections 
with retrograde extension into the arch. 
Rarely, a three-channelled dissection can occur where dissection occurs 
twice in the natural history of an individual patient (A + B or B + B, rarely 
A + A) in whom there is usually a high incidence of Marfan’s syndrome. 
A more recent classification, the Svensson classification, is based on 
the pathophysiological features of the aortic lesion rather than its 
location: 
• 	 class 1: classic aortic dissection with true and false lumen 

associated with an intimal tear;
 
• 	 class 2: intramural haemorrhage or haematoma; 
• 	 class 3: ulceration of aortic plaque following plaque rupture; 
• 	 class 4: subtle or discrete aortic dissection with bulging of the 
aortic wall; 
• 	 class 5: iatrogenic or traumatic aortic dissection, illustrated by a 
catheter-induced separation of the intima. 
Pathophysiology 
Contemporary information relating to clinical factors underlying 
aortic dissection in a large group of subjects is available from the IRAD 
database. Acute aortic dissection is strongly associated with systemic 
hypertension (due to a sustained high intraluminal pressure) and with 
advancing age, but less so with atherosclerosis per se. Cystic medial 
degeneration in the aortic wall is an intrinsic feature of several 
connective tissue disorders which are associated with dissection such 
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giant cell aortitis. These patients are at particular risk of dissection,
often at a young age. There is an increased association with a bicuspid
aortic valve and coarctation of the aorta, and thus with Turner’s
syndrome as well as Noonan’s syndrome. Dissection can be seen in the
last trimester of pregnancy and at the site of a previous surgical
aortotomy. The presence of atherosclerosis per se does not predispose
to thoracic aortic dissection but is associated with saccular aneurysmal
dilatation. However, rupture of an intimal plaque in older patients
remains a mechanism for dissection. In younger patients, cocaine use is
an emerging risk factor. 
Degeneration of the collagen and elastin matrix within the aortic medial
layer is the chief predisposition in most cases of aortic dissection. The 
direct mechanism of dissection is unclear as the same pathological
process may occur either through intimal rupture with secondary 
dissection into media or primary medial haemorrhage with local 
disruption of the intima. 
The formation of a tear in the aortic intima allows penetration of blood
into the diseased medial layer at arterial pressure, separating the
laminar plane of the media and dissecting the aortic wall. This
dissection process may extend a variable distance, usually in an
antegrade direction, but sometimes retrogradely from the site of the
tear. The blood-filled space between the dissected layers of the aortic
wall becomes the false lumen. Shear forces may cause further tears in
the intimal f lap, producing exit sites or additional entry sites for blood
flow in the false lumen. Eventually, distension of the false lumen at
systemic arterial pressure may cause the intimal f lap to bow into the
true lumen, thereby narrowing its calibre and distorting its shape. The
circulation of any major arterial vessel can be compromised by the
dissection process, leading to ischaemia. The aortic valve may be
disrupted, leading to aortic regurgitation. The dissecting process may
rupture through the adventitia at any point, commonly into the
pericardial space or left pleural cavity. 
An intimal tear is not absolute in the pathology of the dissecting 
process as both penetrating atherosclerotic ulceration and intramural
haematoma formation may occur without a discernible intimal 
disruption (see below). It is likely that these conditions may be precursors
of classical dissection rather than separate entities, and all three 
conditions should be considered as belonging to a spectrum of acute 
aortic syndromes.
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CLINICAL MANIFESTATIONS OF AORTIC DISSECTION 
Aortic dissection can mimic several different intrathoracic pathologies in 
the evolution of the symptoms and signs. The common clinical features are: 
• 	 Severe chest pain: this is the commonest symptom of dissection. It 
is as severe at its outset as at any other time and is unremitting. It is 
often described as ‘tearing’ in nature. The pain tends to migrate as 
the dissecting haematoma extends. Anterior chest pain is common 
with proximal dissection whereas interscapular pain is common in 
descending aortic dissection and may be in both areas where a type 
I dissection has occurred. Pain may be noted in the neck and jaw 
where the ascending aorta or arch is involved. 
• 	 Vasovagal symptoms: acute diaphoresis with sweating, 

apprehension and syncope are common.
 
• 	 Altered blood pressure: many patients are hypertensive at 
presentation. Conversely, hypotension may occur through cardiac 
tamponade (from rupture of the intrapericardial aortic root or 
from inflammation of the pericardium), aortic rupture, or 
dissection in the head and neck vessels, leading to a reduced 
perfusion pressure in the brachial artery (pseudohypotension) and 
thus pulse deficits. Pulse deficits are commonly associated with 
proximal dissection in the brachiocephalic vessels or less 
commonly through involvement of the left subclavian artery from a 
distal dissection. The loss of a pulse may occur either through an 
occlusive intimal flap at a vascular orifice or through direct 
compression of an artery lumen. 
• 	 Aortic valve regurgitation: this occurs either through a 
circumferential tear opening up the annulus and reducing 
coaptation, distortion of the valve apparatus through asymmetric 
dissection, or through direct disruption of the annular support, 
leading to a flail leaflet. It occurs in up to two-thirds of proximal 
dissection. If severe, acute left ventricular failure may ensue from 
acute aortic insufficiency. 
• 	 Right coronary artery dissection: leading to an acute inferior 
myocardial infarction (MI). 
• 	 Acute neurological deficits: ischaemic stroke, altered consciousness 
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• 	 Mediastinal complications: these occur through the expansion of
the dissection with compression of the superior cervical
sympathetic ganglion (Horner’s syndrome), compression of the left
recurrent laryngeal nerve (hoarseness), superior vena caval 
compression and tracheal compression. 
• 	 Pleural effusion: usually occurs on the left and is due to 
either rupture into the pleural space or an inflammatory
exudate. 
• 	 Acute rupture: in addition to the pericardial space and pleural and 
intra-abdominal cavities, haemorrhage into the lung, oesophagus
or rupture into right atrium may, rarely, occur. 
• 	 Visceral infarction: mesenteric and renal infarction may occur in
dissections spreading into the abdominal aorta. 
DIAGNOSIS OF AORTIC DISSECTION 
Sudden onset of chest pain is common in several acute cardiovascular 
disorders. Because symptoms may mimic more common disorders such as 
ACS or acute pulmonary embolism (PE), and because characteristic 
physical findings such as a pulse deficit may be absent, dissection may be 
difficult to diagnose. It should be suspected in any patient presenting with 
chest or interscapular pain and diaphoresis. 
Diagnosis is established with multi-slice computed tomography 
(MSCT), although transoesophageal echocardiogram (TOE) was the 
preferred diagnostic method in some places as it is portable, rapidly 
performed, sensitive and specific, and does not require the use of 
contrast agents. The choice of imaging modality should be determined 
by availability and expertise within individual centres. Where clinical 
suspicion is high, failure to diagnose dissection by one modality should 
prompt further investigation with another technique. 
The important diagnostic investigational features are: 
• 	 12-lead ECG: this may be within normal limits or may show 
evidence of left ventricular hypertrophy due to commonly 
associated hypertension. If the dissection flap occludes one of the 
coronary ostia, this will produce ST elevation consitent with 
myocardial infarction. The right coronary ostium is more 
frequently invoved than the left. 
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• 	 Chest x-ray: a widened mediastinum is a classical finding in
thoracic aortic dissection. There may be an additional local bulge at 
the site of dissection. The presence of a left pleural effusion and 
tracheal deviation is often seen. Separation of calcification in the 
aortic arch from the apparent adventitial border is a powerful sign
of dissection. However, extensive dissection can occur in the 
presence of a normal chest x-ray. 
• 	 Echocardiography: transthoracic echocardiography (TTE) may 
detect a proximal dissection where a dilated aortic root is present but 
is limited in any further delineation of a dissection. The accuracy of
this assessment is also limited by the echogenicity of the patient. 
However, even if a flap is not identified, TTE can readily 
demonstrate several high-risk associated features of dissection: 
aortic root dilatation; presence and severity of aortic regurgitation 
(as well as revealing the presence of e.g. bicuspid valves); pericardial 
effusion; left ventricular regional wall motion abnormalities 
(implying coronary ostial occlusion). TOE allows visualization of the 
aortic root, proximal ascending aorta and descending aorta. With
colour-flow Doppler, entry and exit sites between true and false 
lumen may be identified. With intramural haematoma, an
echolucent crescentic region should be seen over a length of the 
aorta. Occasionally, the haematoma is circumferential and can be
difficult to differentiate from common atherosclerotic thickening. A 
disadvantage is its limited ability to visualize the distal ascending 
aorta and proximal arch due to interposition of the trachea and left 
main bronchus. Furthermore, TOE is unable to image beyond the 
distal thoracic descending aorta and thus cannot assess the iliac 
vessels – an important limitation where endoluminal repair is being 
considered. 
• 	 Multi-slice computed tomography: MSCT with an intravenous
contrast injection to enhance the intraluminal phase is the 
investigation of choice in most acute medical environments, given a 
reported sensitivity and specificity approaching 100 per cent. With
the presence of a membrane (intimal flap), the false and true 
lumina can be identified. The false lumen is usually the larger of
the two. Tomographic imaging enhances the diagnostic accuracy
by demonstrating an abnormal tissue signature, although it is
unable to provide haemodynamic information, and it relies upon
the use of potentially nephrotoxic contrast agents, and may be
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unable to depict branch-vessel involvement. MSCT is also useful in 
the follow-up of dissection by allowing detailed assessment of early 
and late changes after surgery or medical treatment such as 
post-operative complications, healing of intramural haematoma, 
progression of intramural haematoma, and aneurysms of the true 
and false lumina. Monitoring of compromised abdominal branch 
vessels may be performed. CT angiography can demonstrate 
complex spatial relationships, mural abnormalities and 
extraluminal pathologies. 
• 	 Magnetic resonance imaging: MRI may be used as an alternative 
imaging technology without the need for contrast and with 
enhanced resolution. MRI gives an improved anatomic delineation 
of the aorta and can provide high-quality images in several planes, 
including a left anterior oblique view that displays the entire 
thoracic aorta. Furthermore, MRI is superior to conventional CT in 
differentiating acute intramural haematoma from atherosclerotic 
plaque and chronic intraluminal thrombus, which is important 
where there is diagnostic uncertainty. 
• 	 Aortic angiography: with the improvements made in 
echocardiographic and tomographic imaging, invasive 
confirmation of dissection is no longer performed. The intention of 
angiography was to identify the site of origin and to delineate the 
extent of the dissection. The procedure carried with it a significant 
mortality, and currently should only be performed for cases where 
the diagnosis is uncertain after other imaging. It is of no help in the 
diagnosis of intramural haematoma. 
There is increasing interest in the identification of highly sensitive and 
specific biomarkers that may aid diagnosis of aortic dissection. Markers 
under scrutiny include D-dimers, elastin fragments and smooth-muscle 
myosin heavy-chain protein. D-dimer assay, widely used in the diagnosis 
of acute PE, seems to be potentially useful as a rule-out test in aortic 
dissection. 
TREATMENT OF AORTIC DISSECTION 
It is the course and propogation of the dissection rather than the intimal
tear itself that leads to the complications of acute aortic dissection. For
this reason, the modern surgical management of a proximal dissection
has focused on excising the intimal tear and obliterating the false lumen
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by oversewing the aortic edges, thus removing the driving force behind 
the propagation of the false channel. An interposition graft may be 
required in the ascending aorta to restore integrity to this section of the 
dissection. If the aortic valve is competent and unaffected directly by the 
dissection, it may be resuspended in the graft at the aortic valve ring or 
it may require replacement with a prosthesis if disrupted. 
Simultaneously, systemic blood pressure and left ventricular 
contractility should be significantly reduced to remove the direct 
pulsatile stress on the aortic wall. 
Immediate therapy 
All patients in whom a thoracic aortic dissection is suspected should be 
monitored and treated in a high-dependency environment for 
haemodynamic and cardiac rhythm monitoring and for central venous 
access. Patients should be cross-matched for the eventuality of either 
dissection or rupture and early surgery. The three initial goals of 
therapy are: 
(1)	  to alleviate pain with intravenous opiate analgesia. 
(2)	  to reduce systolic pressure to a range of 100–120 mmHg, equivalent 
to a mean arterial pressure of 60–75 mmHg, and sufficient to 
maintain vital organ perfusion. 
(3)	  to reduce the velocity of left ventricular ejection (the dP/dt) by
  




Blood pressure lowering is achieved by an infusion of intravenous sodium 
nitroprusside up to a maximum dose of 400 μg/min (5 μg/kg/min). The 
infusion should not be given for more than 48 hours due to the risk of 
cyanide toxicity. Frequent blood gases should be taken for acid–base 
status (a metabolic acidosis tends to develop with cyanide toxicity). 
Concomitant infusion of vitamin B12 (hydroxocobalamin) reduces plasma 
cyanide levels through the formation of cyanocobalamin. Sodium 
nitroprusside reduces the blood pressure but may actually increase the 
dP/dt through afterload reduction. Intravenous beta-blockade is used to 
reduce dP/dt. The most popular agent used is labetalol, which is a 
non-selective beta-blocker and alpha-blocker. It can be given either as 
bolus doses of 5–20 mg up to a total of 300 mg or may be given as an 
infusion (see Appendix A). Beta-blockers (and other rate-limiting agents) 
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Definitive treatment 
The accepted paradigm in dissection management is that surgical
treatment is superior to medical treatment in the management of type A 
dissection, whereas medical therapy is superior in uncomplicated type B 
dissection (see Box 5.1). This comes about through surgery preventing 
progression of dissection and potentially fatal consequences. Patients with
distal dissection tend to be older with atherosclerotic vascular disease,
often with a reduced cardiac reserve, and tend to tolerate surgery less well, 
favouring medical therapy. The attrition rate in patients with proximal
dissection treated surgically occurs through complications having already 
occurred or through the friability of the aortic wall at surgery. 
In practice, the decision to intervene in chronic dissection is based upon
evidence of progressive pathological change over time. In patients with
symptoms or signs of peripheral ischaemia, the indication for 
intervention is clear. In asymptomatic individuals, intervention is
recommended for progressive aortic dilatation (>5 cm maximum 
diameter), and when there is evidence of a persistent false lumen in
communication with the true lumen.
Surgery 
• Acute type A dissection 
• Acute type B dissection with complications 
 – compromised perfusion to vital organs 
 – rupture/ threatened rupture
 –  retrograde dissection to ascending aorta/aortic valve 
regurgitation
 – Marfan’s syndrome 
 – inability or control pain 
 – saccular aneurysm formation 
• Chronic dissection with complications 
 – progressive aortic dilatation (>50 mm maximum diameter)
 –  persistent false lumen in communication with the true 
lumen
 – persistent pain 
Medical therapy 
• Uncomplicated type B dissection 
• Uncomplicated arch dissection 
• Stable chronic dissection 
Box 5.1  Indications for specific treatment of 
aortic dissection 
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Surgery 
Current practice dictates that the proximal dissection should be repaired
early to prevent extension and rupture, and to operate on distal
dissections extending proximally using cardiopulmonary bypass. Of
patients with type A dissections, the IRAD database revealed lower
30-day mortality in surgically treated patients than those treated 
medically (see Clinical outcomes in aortic dissection). 
The goal of surgery is to prevent progression of the dissection and to
relieve obstruction in peripheral branches: thus, the intimal tear is
excised and the origin of the false lumen excluded by proximal and
distal suturing of the edges of  the aorta. A prosthetic Dacron graft may
be needed to approximate the ends of the aorta. Surgery requires a
period of deep hypothermic circulatory arrest. Where the aortic valve is
involved, the false channel is decompressed by the surgery described
above, but may still require replacement or repair. Where the aorta is
very friable, the whole ascending aorta and valve may be replaced using
a composite graft containing a prosthesis with resuturing of the
coronary arteries to the conduit. Preservation of the native aortic valve,
which avoids the complications associated with a prosthetic valve,
usually requires approximation of the two layers of dissected aortic wall
and resuspension of the commissures with pledgeted sutures. However,
prosthetic valve replacement is frequently advisable in the setting of
pre-existent valve disease or in Marfan’s syndrome to reduce the
likelihood of re-operation. 
Surgical fenestration has been used as a means of decompressing an
occlusive false lumen in the descending aorta in patients with visceral or
limb ischaemia. Fenestration may be performed alongside ascending 
aortic surgery and additional abdominal aortic grafting. It should ideally 
be performed within 48 hours of presentation to prevent thrombotic 
occlusion of the false lumen. In one series, surgical fenestration in
decending aortic dissection was associated with mortality rates of 77 and 
53 per cent at 3 and 5 years, respectively. Fenestration can also be done 
percutaneously and is usually done in the pararenal or infrarenal area
(see below). 
Percutaneous interventional treatment 
In type B dissection, the persistence of a false lumen has an adverse effect
of clinical outcome (higher rates of re-operation and mortality) where an
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to where there is thrombosis of the false lumen. The deployment of
balloon-expandable or self-expanding endoluminal stents may be
performed to re-establish flow into branch vessels compromised by
dissection into the origin of the vessel. If a branch vessel is compromised 
by pressure from the false lumen over the origin of the vessel, a 
fenestration procedure may be undertaken to decompress the false lumen. 
Similarly, endoluminal exclusion with a stent graft prosthesis (consisting 
of circumferential nitinol stent springs arranged as a tube and covered 
with a Dacron or polytetrafluoroethylene [PTFE] graft exterior) placed
over the false lumen entry site will decompress the false lumen, causing 
the flap to oppose the aortic wall and relieve branch vessel compromise. 
The advantage of endoluminal exclusion in acute dissection is that it
combines closure of the false lumen and prevents subsequent dilatation
with relief of branch vessel obstruction.
Stent grafts are sized by measurement from pre-procedure imaging.
They require a proximal neck of ideally 20 mm of ‘normal aorta’ above
the false lumen origin to ensure secure deployment against the aortic
wall. The potential for ischaemia through occlusion of the left
subclavian artery may be predicted by preliminary occlusive balloon
inflation for 20 minutes at its origin to assess the integrity of the
collateral circulation, perhaps using a partially covered graft if
necessary. The position of the undeployed graft may be obtained using
aortography, intravascular ultrasound or TOE. The distal neck may be
normal supracoeliac aorta or biluminal descending thoracic aorta. In
the absence of a distal neck, the shortest graft that effectively covers the
entry site is used. 
These techniques are being increasingly used in type B dissections,
particularly when complications ensue. Short-term results from stenting 
may appear encouraging, with overall major events seen in 11 per cent, 
including in-hospital mortality of 5 per cent, stroke rate of 2 per cent, 
paraplegia in 1 per cent. Further, 2 per cent of cases were complicated by
transformation to type A dissection. The INvestigation of STEnt grafts in
patients with type B Aortic Dissection (INSTEAD) trial compared the 
use of covered stents with medical therapy alone for uncomplicated type
B dissection. Short-term results at 12 months indicated equivalent
mortality in patients with uncomplicated acute type B dissection who 
were treated with conventional medical therapy alone or with
endovascular stenting. Registry data relating to 180 patients treated with
the endovascular Talent thoracic stent graft for acute or chronic aortic 
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dissection are also available. Intermediate term (mean 22 months)
follow-up yielded survival rates of 91 per cent and 82 per cent at 24 and 36
months, respectively. Emergency status (vs elective cases) was an
independent predictor of major adverse events. Analysis of the IRAD
database suggests that endovascular treatment seems to provide better 
in-hospital survival in patients with acute type B dissection: in-hospital 
complications occurred in 20 per cent of patients treated with an
endovascular technique and in 40 per cent of patients who underwent
open surgical repair. In-hospital mortality was significantly higher after 
open surgery than after endovascular treatment with a three-fold
increase in risk for open surgical repair. 
Thus, there are many uncertainties relating to use of stent-graft 
techniques in aortic dissection. A key question to be answered by furture 
studies is whether there is any role for stenting with or without 
conventional surgery for type A dissections.
As described above, the fenestration technique may be employed using an
endovascular approach (usually as a bridge to definitive endoluminal
repair) using a needle to pass a guide wire through the intimal flap, then 
balloon dilatation of the puncture site. Several fenestrations can be
performed in order to equalize pressures in the true and false lumina, and 
stenting of branches may be performed to optimize flow. In cases where 
endoluminal repair or fenestration is considered, digital subtraction
angiography, or magnetic resonance angiography, is an essential prelude
to allow assessment of the access arteries (usually the iliacs), measurement 
of the aorta to permit selection of the correct device length and diameter, 
confirmation of branch vessel involvement and biluminal manometry 
prior to fenestration. 
PENETRATING ATHEROSCLEROTIC ULCERATION AND 
INTRAMURAL AORTIC HAEMATOMA 
These entities are radiologically distinct from classical dissection, with
no intimal f lap evident. In penetrating atherosclerotic ulcers (PAU), a 
visible crater extends into the aortic wall and is associated with
haematoma within the media of the aortic wall. An intramural
haematoma (IMH) is present where significant thickening or
enhancement of the aortic wall is seen in the absence of a f lap or
dissection. The clinical features of these two variants may differ from 
dissection. Patients with PAU/IMH are older than patients with both
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and ninth decades. Patients with PAU/IMH are almost always
hypertensive (94 per cent). PAU and IMH are most common in the 
descending aorta (90 per cent and 71 per cent, respectively). PAU and 
IMH tend to occur in more dilated aortas and have an association with
abdominal aortic aneurysms. The presentation with anterior or posterior
chest pain is similar to, and may be indistinguishable from, that of
classical dissection. In one review of over 200 cases presenting as aortic
dissection, one-eighth of cases were reclassified to either PAU or IMH.
However, PAU/IMH generally do not cause arterial vessel compromise
and thus distal limb ischaemia or visceral compromise, and tend to be
focal without propagation. 
Penetrating atherosclerotic ulceration
Penetrating ulcers occur within severely atherosclerotic, frequently 
calcified descending thoracic or abdominal aortae, in contrast to classical
dissection, which is more often associated with hypertension. Ulcers are 
generally focal lesions appearing as an irregular outpouching of the aortic 
wall. Ulceration may precede both IMH or dissection; dissection
following PAU is usually shorter, and contained by neighbouring fibrosis
and calcification, with a thicker flap. When compared to dissection and 
IMH, PAU is most commonly associated with aortic rupture. Optimal
treatment of PAU is yet to be established. Medical treatment has been 
shown to be effective in most patients; additionally, several registries have
shown favourable outcomes with open surgery and endovascular repair in
selected patients. A large series of patients presenting with PAU identified
rupture at presentation as the main indicator of medical failure. Therefore 
these patients are more likely to benefit from early intervention. Patients 
who are asymptomatic or found to have PAU as an incidental finding 
rarely require intervention but should be followed up for any progressive 
increase in size of the ulcer. 
Intramural aortic haematoma 
IMH occurs when blood accumulates in the vessel media in the absence of
a flap. Formation of an IMH may follow rupture of the vasa vasorum, or
from extension of a PAU (which is identified in 20 per cent of IMH). 
Extension of IMH towards the intima may lead to a tear and subsequent 
dissection. It is thought likely that the radial level in the wall at which an
IMH occurs determines whether an acute dissection or haematoma
develops. It may be that if blood collects closer to the adventitia, there is
less likelihood of intimal rupture. This would also explain a higher 
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external rupture rate with IMH, which tends to run a more malignant 
course than typical descending aortic dissection. 
The diagnosis of IMH requires identification of an expanded aortic wall, 
usually <15 mm, without a connection with the aortic lumen. 
Echocardiographically, an aortic wall thickness of >7 mm is diagnostic;
there may be echo-lucent zones seen within a crescentic aortic wall
thickening. 
The classification of IMH is similar to that of classical aortic
dissection (Stanford A and B according to involvement of the
ascending aorta), and this inf luences management as with true
dissection. A meta-analysis of 168 patients with IMH has shown that
around one-quarter of type A IMH progressed to dissection or
rupture. Overall, the 30-day mortality with surgery was 18 per cent
compared to 60 per cent with medical treatment. In contrast, medical
treatment improved mortality compared to surgery in type B patients
(8 per cent vs 33 per cent, respectively). Accordingly, type B IMH may
be successfully managed by medical treatment alone, with
beta-blockers the mainstay of treatment where possible. However,
there are certain features which portend an adverse prognosis in IMH
even without ascending aorta or arch involvement (Box 5.2)
Unfortunately, surgical intervention for type B IMH may be
complicated by paraplegia owing to disruption of blood f low to the
spinal arteries. Endovascular stenting in this setting is an emerging
option, particularly for localized lesions associated with PAU,
although the precise role is currently unclear. 
Box 5.2 High risk features in aortic intramural
haematoma 
• Type A intramural haematoma 
• Increased aortic diameter (>50 mm) 
• Haematoma thickness >11 mm 
• Recurrent chest pain 
• Progressive enlargement 
• Penetrating finger-like projections 
• Pleural or pericardial fluid 
• Associated ulcer with diameter >20 mm or depth >10 mm 
Adapted with permission from Bolger AF Heart 2008; 94: 1670–4. 
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CLINICAL OUTCOME IN AORTIC DISSECTION 
From the International Registry of Acute Aortic Dissection, overall 
in-hospital mortality was 27.4 per cent: 
• Type A 
– surgical management 26 per cent 
– medical management 58 per cent 
• Type B 
– surgical management 31 per cent 
– medical management 11 per cent 
These high mortality rates have been confirmed in several other large 
series. Moreover, for acute disease complicated by end-organ ischaemia, 
surgical mortality exceeds 50 per cent, with a substantial risk (7–36 per 
cent) of paraplegia (or paresis), dependent upon the extent of aortic 
dissection and the duration of cross-clamping, amongst those who 
survive. Chronic aortic dissection (presentation up to 2 weeks after the 
onset of symptoms) has a higher in-hospital survival of around 90 per cent 
whether they are treated medically or surgically, largely through 
self-selection due to the lack of acute complications in the initial phase of 
dissection. 
The initial success of surgical or medical therapy is usually sustained at 
long-term follow-up with typical 5-year survival rates of 75–82 per cent. 
A number of clinical factors have been linked with poor prognosis in 
addition to the anatomy of the dissection. Acute complications at the time 
of acute presentation, such as a cerebrovascular accident, MI, severe aortic 
regurgitation, renal failure, mesenteric infarction and lower limb 
ischaemia, in addition to aneurysmal dilatation of the dissected aorta and 
increasing age, predict an adverse outcome. 
The incidence of aneurysm formation at a site remote from the original 
surgical repair is 17–25 per cent, with the majority appearing within 
2 years. Many arise from dilatation of the residual false lumen in the distal 
unresected aortic segments and are prone to rupture owing to their 
relatively thin outer wall. To identify such a development, careful 
long-term follow-up with serial aortic imaging, usually using MRI, is 
recommended. Patients are at highest risk during the first 2 years and 
should be assessed every 3–6 months during this period. Thereafter, they 
should be re-evaluated every 6–12 months according to their perceived 
individual risk. 
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KEY POINTS 
• 	Acute aortic dissection in a high-mortality condition with a 48-hour
mortality of 50 per cent, with 70 per cent dead at 1 week and 90 per cent
dead at 3 months, if left untreated. With treatment, overall hospital
mortality is 27 per cent. 
• 	Acute thoracic dissection is strongly associated with systemic
hypertension and with advancing age. Several connective tissue 
disorders (of which Marfan’s syndrome is the commonest) are 
associated with dissection due to cystic medial degeneration in the
aortic wall. 
• 	There are pathological variations accounting for one-eighth of cases of
‘aortic dissection’. In penetrating atherosclerotic ulcers (PAU), no 
intimal flap is demonstrable with a crater visible extending into the 
aortic wall associated with haematoma within the media of the aortic 
wall. IMH occurs where significant thickening or enhancement of the 
aortic wall is seen in the absence of a flap or dissection. 
• 	Aortic dissection can mimic different conditions in the evolution of 
the symptoms and signs such as severe chest pain, vasovagal 
symptoms and hypotension, severe hypertension, acute aortic 
regurgitation, myocardial infarction, stroke, pleural effusion and 
visceral infarction. 
• 	The diagnosis is most accurately done with spiral computed
tomography (with contrast enhancement), although TOE has been an
alternative in many centres as it is portable, rapidly performed,
sensitive and specific, and does not require the use of contrast agents. 
MRI gives an improved anatomic delineation of the aorta and can 
provide high-quality images in several planes. Prior to definitive
imaging, high-risk features can be picked up with transthoracic
echocardiography. 
• 	Patients in whom thoracic aortic dissection is suspected should be
monitored and treated in a high-dependency environment, and 
prepared for the possibility of early surgery. The two initial goals of
therapy are pain relief and the reduction of the systolic pressure to a 
range of 100–120 mmHg (equivalent to a mean arterial pressure of
60–75 mmHg and sufficient to maintain vital organ perfusion). Where 
possible, left ventricular contractility should be reduced by 
beta-blockade independently of systemic blood pressure lowering. 
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• 	Urgent surgery is indicated in ascending thoracic aortic dissection and 
in descending thoracic aortic dissection where there are complications 
such as visceral ischaemia, threatened rupture and retrograde 
dissection to ascending aorta. 
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ACUTE PULMONARY EMBOLISM 
CHAPTER 6 
Epidemiology 
Venous thromboembolism (encompassing deep venous thrombosis 
[DVT] and pulmonary embolism [PE]) is a great constant in acute 
medicine with no major difference in its incidence or mortality in the past
20 years. The age- and sex-adjusted incidence rate is 117 cases per 100 000
person-years. The incidence rises particularly in those aged >60 years,
irrespective of gender, largely driven by PE. 
Pulmonary embolism is a life-threatening condition associated with a 
high mortality rate. There is a direct relationship between age and 
mortality. In almost a quarter of patients with PE, the initial clinical
manifestation is sudden death. Mortality is at least 10 per cent in the first 
few hours of presentation and exceeds 15 per cent at 3 months post
diagnosis. Unfortunately, PE is undiagnosed in many cases, and the 
majority of patients with fatal PE do not have specific symptoms to aid 
diagnosis. Indeed, PE occurs more frequently among patients with
alternative causes of dyspnoea, such as those with heart failure and 
chronic obstructive airways disease. For example, the relative risk of PE in
heart failure patients is twice that of those without heart failure, and 
increases as left ventricular systolic function declines. Furthermore, PE
patients with heart failure have higher overall mortality and readmission 
rates than those without heart failure. 
Pathophysiology of venous thromboembolism 
Pulmonary emboli occur following dislodgment of a venous thrombus
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pulmonary arterial circulation. The risk of PE with a proximal DVT 
above the calf is as high as 50 per cent, with a lower risk in thromboses 
confined to the calf. 
The clinical signs of embolism are determined by: 
(1) the level at which the thrombus is occlusive, and 
(2) to what extent pulmonary blood flow is diminished. 
Additional determinants of the clinical effect of embolism include 
the patient’s pre-existing cardiorespiratory reserve, and the humoral 
effect of vasoactive factors such as serotonin and thromboxane 
A2 released by activated platelets at the site of pulmonary artery 
occlusion. These peptides have a direct bronchoconstrictor effect 
in addition to a vasoconstrictor action, and can potentiate the increase 
in pulmonary hypertension due to mechanical effects of the 
thrombus. 
The development of a venous thrombus is triggered by Virchow’s triad 
of local injury, hypercoagulability and stasis of flow. A hypercoagulable 
state is commonly acquired, although there are a few rare primary 
conditions that predispose to a venous thrombus, usually in a younger age 
group (<45 years old) with an unexpected thromboembolism. Such 
hypercoagulable conditions exist in antithrombin III deficiency, protein C 
deficiency, protein S deficiency and in inherited conditions with defective 
tPA (tissue plasminogen activator) release. The presence of the ‘lupus 
anticoagulant’ (with or without systemic lupus) that interferes with 
phospholipid-dependent coagulation is associated with venous 
thrombosis. Some of these patients have anticardiolipin antibodies 
that paradoxically prolong the activated partial thromboplastin time 
(aPTT). 
It is much commoner to see venous thromboembolism in certain clinical 
situations occurring secondary to acquired pro-thrombotic abnormalities 
in coagulation, in platelets and in venous blood flow. The commonest 
situations increasing risk for developing PE include: 
• 	 recent surgery, particularly orthopaedic procedures 
• 	 cancer, with venous thrombosis often occurring before overt 
malignancy 
• 	 an altered hormonal state, such as the early post-partum period in 














Clinical situation Low risk Intermediate risk High risk 
General surgery Age <40 years Age 40–60 years Age >60 years 
Surgery <30 min Surgery 30–60 min Surgery >60 min 
No risk factors + risk factors 
 Orthopaedic Minor trauma Leg plaster cast Hip/knee surgery 
surgery Hip fracture 
Multiple trauma 




Distal DVT 2% 10–40% 40–80% 
Proximal DVT 0.4% 6–8% 10–15%
Symptomatic PE 0.2% 1–2%  5–10% 
Fatal PE 0.002% 0.1–0.8% 1–5% 
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Table 6.1 Incidence of pulmonary embolism in different clinical situations 
Adapted from Riedel (1996). 
Platelet aggregation may be enhanced in heparin-induced 
thrombocytopenia and in myeolproliferative disorders leading to 
thrombosis. Similarly, patients with hyperviscosity syndromes
(polycythaemia, leukaemia and sickle cell disease) are more likely to have
thrombotic complications. Venous thrombosis is common in the
nephrotic syndrome. 
Venous stasis may also be promoted by mechanical variables such as
immobilization with chronic illness and obesity. Prolonged central 
venous cannulation for long-term drug therapy or parenteral nutrition 
can lead to right atrial thrombus formation and subsequent embolism.
The relative risk of pulmonary embolism in different clinical situations is
shown in Table 6.1. 
DIAGNOSIS OF DEEP VENOUS THROMBOSIS 
Venous thromboembolism is a clinical situation where the diagnosis is
more often not made than made. The clinical suspicion of a DVT (leg
swelling, calf tenderness, venous distension of subcutaneous vessels,
discolouration) should be confirmed objectively. This is necessary due to 
the lack of predictive accuracy in the clinical examination: calf pain has
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66–91% sensitivity and 3–87% specificity for DVT. No single investigation
for the diagnosis of DVT has ideal properties (100% sensitivity and 
specificity, low cost, no risk), and often several tests are performed, either 
sequentially or in combination. Contrast venography and pulmonary
angiography for PE were the gold standards for diagnosis through default 
and are largely used for comparison in trials. 
Investigations are often integrated with clinical criteria in order to 
construct diagnostic algorithms. 
D-dimers. Plasma D-dimers are specific cross-linked fibrin derivatives,
formed and released during fibrin degradation by plasmin; thus,
concentrations are elevated with venous thromboembolism. Whilst 
sensitive for diagnosisng venous thromboembolism, elevated D-dimer
levels are non-specific as they occur in other disorders (e.g. during 
infection, in malignancy, after surgery, in heart failure and in pregnancy). 
Nevertheless, D-dimer testing generally has a high negative predictive
value, and is useful in excluding venous thromboembolism when 
combined with clinical probability assessment. 
Compression ultrasound with venous imaging. In the current era,
ultrasonography is the imaging test of choice in confirming suspected 
DVT. The combination of colour Doppler measurement of venous flow
with 2D cross-sectional assessment of lower extremity veins is termed 
duplex ultrasound. It is non-invasive and portable, and can also identify
other causes of calf/thigh symptoms (e.g. Baker’s cysts, haematomas,
lymphadenopathy, femoral artery aneurysm, superficial thrombophlebitis 
and abscesses). Compression of opposing venous walls is applied by the 
transducer, with the primary diagnostic criterion being the 
non-compressibility of a vein. The presence of intraluminal echogenic 
thrombus, venous distension, absence of a colour-flow Doppler signal and 
loss of phasic flow are secondary criteria. Its diagnostic accuracy is limited 
in pelvic and calf DVT, in recurrent DVT and in asymptomatic proximal
DVT, as well as in the presence of severe obesity or oedema. Acute DVT may
be differentiated from chronic DVT by an increased compressibility and 
reduced echogenicity of thrombus seen. Of note, however, ultrasound
findings may not return to normal after a DVT, and ultrasonography may 
be less useful for diagnosing recurrent DVT. For proximal DVT, a
sensitivity of 89–100% and specificity of 95–100% is reported with
ultrasound. In the smaller, more anatomically variable calf veins,
ultrasonographic sensitivity falls to 73–87%, with a specificity of 
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Impedance plethysmography (IPG). This is a safe, non-invasive,
operator-dependent, portable technique which may be used to screen for 
the presence of DVT, particularly in the proximal (rather than calf) deep
veins. The test is based on the principle that the volume of blood in the leg 
affects its ability to conduct an applied current (inversely proportional to 
the impedance in two limb electrodes). Venous outflow is obstructed by a 
thigh cuff that causes a fall-off in impedance. Release of the cuff leads to an
increase in proximal blood flow as well as impedance. If a DVT is present
in a major vein from the popliteals to the iliacs, the rate of venous emptying 
(and increase in impedance) is slower. Studies have demonstrated
sensitivities of 92–98% for symptomatic proximal DVT, compared to a 
sensitivity of only 20% for calf DVT. Negative IPG has been associated with
a small rate of subsequent pulmonary embolism of around 2.5%. Thus, 
plethysmography is only useful for early recurrences where IPG 
normalization has been demonstrated. 
Contrast venography. In light of improvements in ultrasound resolution,
the need for invasive venography has diminished. It should be reserved for 
situations where the ultrasound examination is equivocal or normal
despite a high clinical suspicion. With large extensive deep thromboses, 
the contrast injected in the foot may not reach the deep veins leading to a 
false-negative venogram. Disadvantages include its invasiveness, allergic 
reaction to dye, toxicity from contrast, and the test may rarely actually 
cause DVT through phlebitis. It is relatively contraindicated in acute renal 
failure and in critical peripheral vascular disease. 
Magnetic resonance imaging (MRI). This has a high sensitivity for 
thrombus (up to 100%) and allows assessment of the pelvic veins and IVC 
in addition to the proximal veins in the thigh. Compared to contrast
venography, it is less sensitive for calf DVT. It is non-invasive and not 
operator-dependent (but is reader-dependent) and allows assessment of
extraneous pathologies. It is more expensive than other technologies and
is precluded by metallic objects and morbid obesity/claustrophobia. Like
venography, it should be undertaken if ultrasonography is either
non-diagnostic or negative in the context of high clinical suspicion. 
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Clinical features 
In patients with acute PE, unexplained dyspnoea (the most common
presenting symptom), pleuritic chest pain and haemoptysis are classical
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symptoms. On examination, tachypnoea and tachycardia are common
signs; other signs may include raised venous pressures, tricuspid 
regurgitation and a louder pulmonary second heart sound. Similarly, 
syncope or sudden hypotension may indicate a large clot burden. 
However, the need for objective testing is necessary in the diagnosis of
PE as the history and examination of the patient are non-specific. A 
systematic review of 18 diagnostic studies (comprising almost 6000
patients) assessed the value of various clinical features in diagnosing PE. 
The most useful features for ruling in PE were syncope, shock,
thrombophlebitis, current DVT, leg swelling, sudden dyspnoea, active
cancer, recent surgery, haemoptysis and leg pain. The most useful features
for excluding PE were the absence of sudden dyspnoea, any dyspnoea and 
tachypnoea. Nevertheless, the authors concluded that individual features
only slightly raised or lowered the probability of PE. Taken alone, they had 
limited diagnostic value and none ought to be used to rule in or rule out 
PE without further testing. 
It is estimated that about 40 per cent of patients with a DVT who have no 
pulmonary symptoms have abnormal lung scintigrams indicating PE. 
Thus, much minor PE remains asymptomatic. In the 10 per cent of these 
patients who obstruct a branch pulmonary artery, pulmonary infarction
will occur with sudden dyspnoea and usually sharp pleuritic pain
associated with haemoptysis. The incidence of infarction is higher in the
presence of chronic respiratory or cardiac disease. In minor embolism, 
there will be no central cyanosis due to relatively insignificant ventilation­
perfusion mismatch and normal right ventricular function with
preservation of the cardiac output. 
A large clot occluding a major pulmonary artery or partially obstructing 
the main pulmonary artery (i.e. >50% of the pulmonary vascular bed) will
result in an acute increase in right ventricular afterload and an elevation
in pulmonary artery pressure, with an increased likelihood of a sudden 
cardiac death. The commonest clinical features in this situation are 
syncope (often in the context of paradoxical bradycardia), acute severe 
dyspnoea, acute right heart failure, cardiogenic shock and cardiac arrest
with electromechanical dissociation/pulseless electrical activity.
Significant cardiorespiratory compromise leads to a sinus tachycardia,
tachypnoea and central cyanosis through ventilation-perfusion 
mismatch. To maintain cardiac output, the pulmonary artery pressure 
rises with consequent pressure load (up to 55 mmHg) on the right 
ventricle increasing right ventricular work. 
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In otherwise fit patients, once more than 25 per cent of the pulmonary 
vascular bed is occlusive, there is an increased afterload or pressure load 
on the right ventricle leading to an increase in right ventricular systolic 
pressure. With increasing pressure load, the right ventricle will dilate 
(against a restrictive pericardium) with the development of functional 
tricuspid regurgitation, an increased right atrial pressure and, ultimately, 
cardiogenic shock. The paradoxical movement of a pressure-loaded right 
ventricle leads to left ventricular diastolic dysfunction in addition to a 
reduction in left ventricular pre-load through a reduced transpulmonary 
blood flow. Echocardiography identifies these features with an increase in 
end-systolic and end-diastolic diameters and septal flattening in both 
phases of the cardiac cycle. Left ventricular end-diastolic diameter is also 
reduced with significant embolism. 
The mechanism of hypoxaemia in massive PE is multifactorial. It occurs 
through significant ventilation-perfusion mismatch, and may also occur 
due to intrapulmonary A-V shunting through areas poorly ventilated with 
residual blood flow. Shunting may also occur at an atrial level where acute 
right heart pressures may reverse the shunt through a patent foramen 
ovale. Where the cardiac output is low, insufficient gas-exchange may 
occur in the residual areas of perfusion leading to systemic further 
desaturation. Hypercapnia is rare in massive PE due to tachypnoea. 
Symptoms of massive PE are severe dyspnoea (not orthopnoea), syncope 
and low cardiac output. Angina may occur through a combination of 
hypoxaemia, tachycardia and hypotension. Central cyanosis and acute 
right heart strain ensue. It may be difficult to hear a right ventricular 
gallop rhythm or widely split second heart sound in the presence of 
significant respiratory distress. 
A differential diagnosis of acute PE includes: 
• acute coronary syndrome 
• acute proximal aortic dissection 
• acute pulmonary oedema 
• acute pneumonia 
• pleurisy 
• acute bronchospasm 
• acute exacerbations of chronic airflow limitation 
• bronchogenic carcinoma 
• pneumothorax 
• chest wall syndrome 
• fractured rib 
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Investigations 
12-lead electrocardiography. Although 87% of patients have an
abnormal ECG, these are largely non-specific and include anterior 
T-wave changes, ST segment abnormalities and left or right axis deviation.
In the Urokinase Pulmonary Embolism Trial (UPET), 32 per cent
of patients with massive PE and 26 per cent of those with massive/ 
submassive PE had ECG signs of acute cor pulmonale such as the S1Q3T3 
pattern, right bundle branch block (RBBB), P pulmonale or right axis
deviation. The ECG may be completely normal in younger, previously fit 
patients. 
Arterial blood gases. Hypoxaemia is very common but not universally
present. In one study, a PaO2 of >11 kPa was found in 29 per cent of
patients younger than 40 compared to only 3 per cent of older patients.
This is true of patients without pre-existing cardiopulmonary disease. 
Chest radiography. Common radiographic appearances are atelectasis, 
pleural effusion, infiltrates and an effusion but non-specific. Decreased 
vascularity is uncommon. The presence of a normal chest x-ray in the 
presence of hypoxaemia in the absence of an intracardiac shunt or
bronchospasm is highly suggestive of PE. Signs such as focal oligaemia 
(Westermark sign), a peripheral wedge-shaped opacity (Hampton’s hump)
or an enlarged right descending pulmonary artery (Palla’s sign) are often 
referred to, but are actually rarely seen. The value of a chest x-ray is that it
allows confirmation of other pathological processes such as pneumonia,
pneumothorax or rib fracture. 
D-dimer. A low plasma D-dimer concentration has a 95% negative 
predictive accuracy. In one study of 308 patients presenting acutely with
suspected PE, patients underwent assessment of clinical probability, 
ventilation-perfusion scan, D-dimer and lower extremity ultrasound. 
Of 198 patients with suspected embolism and a D-dimer level <500 μg/L, 
196 were free of PE. Of course, D-dimer levels may also be raised
due to co-morbid conditions which may themselves predispose to 
developing PE. 
Computed tomography pulmonary angiography (CTPA). This
technique allows rapid tomographic imaging with continuous volume 
acquisition during a single breath-hold; the pulmonary vasculature is
visualized with a contrast dye injection. The technique is limited by
poorer visualization of the peripheral areas of the upper and lower lobes. 






















High 96% 88% 56% 
Intermediate 66% 28% 16% 
Low 40% 16% 4% 
Near normal/normal 0 6% 2% 
Total 68% 30% 9% 
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suspected PE, with accuracy acomparable with that of invasive pulmonary 
angiography. In a systematic review of 15 diagnostic studies comprising
3500 patients with suspected PE, the negative predictive value of CTPA
was 99.1 per cent for PE, and was 99.4 per cent for death due to PE. This
modality has the greatest sensitivity for emboli in the main, lobar or
segmental pulmonary arteries with a reduced sensitivity in the 
subsegmental branches (e.g. a pick-up rate of 25–30 per cent), although
this has improved with multidetector scanners: the PIOPED II study 
reported a sensitivity of multidetector CT of 83 per cent and a specificity 
of 96 per cent. An additional advantage of spiral CT is the ability to define 
non-vascular structures such as lymphadenopathy, lung tumours and 
emphysema and other parenchymal and pleural disease.
Ventilation-perfusion (V/Q) scan. Although often used to diagnose PE, 
the V/Q scan is quite non-specific and is often non-diagnostic (normal or 
high probability in a minority of cases). In the PIOPED study, which
evaluated the V/Q scan by comparison with pulmonary angiography or
post-mortem, it was apparent that PE was actually present despite 
non-diagnostic scans in 40 per cent of cases (Table 6.2). With an
increasing background of cardiorespiratory disease (particularly chronic 
obstructive airways disease), the V/Q scan becomes less diagnostic with
an increase in intermediate-probability scans. If a ventilation scan cannot
be performed, an isolated perfusion scan is useful if it is high probability,
low probability, near normal or normal. In the interpretation of perfusion 
scans, it is imperative that one or more segmental perfusion defects are 
considered diagnostic of embolism. 
Table 6.2 Clinical assessment and ventilation-perfusion scan probability 
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Pulmonary angiography. Pulmonary angiography is the invasive 
gold standard for diagnosing PE and was previously used where a 
ventilation/perfusion scan was non-diagnostic. A positive finding is an
intraluminal filling defect in two views and the demonstration of an
occluded pulmonary artery with or without a trailing edge. Less specific 
criteria are reduced perfusion, abnornmal parenchymal stain and a 
delayed venous return. In the PIOPED study, where 1111 pulmonary
angiograms were performed, 35 per cent were positive, 61 per cent were
negative, with 3 per cent non-diagnostic and 1 per cent non-completion. 
The interobserver agreement on findings reduces as the PE becomes 
smaller, i.e. from lobar to segmental to subsegmental. The mortality of
pulmonary angiography is 0.5 per cent with severe cardiopulmonary
compromise in 0.4 per cent, and morbidity tends to be higher in critically 
ill patients from intensive care. This technique requires invasive expertise 
and has been superseded by CTPA, but may be an appropriate 
investigation in patients with massive PE who are candidates for 
percutaneous intervention (see below). 
Magnetic resonance imaging.  With experienced readers, the sensitivity 
and specificity of MRI to detect PE is 73 and 97 per cent respectively 
(with the potential to improve sensitivity with gadolinium injection). The 
technique is more rapid, less invasive and avoids standard nephrotoxic 
contrast compared to pulmonary angiography. However, there is a lesser 
evidence base for MRI than for CTPA at present but given its proven 
ability to detect DVT (along with lung perfusion imaging), there is an
obvious appeal for a combined technique. 
Lower limb evaluation. If a lung scan is non-diagnostic, evaluation 
of the lower extremities is an alternative means by which to assess the 
need for anticoagulation. With a near-normal or low-probability scan, a 
negative lower limb study and a low clinical suspicion, no treatment is
needed. With a low-probability scan and negative leg study, but an
uncertain or high clinical suspicion, the PE estimate is between
9–25 per cent. With intermediate-probability scans, but a negative leg 
study, either pulmonary angiography or serial non-invasive leg studies 
should be done, depending on the stability of the patient. In one study to 
evaluate the latter course, stability was defined as absence of pulmonary 
oedema, right ventricular failure, systolic blood pressure <90 mmHg, 
syncope, tachyarrhythmia, FEV1 <1.0 l, FVC <1.5 l, PaO2 <7 kPa and 
PaCO2 >6 kPa. Of 627 patients with non-diagnostic lung scans and
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1.9 per cent had a venous thromboembolic complication. This compares
with 0.7 per cent of untreated patients with normal lung scans and 
5.5 per cent of high-probability scans who received treatment. 
Echocardiography. Acute PE causes an abrupt increase in right 
ventricular afterload, with subsequent dilatation and hypokinesis of the 
right ventricle (although other causes of pulmonary hypertension may 
also cause this appearance). Such echocardiographic dysfunction is
associated with a high risk of mortality in patients with acute PE. For
example, a right to left ventricular end-diastolic diameter ratio ≥0.9 has 
been shown to be an independent predictor of in-hospital death even 
among normotensive subjects. Right ventricular failure frequently 
accompanies massive PE and correlates with larger emboli and with the
recurrence of PE. Akinesis of the mid-free wall with apical sparing
(McConnell’s sign) may be more common in acute PE (77 per cent
sensitivity, 94 per cent specificity). It should be borne in mind that the
quality of the imaging will be limited by chronic airflow limitation and 
obesity Transoesophageal echocardiography may permit visualization of 
massive emboli in the proximal pulmonary arteries, which may be
enhanced by contrast. An important role of echocardiography is its use to 
exclude alternative cases of acute cardiorespiratory compromise such as
aortic dissection, acute ventricular septal rupture, large myocardial
infarction and cardiac tamponade). 
Troponins and brain natriuretic peptides (BNP). Simple biomarker 
testing has been shown to provide prognostic information. Markers 
indicating myocardial damage (troponins) and ventricular stretch (BNP) 
in response to acute pulmonary hypertension indicate worse outcomes
among patients with PE. Meta-analyses show that elevated troponins are 
associated with increased mortality in PE, irrespective of systemic blood
pressure. However, among normotensive patients, the extra risk appeared 
to be modest, and levels do not sufficiently distinguish high-risk,
normotensive patients from lower-risk counterparts. Similarly, patients
with PE and high levels of BNP or NT-pro-BNP have been shown to have a 
higher risk (seven-fold) of in-hospital adverse events and 30-day all-cause 
mortality. 
In contemporary practice, the diagnosis of PE is based on validated 
clinical criteria combined with selective testing in view of non-specific
symptoms and signs. These clinical criteria have been incorporated into 
scoring systems. The most commonly used system to predict clinical
probability is the Wells score (see Table 6.3). The initial system has been 
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Clinical variable Score 
 Clinical signs and symptoms of DVT (minimum of leg swelling
and pain with palpation of the deep veins) 
3 
PE as or more likely than  an alternative diagnosis 3 
Heart rate greater than 100 1.5 
Immobilization or surgery in the previous 4 weeks 1.5 
 Previous DVT/PE 1.5 
Haemoptysis 1
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Table 6.3 Wells score for diagnosis of PE 
 
DVT, deep vein thrombosis; PE, pulmonary embolism. > 4, probability of PE is
‘likely’. �4, probbility for PE is ‘unlikely’. Alternatively, < 2 is low probability, 
moderate is 2–6 and high is > 6. 
revised, resulting in assignment of different levels of probability
depending on the version used. 
The European Society of Cardiology algorithm for the diagnostic 
approach to acute PE according to the haemodynamic stability of the 
patient is presented in Figure 6.1. 
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The overriding strategy in the treatment of PE is the reduction of 
thrombosis, i.e. both the development and propagation of venous 
thrombus and the fibrinolysis or break-up of established, embolized clot. 
With the acute presentation of a PE, it is imperative that the diagnosis is 
made quickly and an assessment of the patient’s haemodynamic state is 
made. The primary therapies are: 
• 	 Heparin. This may be done as an initial therapy at the start of the 
diagnostic process. 
• 	 Oxygen supplementation. Initially by face mask, although 
supportive ventilation may be necessary. Mechanical ventilation, 
when needed, should be used cautiously to limit any associated 
adverse haemodynamic effects. For example, the increased 
 
Suspended high-risk PE, 
i.e with shock or hypotension 







No other tests available# Negative Positive 
or patient unstable 
Search for other causes 
Thrombolysis/embolectomy PE-specific treatment Search for other causes 
not justified justified Thrombolysis/embolectomy 
Consider thrombolsis not justified 
or embolectomy 
 Figure 6.1 (a) Proposed algorithm for diagnosis of high-risk PE (presenting 
with shock/hypotension). *CT is considered not immediately available also 
if the critical condition of a patient allows only bedside diagnostic tests. 
#Transoesophageal echocardiography may detect thrombi in the pulmonary 
arteries in a significant proportion of patients with right ventricular 
overload and PE that is ultimately confirmed by CT; confirmation of DVT 
with bedside lower limb ultrasound might also help in decision-making. 
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intrathoracic pressure induced by mechanical  ventilation may 
reduce venous return and potentiate right ventricular dysfunction 
in  patients with massive PE. 
• 	 Haemodynamic support. Noradrenaline may be used in small 
doses to support the acute failure of the right ventricle, but only 
where the patient is in cardiogenic shock as it may be counter­
productive with respect to cardiac rhythm. Right heart filling 
pressure should be supported to maintain right ventricular stroke 
volume, although this is finely balanced as volume loading may 
exacerbate paradoxical septal motion leading to a reduction in left 
ventricular stroke volume. In the absence of circulatory failure, a 
strategy of anticoagulation is required. With haemodynamic 
compromise, thrombolysis and/or clot fragmentation is required. 
Heparin anticoagulation 
The heparin–antithrombin III complex inactivates thrombin and, to a 
lesser extent, activated factors IX and X. The efficacy of heparin in PE is 
through prevention of further fibrin generation from thrombin 
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Suspended non-high-risk PE, 
i.e without shock or hypotension 
Assess clinical probability of PE 
implicit of prediction rule 
Low-intermediate clinical probability High clinical probability 






No PE‡ No PE† No PE
‡ PE 
Multidetector CT 
No treatment* or No treatment*No treatment* No treatment* 
investigate further# 
Figure 6.1 (b) Proposed algorithm for diagnosis of non-high-risk PE
(presenting without shock/hypotension). *Anticoagulant treatment for PE. 
†CT is considered diagnostic of PE if the most proximol thrombus is at least
segmental. ‡If single detector CT is negative, a negative lower limb venous
ultrasonography is required in order to safely exclude PE. #If multidetector
CT is negative in patients with high clinical probability, further investigation
may be considered before withholding PE-specific treatment. 
Reproduced with permission from Torbicki, et al. (2008). 
activation, thus allowing the endogenous fibrinolytic system to dissolve
residual thrombus. Unfractionated heparin (UFH) should be given
early to achieve an adequate plasma concentration, and through this
and subsequent oral anticoagulation, the risk of recurrent venous
thromboembolism and death is considerably reduced. By convention,
UFH is given by initial bolus and intravenous infusion to achieve
adequate anticoagulation. If the aPTT is prolonged prior to heparin
therapy, consider antiphospholipid antibodies as a prothrombotic
inf luence (and direct anticoagulation by the heparin level itself rather
than by aPTT monitoring). Rarely, antithrombin III deficiency will
lead to true heparin resistance. 
The problem with UFH lies in its unpredictable haematological response
due to the binding of heparin to plasma and endothelial proteins, 
regardless of weight adjustment. To control for this, the aPTT should also
be measured 4–6 hours after initiation and similarly after any dose change 
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anticoagulation should be started simultaneously with heparin 
discontinued once the INR is >2.0 on two consecutive days. Serious 
complications from heparin therapy occur in less than 5 per cent of
patients and haemorrhagic sequelae occur where there is an existing 
bleeding diathesis or pathology such as active or previous peptic ulcer
disease/varices/angiodysplasia, recent surgery, severe hypertension or
recent haemorrhagic stroke. Long-term (>2 months) heparin therapy is
associated with osteoporosis and skin rashes and hypersensitivity
reactions can occur. Heparin-induced thrombocytopenia (HIT) may be
mild within the first few days of treatment due to direct aggregation, but 
if severe (<100 X 109/L), when it occurs due to antibody formation after 
5–7 days, it should be discontinued with substitution by a direct
antithrombin drug, e.g. hirudin or bivalirudin, as significant
pro-thrombotic risk exists. This HIT with thrombosis is very serious and
any potential effect of heparin on platelets should be monitored with
immediate discontinuation if the platelet count drops. The direct
thrombin inhibitors such as hirudin or lepirudin (recombinant hirudin)
are peptides that inhibit fibrin deposition inside thrombus better than the
larger heparin–antithrombin III complex giving a better inhibition to 
thrombus development. They have a short half-life (<2 hours) but can be
monitored by the aPTT also. 
Low-molecular-weight heparin 
LMWH has become the treatment of choice for venous thromboembolism.
It is produced by depolymerization of UFH leading to small molecules 
capable of inhibiting activated factor X in preference to thrombin
(activated factor II). Given a longer half-life and less ancillary binding, the 
anticoagulant dose is predictable after subcutaneous dosing. As the aPTT
measures antithrombin activity, LMWH, if necessary, should be
monitored by its anti-Xa activity. Its administration subcutaneously 
requires less supervision and may be given once or twice daily (depending 
on exact LMWH type) to give as effective a therapy as UFH in the 
treatment of proximal DVT and acute PE. Its role in massive pulmonary 
embolism is less well validated, however. 
The use of LMWH can be problematic and it should be given with care in
patients with renal failure. Intravenous UFH, which is not renally cleared,
should be the preferred mode of initial anticoagulation for patients with
severe renal impairment (creatinine clearance <30 mL/min); it may also be
preferable among those at high risk of bleeding, as its anticoagulant effect
can be reversed quickly. 
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Thrombolytic therapy 
Thrombolytic therapy is indicated in the treatment of massive PE (shock, 
severe hypoxaemia) or PE with echocardiographic right ventricular 
dysfunction. Because of its ability to promote fibrinolyis it has additional 
benefit in breaking up residual deep venous thrombus and reduces the 
risk of recurrent PE and chronic thromboembolism. There are several 
thrombolytic agents that have been used, streptokinase, urokinase, 
and the more fibrin-specific tissue plasminogen activator and reteplase, 
which work through different means to activate breakdown of 
plasminogen to plasmin which degrades fibrin in clot. All appear to be 
equally effective and safe. Thrombolysis has been shown to resolve 
thrombotic obstruction and to improve haemodynamic parameters. 
However, despite the appeal, there are few data from randomized trials of 
thrombolytic therapy against heparin powered to demonstrate a 
difference in hard clinical outcomes. 
Contraindications to thrombolytic therapy are similar to those in the 
treatment of myocardial infarction. However, while most benefit is  
derived when treatment is started within 48 hours of symptom  onset, 
thrombolysis can still be useful in patients up to 2 weeks later. Heparin 
should be withheld until the aPTT is less than 2:1 after thrombolysis. The 
risk of bleeding is greatest where the administration of thrombolysis is 
prolonged or where vascular puncture sites are present. If persistent major 
bleeding occurs, plasmin activity can be reversed by intravenous 
aprotinin and fibrinogen replenished with clotting factors in fresh frozen 
plasma (which will contain plasminogen). 
Suggested doses for thrombolytic drugs for pulmonary embolism are: 
• 	 streptokinase 0.25–0.5 M over 15 minutes followed by 0.1 MU/h 
for 24 hours 
• 	 urokinase 4400 U/kg over 10 minutes then 4400 U/kg for 12 hours 
• 	 tPA 10 mg bolus, then 90 mg over 2 hours 
• 	 reteplase two 10 U boluses 30 minutes apart 
Pulmonary embolectomy 
The rapid restoration of pulmonary blood flow is likely to be a major 
determinant in preventing the mortality from massive PE. In the past, 
surgery was considered the best means of removing significant clot load. 
The vogue for surgical embolectomy even in extreme situations is 
diminishing. Historically, patients in shock despite inotropic support who 
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thrombolysis have been considered for surgical embolectomy. 
Retrospective series largely pre-date the use of thrombolysis and include 
procedures outside the emergency setting. High operative mortality of up 
to 50 per cent has been reported, and current practice has included 
femoral-to-femoral bypass for haemodynamic support prior to full
cardiopulmonary bypass. The need for cardiopulmonary resuscitation 
prior to surgery predicts an adverse outcome from surgical embolectomy. 
With survival from the procedure, most late morbidity is neurological. 
Mechanical thrombectomy 
In the modern era of percutaneous intervention, attempts have been made
to provide an alternative to surgical embolectomy. Initial techniques have
focused on retrieval devices to hold and extract a thrombus from the main
pulmonary artery in patients with massive PE. However, this approach has
been of limited success. Clot fragmentation has been described in
uncontrolled studies using a pigtail catheter. The theoretical benefit of this
approach is that the clot will fragment into a smaller vascular area as it
embolizes distally and will be more susceptible to thrombolysis. This will
reduce pulmonary artery pressure and improve transpulmonary flow in
most cases. In cases where pulmonary artery pressure remains high, this
may occur through release of vasoconstrictor hormones such as
thromboxane A2 arguing for the actual removal of clot rather than simple 
embolization of it. Again, outcome data for this technique are limited.
However, newer devices are becoming available which both fragment and 
aspirate clots such as the Hydrolyser™, Amplatz™ and Günther catheters.
The most promising device may be the Arrow-Trerotola percutaneous
thrombolytic device (PTD), which consists of a motor-driven 5F outer
catheter connected to a fragmentation basket which rotates at 3000 rpm.
The latest version of this device may be introduced over-the-wire through a 
guide catheter into the thrombus and activated to fragment the thrombus. 
Clinical studies are also ongoing with respect to the fragmentation of 
ileofemoral thrombus via the transjugular route using this device. It can 
be deployed in the pelvic veins with the adjunctive use of a temporarily 
deployed wallstent in the inferior vena cavae to act as a filter for old 
thrombus which can then be removed back into a large 15F guide catheter. 
Chronic treatment of acute pulmonary embolism 
Oral anticoagulation 
It is imperative that warfarin is started after diagnosis is made and acute
treatment started so that an overlap can occur for a 5-day period to avoid
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the pro-thrombotic state created by a reduction in protein C with oral
anticoagulation. The prothrombin time expressed as the INR should be
adjusted to a therapeutic window of 2.0–3.0, or higher where the
antiphospholipid syndrome is the cause of the thromboembolism. In the
medium-term treatment of the patient, obvious risk factors should be
corrected which may allow a shorter period of anticoagulation compared to
the standard period of 3 months for a first PE. In the presence of a persistent
procoagulant stimulus such as malignant disease or proven thrombophilia
or where recurrent PE has occurred (prior PE is the best predictor of
recurrent DVT) or where the patient has chronic thromboembolic disease,
treatment should be prolonged or lifelong. Significant bleeding
complications with over-anticoagulation should be treated with a bolus of
0.5–1.0 mg of vitamin K that will bring the INR back into the normal range.
This can take up to 24 hours so clotting factor concentrates or fresh frozen
plasma should be given for quicker restoration of haemostasis. 
Anticoagulation is required to reduce the risk of proximal propagation 
and embolism to the pulmonary circulation. DVT proximal to the calf
and symptomatic calf (popliteal) DVTs require LMWH injections and an
arbitrary 3-month course of warfarin. A 20 per cent recurrence rate has 
been reported in the literature. Patients with symptomatic DVT do not all 
require hospital admission and patients may be risk stratified according to 
PE risk (see Table 6.1). Long-term anticoagulation is required in
significantly obese patients and in those with cancer and previous DVT.
Anticoagulation is not mandatory in asymptomatic calf DVTs as long as
serial ultrasound monitoring confirms no proximal extension. A majority
of patients develop chronic venous insufficiency after anticoagulant 
therapy and the use of high-pressure support stockings prevent venous
wall distension on ambulation, which may reduce this risk. 
Inferior vena caval filters 
These filters can be introduced, delivered and deployed percutaneously to 
prevent significant thrombus reaching the pulmonary circulation. Their 
use should be restricted to situations where recurrent DVTs occur despite 
adequate anticoagulation or used in patients who cannot tolerate warfarin
on a temporary or permanent basis. The long-term outcome of these 
devices is less good with caval thrombosis at the filter site, filter fracture 
and migration and occasional vessel wall perforation. 
Thromboembolic pulmonary disease 
Patients with recurrent PE may go on to develop chronic thromboembolic 












ACUTE PULMONARY EMBOLISM 
occurs where recurrent PE has been undiagnosed over several weeks to 
months without oral anticoagulation. The best treatment option for this
rare condition is surgical thromboendarterectomy with removal of 
organized clot ideally as a cast of the pulmonary vascular tree. As with
acute surgical embolectomy, this operation carries a significant mortality 
and it is likely that a percutaneous thrombectomy technique will
supersede this approach in the future. 
KEY POINTS 
• 	PE occurs through dislodgment of a venous thrombus from the deep
leg or the pelvic veins into the pulmonary arterial circulation. The 
clinical signs of embolism are determined by the level at which the 
thrombus is occlusive. 
• 	The development of a venous thrombus is determined by Virchow’s
triad of local injury, hypercoagulability and stasis of flow. 
• 	Venous thromboembolism is a clinical situation where the diagnosis 
is more often not made than made. The clinical suspicion of a DVT 
(leg swelling, calf tenderness, venous distension of subcutaneous
vessels, discolouration) should be confirmed objectively, due to the lack
of predictive accuracy in the clinical examination. 
• 	 In the presence of a suspected acute DVT, either compression 
ultrasound or impedance plethysmography should be done. If
inconclusive or inadequate, venography or MRI should be done. 
• 	 In acute PE, classic symptoms are unexplained dyspnoea, pleuritic 
chest pain and haemoptysis with tachypnoea in particular and 
tachycardia being common signs, but all are non-specific. 
• 	The V/Q scan is often non-specific and in one study which evaluated 
the V/Q scan by pulmonary angiography or post-mortem, it was 
apparent that PE was often present in the presence of non-diagnostic 
scans in 40 per cent of cases. 
• 	CTPA is limited by poorer visualization of the peripheral areas of the 
lung but is associated with 95 per cent specificity and sensitivity for PE. 
CTPA has the greatest sensitivity for emboli in the main, lobar or
segmental pulmonary arteries. 
• 	The treatment of acute PE includes intravenous heparin, oxygen 
supplementation and haemodynamic support with noradrenaline and 
careful volume balance. In the absence of circulatory failure, a strategy
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ACUTE PULMONARY EMBOLISM 
of anticoagulation is required. With haemodynamic compromise, 
thrombolysis and/or clot fragmentation is required. 
• 	Clinical studies are ongoing with the percutaneous use of a 
thrombolytic device which consists of a motor-driven catheter 
connected to a fragmentation basket rotating at high speed. Other 
percutaneous devices use the Venturi effect to aspirate fresh clot both 
in the deep venous system and in the pulmonary circulation. 
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BACKGROUND 
Epidemiology and pathophysiology 
Strictly speaking, infective endocarditis (IE) is a disease in which an
infective organism colonizes the heart valves, septal defects or mural
endocardium. However, in clinical practice the definition extends to
include infections on arteriovenous shunts, arterio-arterial shunts and
aortic coarctations, as the clinical presentation is often indistinguishable.
The infection evolves to produce a vegetation that comprises an amorphous
mass of organisms, inflammatory cells, fibrin and platelets. Following
successful treatment for IE, healing occurs by fibrosis and calcification. 
Overall, there are approximately 1500 cases of endocarditis in the UK per 
year, with an estimated in-patient mortality between 15 and 20 per cent. 
IE can occur not only on congenital or acquired structural cardiac
abnormalities but also on normal, previously healthy valves. Traditionally,
endocarditis has been divided into acute and subacute forms. Acute 
bacterial endocarditis is usually due to a virulent organism such as
Staphylococcus aureus, which can rapidly lead to complications within
days or weeks if left untreated. Subacute bacterial endocarditis is more
indolent, usually presents weeks to months after the initial infection and 
is caused by organisms such as Streptococcus viridans or coagulase­
negative staphylococci. This classification was initially based on untreated 
disease. Since devastating complications such as valve perforation and 
cerebral embolization can arise with a variety of different organisms and 
bacteria are not always implicated, the term IE is more appropriate and is
























In the past, IE occurred mainly in patients with underlying rheumatic or
congenital heart disease. The incidence and prevalence of rheumatic heart 
disease has decreased in developed countries. Contemporary causes of IE
affecting the native valves include mitral valve prolapse (accounting for 
up to one-third of cases in adults), bicuspid aortic valves, degenerative/ 
sclerotic valves (particularly in an ageing population) and intravenous
drug use (IVDU). IE associated with IVDU is usually associated with
right-sided valve lesions, and can affect up to 7 per cent of subjects with
previous IVDU. In the United States, up to 12 per cent of acute 
drug-related presentations relate to IE. Staphylococcus aureus is
responsible for more than 50 per cent of these infections. Unusual 
organisms such as Corynebacterium species, Bacillus cereus, Lactobacillus, 
Candida and polymicrobial infections can sometimes be found in this
population. In addition, it is now recognized that many older patients are 
developing IE as a result of invasive procedures and nosocomial
infections. Congenital heart disease is more important as a cause of IE in
young adults. 
In developed countries, epidemiological studies suggest that 10–20 per 
cent of patients with prosthetic heart valves develop endocarditis. The risk
is greatest during the first 6 months after valve surgery and thereafter 
declines to about 0.2–0.35 per cent per year. The term ‘early’ is often used
to describe prosthetic valve endocarditis when it occurs within 2 months
following surgery, when it is considered to be a complication of valve 
surgery. Prosthetic valve endocarditis occurring more than 12 months
after surgery is termed ‘late’ and, like native valve endocarditis, is likely to 
be associated with community-acquired infections. Cases occurring
between 2 and 12 months after surgery are a mixture of hospital-acquired
episodes caused by less virulent organisms and community-acquired
episodes. Hence, the timing of infection reflects different pathogenic 
mechanisms, which in turn influence the epidemiology, microbiology,
pathology and clinical manifestation. The risk of invasive infection is
increased among patients with prosthetic valve endocarditis within the
first year after implantation, particularly those with infection of an aortic 
valve prosthesis. Table 7.1 summarizes the microbiology of IE in native 
and prosthetic heart valves, and in subjects with a history of IVDU. 
The pathogenesis of IE involves turbulent blood flow from a high to a low 
pressure zone, resulting in damage and ulceration to the endocardium.
The contact between blood and the subendothelial surfaces promotes 

















Streptococcus viridans 50 10  8 30 
Enterococci  5  8  2  6 
Other streptococci  5  2 
Staphylococcus aureus 20 57 15 10 
Staphylococcus
epidermidis




 6 7  17  
Fungus  1  5 10  5 
Culture negative  5  5  5  5 
Diphtheroids  8  3 
Mixed/Others  3  3  2  2 







   
 
INFECTIVE ENDOCARDITIS 
Table 7.1 Microbiology of infective endocarditis 
29  
10  
aThe HACEK group of organisms consists of Haemophilus species, Actinobacillus
species, Cardiobacterium species, Eikenella species and Kingella species. These
Gram-negative coccobacilli are fastidious and slow growing, and have become an
important cause of IE. They are part of the respiratory tract and oropharyngeal f lora. 
seed to the thrombus and proliferate, resulting in IE. In addition, 
Staphylococcus aureus possesses binding proteins on its surface, which 
facilitates adhesion to focal areas of local inflammation that are rich in
fibronectin. Vegetations are usually located along the line of closure of a 
valve leaflet on the low pressure side of the valve where turbulence occurs
(i.e. the atrial surface for atrioventricular valves or the ventricular surface 
for semilunar valves). The absence of a pressure gradient across an ostium
secundum atrial septal defect explains the low risk of endocarditis in
this group. 
CLINICAL PRESENTATION 
The clinical syndrome of IE consists of fever, changing murmurs, septic
embolization to any organ and petechial lesions of the skin. The 
diagnosis should be suspected in anyone who presents with pyrexia and 
 
INFECTIVE ENDOCARDITIS 
multisystem involvement in the presence of cardiac disease or 
prior IVDU. 
Acute IE presentations are usually characterized by a toxic, unwell 
patient with high fevers and rigors. Subacute or chronic presentations often 
occur weeks or months after the initial infection, and can be associated with 
a low-grade fever, night sweats, weight loss and anaemia (normochromic 
normocytic). Other associated symptoms and signs may include lethargy, 
anorexia, vague abdominal or flank pain, confusion, arthralgia, myalgia 
and finger clubbing. Peripheral manifestations as a result of an 
immunologically mediated vasculitis or septic embolization can give rise to: 
• 	O sler’s nodes (tender, subcutaneous nodules seen in the pulps of the 
digits); 
• 	 Janeway lesions (non-tender, erythematous or haemorrhagic 
macular lesions seen on the palms and soles); 
• 	 splinter haemorrhages in the fingernails or toenails; petechiae on 
the conjunctivae and buccal mucosa; 
• 	 focal glomerulonephritis and splenic infarcts; 
• 	mycotic aneurysms and occlusion involving any vessel, 
commonly seen in the cerebral arteries, abdominal aorta, 
coronary arteries, gastrointestinal arteries, limb arteries and 
renal arterioles; 
• 	 retinal infarcts (Roth’s spots), causing an oval-shaped haemorrhage 
with a pale centre; 
• 	neurological involvement in 30–40 per cent of patients with IE, the 
majority of which are embolic strokes, with intracranial 
haemorrhages occurring in 5 per cent; 
• 	 congestive cardiac failure as a result of valve destruction or rupture 
of a chorda and, rarely, intracardiac fistulae, myocarditis or 
coronary artery embolism; 
• 	 perivalvular extension beyond the valve ring either in native or 
prosthetic valve IE, giving rise to paravalvular regurgitation, valve 
dehiscence, septal and myocardial abscesses, fistulous tracts, 
pericarditis and conduction disturbances such as first degree AV 
block; 
• 	 a change in the quality of the audible prosthetic clicks can reflect 
valve obstruction by vegetation overgrowth. 
Because patients with prosthetic heart valves are always at risk for IE, the 
presence of fever or new prosthesis dysfunction at any time warrants 
consideration of the diagnosis. 
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Heart murmurs are heard in 80–85 per cent of patients with IE but may 
be difficult to detect or be absent in patients with tricuspid valve 
involvement. Careful auscultation in full inspiration is often useful in
diagnosing right-sided murmurs. Septic pulmonary embolization from 
right-sided valvular IE (frequently seen in IVDU-related IE) can give rise
to shortness of breath, haemoptysis, pleuritic chest pain and pulmonary 
abscesses. 
Poor prognostic factors include increased age, infection of a prosthetic 
valve, patients with cardiac complications on admission, persistent sepsis, 
type of organism involved (Staphylococcus, fungal and nosocomial 
infections carry a higher risk than Streptococcus viridans infection), and the 
presence of associated diseases such as chronic renal disease, chronic liver 
disease, neoplasms and HIV. 
DIAGNOSIS AND INVESTIGATIONS 
IE is largely a clinical diagnosis, based on history and clinical
examination, that is confirmed with blood cultures and
echocardiography. It is important to search for a portal of entry of
infection, which may give a clue to the type of organism causing the 
infection. For instance, Streptococcus viridans infections frequently occur
following dental procedures or poor oral hygiene, enterococcal infections
occur after genitourinary and gastrointestinal procedures or in women 
after abortion or giving birth, and staphylococcal, Gram-negative 
bacterial and fungal infections in drug abusers and after open heart 
surgery. Alternatively, the causative organism may be associated with an
underlying condition, for instance Streptococcus bovis IE is frequently
associated with colonic polyps and cancer. Most cases of procedure-
related IE occur with a short incubation period of approximately 2 weeks 
or less following the procedure. 
The variability in the clinical presentation of IE requires a diagnostic 
strategy that is sensitive for disease detection and specific for its exclusion.
Use of the Duke criteria (developed at Duke University, United States in
1994) is currently recommended by the American College of Cardiology/ 
American Heart Association (ACC/AHA) and has been adopted 
internationally to aid the diagnosis of IE. A definite diagnosis of IE can be
made either pathologically or clinically. A pathological diagnosis is made 
when pathological specimens from surgery or autopsy reveal positive






presence of major and/or minor criteria as seen in Box 7.1. A diagnosis of
IE is made if there are two major or one major and three minor or five
minor criteria. 
Blood cultures are paramount for diagnosis and monitoring treatment.
Three sets of cultures (aerobic and anaerobic) containing at least 10 mL
Box 7.1 D efinitions of terms used in the modified 
Duke criteria for the diagnosis of IEa 
Major criteria 
Positive blood culture for IE 
Typical micro-organism consistent with IE from 2 separate blood 
cultures as noted below: 
(1)  viridans streptococci, Streptococcus bovis, HACEK group, 
Staphylococcus aureus or 
(2)  community-acquired enterococci in the absence of a primary 
focus, or 
micro-organisms consistent with IE from persistently positive blood 
cultures defined as: 
(1) >2 positive cultures of blood samples drawn >12 hours 
apart or 
(2) all of 3 or a majority of >4 separate cultures of blood (with first 
and last sample drawn >1 hour apart). 
Positive blood culture for Coxiella burnetii or antiphase 1 IgG antibody 
titre .1:800. 
Evidence of endocardial involvement 
Positive echocardiogram for IE defined as: 
(1) oscillating intracardiac mass on valve or supporting structures, 
in the path of regurgitant jets, or on implanted material in the 
absence of an alternative anatomical explanation, or 
(2) abscess, or 
(3) new partial dehiscence of prosthetic valve, or new valvular 
regurgitation (worsening or changing of pre-existing murmur 
not sufficient). 
Note: TOE is recommended in patients with prosthetic valves who are 
rated as having at least possible IE by clinical criteria, or who have 
complicated IE such as paravalvular abscesses, etc. 
Continued 
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(1)	  Predisposition: predisposing heart condition or intravenous 
drug use 
(2)	  Fever: temperature >38.0°C 
(3)	  Vascular phenomena: major arterial emboli, septic pulmonary 
infarcts, mycotic aneurysm, intracranial haemorrhage, 
conjunctival haemorrhages, and Janeway lesions 
(4)	  Immunological phenomena: glomerulonephritis, Osler’s nodes, 
Roth spots, and rheumatoid factor 
(5)	  Microbiological evidence: positive blood culture but does 
not meet a major criterion as noted above or serological 
evidence of active infection with organism consistent 
with IE 
aA diagnosis of IE is made if there are two major or one major and three 
minor or five minor criteria. Possible IE is suspected if there is one major 
and one minor criterion, or three minor criteria. 
Adapted from Li, et al. Clin Infect Dis 2000; 30: 633–8. 
of blood should be taken from different sites, at different times 
(30–60-minute intervals), and before commencement of antibiotics. 
Blood cultures are negative in ≤5 per cent of patients with IE diagnosed 
by strict diagnostic criteria. Negative blood cultures may occur as a 
result of inadequate microbiological techniques, infection with highly 
fastidious bacteria or non-bacterial organisms, or administration of 
antibiotics prior to obtaining blood cultures. Specialized microbiological 
techniques and culture media, prolonged incubation periods as well as 
serology (for organisms such as Brucella, Legionella, Bartonella, Coxiella 
burnetii or Chlamydia species) may be needed to diagnose unusual 
organisms. The use of blood tests for polymerase chain reaction (PCR)
may also become more widely used in difficult to culture organisms.
Swabs should be taken from skin lesions, cannulation sites and the nasal
cavity. Early and close liaison with the microbiology department is
essential. 
Echocardiography is not an appropriate screening test in the evaluation
of patients with fever or a positive blood culture that is unlikely to
reflect IE. Nevertheless, echocardiography should be performed in all










500 patients with suspected endocarditis assessed whether clinical 
features could guide decisions to use transthoracic echocardiography. 
The collective absence of the following five clinical factors was 
associated with a zero probability of the transthoracic echocardiography 
showing evidence of endocarditis. These factors are in descending 
order  of risk: 
• vasculitic or embolic phenomena 
• the presence of central venous access 
• a recent history of injected drug use 
• the presence of a prosthetic valve 
• positive blood cultures. 
Transthoracic echocardiography is readily available, non-invasive and 
has a sensitivity of <60 per cent for vegetations <2 mm and a specificity of 
98 per cent. In patients in whom IE or its complications are strongly 
suspected, a negative transthoracic echo will not definitely rule out 
IE and transoesophageal echocardiography (TOE) is recommended. 
TOE has a sensitivity of 76–100 per cent and a specificity of 94 per cent. 
It can diagnose vegetations <1 mm and is useful in evaluating and 
monitoring patients who develop complications and in patients with a 
suspected diagnosis of prosthetic valve endocarditis (compared to 
transthoracic echocardiography, TOE allows better visualization of 
prosthetic valves).
Haematological indices are frequently abnormal and include a raised
erythrocyte sedimentation rate (ESR), leucocytosis, normochromic 
normocytic anaemia, low serum iron and a low serum iron binding 
capacity. Findings of immune stimulation and ongoing inflammation
include a raised C-reactive protein (CRP), rheumatoid factor, 
hypocomplementaemia (decreased C3/C4) and cryoglobulinaemia. 
Urine analysis may show haematuria, red cell casts and proteinuria as
a result of glomerular involvement. Although there may be no specific
changes on the ECG, the development of PR interval prolongation 
may signify the presence of an aortic root or septal abscess. Chest x-ray 
may show signs of heart failure and pulmonary infiltrates from septic 
emboli. 
It is important to recognize that the majority of symptoms, signs and 
laboratory investigations seen in IE are not specific and can also occur in
other diseases such as connective tissue disorders, atrial myxoma, acute
rheumatic fever and lymphomas. 
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ANTIMICROBIAL TREATMENT AND MONITORING 
If the diagnosis is suspected and cultures have been taken, then IV
antibiotics should be commenced. The choice of agents used for empirical 
treatment has changed over the years with the change in incidence of
endocarditis due to Staphylococcus aureus. The Working Party of the 
British Society for Antimicrobial Chemotherapy recommend empirical 
treatment based on presentation: 
Acute presentation	 Flucloxacillin (8–12 g IV daily in
4–6 divided doses) 
plus gentamicin (1 mg/kg IV 8 hourly, 
modified according to renal function) 
Indolent presentation	 Penicillin (7.2 g IV daily in 6 divided doses) 
or ampicillin/amoxycillin (2 g IV 6 hourly) 
plus gentamicin (1 mg/kg IV 8 hourly, 
modified according to renal function) 
Penicillin allergy or Vancomycin (1 g 12 hourly IV, modified
intracardiac prosthesis according to renal function) plus
or  suspected MRSA rifampicin (300–600 mg 12 hourly by
mouth) plus gentamicin (1 mg/kg IV
8 hourly, modified according to renal 
function) 
The choice and duration of antimicrobial therapy for patients with
IE should eventually be dictated by the pathogens identified from
blood cultures. Full discussion of the specific therapeutic regimens is
beyond the scope of this chapter and should be decided upon in
collaboration with the microbiologists. Close collaboration with the 
microbiologist is essential, in particular when blood cultures are negative
in order to avoid inappropriate treatment and to discuss alternative
investigation. 
Most patients with IE respond to appropriate antibiotic treatment within
72 hours, with a reduction in fever and improvement in general
well-being. If fever persists or recurs, then further blood cultures should 
be taken. The recurrence of fever during treatment does not necessarily 
indicate an unsatisfactory response to antibiotics, but may indicate a 
hypersensitivity reaction to drugs, phlebitis, an infection elsewhere or
major immune activation (Table 7.2). Urine analysis should be done daily,
ECGs should be obtained twice weekly and echocardiography weekly. 













Intracardiac: Paravalvular/intracardiac abscesses 
 Extracardiac: Line infection, metastatic infection, mycotic aneurysms, spinal
abscess, vertebral osteomyelitis, discitis, etc. 
Antibiotic resistance: seldom a cause especially if the infecting bacteria has 
been cultured and sensitivity determined 
Antibiotic sensitivity 
Can be associated with or without a rash, eosinophilia and a rise in CRP in a 
patient who had been previously doing well 
Major immune activation 
Associated with progressive renal failure, vasculitis, emboli, etc. 
Multiple organisms 
Usually seen in intravenous drug abusers 
Wrong diagnosis 
Lymphoma, sarcoidosis, AIDS, tuberculosis, atrial myxoma, acute rheumatic 
fever, autoimmune disease such as SLE, etc. 
INFECTIVE ENDOCARDITIS 
Table 7.2 Some causes of persistent or recurrent fever during treatment of 
infective endocarditis 
ANTICOAGULANT THERAPY 
Anticoagulant therapy has not been shown to prevent embolization in IE
and may increase the risk of intracerebral haemorrhage.  Patients with
prosthetic valve endocarditis who are receiving chronic anticoagulant 
therapy should be allowed to cautiously continue. However, in the 
presence of cerebral emboli with haemorrhage, temporary
discontinuation of anticoagulation is appropriate. In unstable patients
or in those for whom surgery is planned, warfarin can be discontinued
and replaced with unfractionated heparin, which can easily be
reversed. 
COMPLICATIONS AND INDICATIONS FOR SURGERY 
Patients should be seen and examined daily to screen for the
development of aforementioned complications. Among the 
complications, heart failure has the greatest impact on prognosis.
Heart failure is more frequently seen with aortic valve infections
(29 per cent) than with mitral (20 per cent) or tricuspid (8 per cent)
disease. The early onset of heart failure signifies the need for surgical
















•  Moderate to severe congestive heart
failure due to valve 
   • Congestive heart failure resolved
with medical therapy dysfunction 
   • Refractory infection (persistent
bacteraemia, relapse after optimal 
 therapy – prosthetic valves) with lack
 of improvement after more than
1 week of antibiotics 
  • Relapse after optimal therapy 
 (native valves)
 • Fungal infection    • Culture-negative endocarditis
with persistent unexplained fever 
 • Unstable valve prosthesis • Vegetations >10 mm 
   • Significant dehiscence of prosthetic
valves 
   • New regurgitation in an aortic
prosthesis 
   • Perivalvular extension with septal and
 myocardial abscesses, fistulous tracts,
 atrioventricular block, rupture of
 sinus of Valsalva aneurysm, rupture of
subaortic aneurysm 
  • Single systemic embolic event 
  • Large vegetation causing obstruction 
 • Recurrent systemic emboli
 – several episodes 
  –  one episode with residual large vegetation 
INFECTIVE ENDOCARDITIS 
intervention. Delaying surgery to the point of marked ventricular
decompensation can dramatically increase operative mortality, from
6–11 per cent for stable patients to 17–33 per cent for patients with heart
failure. The incidence of reinfection of the newly implanted valve in
patients with active IE has been estimated to be 2–3 per cent, which is
far less than the operative mortality rate. Therefore, surgery should
never be delayed to prolong pre-operative antibiotic treatment. Other
indicators for acute surgical intervention also include intracardiac
abscesses and fistulous tracts, unstable valve prosthesis, persistent
bacteraemia despite antimicrobial therapy, fungal infections,
recurrent systemic embolization (>2 major embolic events) and large
obstructive vegetations (>10 mm) (see Table 7.3). The duration of
antibiotic therapy following surgery is dependent on the antibiotic
Table 7.3 IE and indications for surgery 










sensitivity of the organism, the presence of paravalvular invasive 
infection and the culture status of the vegetation. Generally, in
endocarditis caused by antibiotic-sensitive organisms with negative 
cultures of operative specimens, pre-operative plus post-operative
therapy should at least equal a full course of recommended therapy.
Patients with positive intraoperative cultures and prosthetic valve
endocarditis should receive a full course of antimicrobial therapy
post-operatively. 
PREVENTION 
IE is a life-threatening disease and carries a high risk of morbidity and 
mortality despite modern antimicrobial and surgical treatment. It is 
therefore imperative, whenever possible, to try to prevent unnecessary 
infections, especially those in high-risk groups. When determining which 
patients need antibiotic cover, it is important to consider the underlying 
cardiac condition (as some conditions are more often associated with 
endocarditis than others), the risk of bacteraemia associated with the 
particular procedure, and the likely organism that may propagate to give 
rise to IE. Currently there is considerable controversy over when antibiotic 
prophylaxis should be given. Recently several guidelines advising on 
antibiotic prophylaxis have changed, reflecting the lack of evidence that 
exists for the benefits of chemoprohylaxis. Additionally, there is evidence 
to  suggest that bacteraemia occurs with everyday activities such as 
chewing or brushing teeth. Consequently, in the UK, the National Institute 
for Health and Clinical Excellence (NICE) has published guidelines 
stating that prophylaxis is not required, except where there is evidence of 
active infection. This is at odds with recommendations of the AHA and 
ESC. The Working Party of the British Society for Antimicrobial 
Chemotherapy (BSAC) guidelines are similar to that of the AHA and ESC 
and are stated below. They recommend prophylaxis for dental procedures 
(involving dento-gingival manipulation) in those at high risk of 
endocarditis such as patients with: 
• previous IE 
• cardiac valve replacement 
• surgically constructed systemic or pulmonary shunt or conduit. 
These patients should be given amoxycillin 3 g po, 1 hour prior to the 
procedure. Those allergic to penicillin should be given clindamycin 
600 mg po. 
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INFECTIVE ENDOCARDITIS 
In addition to the above high-risk group, for non-dental procedures BSAC 
also defines the following groups as high risk: 
• 	 complex congenital heart disease (except secundum atrial septal 
defects) 
• 	 complex left ventricular outflow abnormalities, including aortic 
stenosis and bicuspid aortic valve 
• 	 aquired valvulopathy and mitral valve prolapse (with 
echocardiographic evidence of substantial leaflet abnormality and 
regurgitation). 
For gastrointestinal diagnostic procedures, such as upper and lower 
gastrointestinal endoscopy, routine use of prophylaxis is not 
recommended except for high-risk patients as above. Prophylaxis is, 
however, recommended for therapeutic procedures such as ERCP or 
oesophageal dilatation and laser probe treatment. In the case of 
genitourinary procedures such as cystoscopy, urethral dilatation, 
transurethral resection of prostate and transrectal prostatic biopsy, 
antibiotic prophylaxis is recommended. For urethral catheterization 
routine prophylaxis is not recommended; however, antibiotics should 
be g  iven if there is evidence of a urinary infection prior to 
catheterization. In obstetric and gynaecology procedure, antibiotics 
are recommended for vaginal hysterectomy and caesarian section. 
They are not recommended in vaginal delivery unless there is 
infection or prolonged rupture of the membranes, in which case 
antibiotics are indicated regardless of the endocarditis risk. For 
these non-dental procedures a single dose of amoxicillin 1 g IV 
(Teicoplanin 400 mg IV if penicillin allergic) and gentamicin 1 g/kg is 
recommended just prior to the procedure or with induction of 
anaesthesia. 
Prophylaxis is also advised in surgery involving the upper respiratory 
tract, nasal packing/intubation (Flucloxacillin 1 g IV or clindamycin 
600 mg IV if penicillin allergic) and for cosmetic piercing of the tongue or 
oral mucosa (as per dental prophylaxis). It is not recommended for 
bronchoscopy. 
KEY POINTS 
• 	 IE is a challenging medical disease, which requires a high index of 


















• 	 IE can involve multiple systems and can often present in a similar way 
to other conditions such as connective tissue disorders, atrial myxoma
and lymphomas, and is therefore a great mimicker. 
• 	Although the number of cases of IE related to rheumatic heart disease 
has decreased, this reduction has been balanced by an increased 
incidence of IE in IV drug abusers and the elderly. 
• 	Advances in microbiology techniques and echocardiographic imaging 
(in particular, TOE) have improved the ability to diagnose IE. 
• 	A multidisciplinary approach is necessary for decision-making during 
treatment, with consultation from cardiology, cardiothoracic surgery 
and the microbiology departments. 
• 	Patients with signs and symptoms of heart failure should be considered 
for early surgical intervention. 
• 	Administration of antibiotic prophylaxis is determined by the
underlying cardiac condition as some conditions are more often 
associated with endocarditis than others, the risk of bacteraemia
associated with the particular procedure, and the likely organism that
may propagate to give rise to IE. 
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DIGOXIN TOXICITY 
Digoxin is commonly used in the treatment of chronic atrial fibrillation
(AF) and heart failure. More than 10 per cent of patients receiving the drug
have been found to have evidence of digoxin toxicity when admitted to
hospital. Digoxin has a narrow therapeutic index (therapeutic concentration
1–2 ng/mL or 1.3–2.6 nmol/L) with toxicity occurring with serum
concentrations >2.5 ng/mL. Serum concentration measurements must be
taken at least 6 hours after the last dose. Toxicity can occur as a result of
deliberate or accidental self-poisoning or more commonly from drug
accumulation over a period of time, particularly in the elderly and patients
with associated renal impairment. Drugs such as verapamil, captopril,
quinine, quinidine, propafenone, flecainide, amiodarone, prazosin,
spironolactone, tetracycline, erythromycin and carbenoxalone can also
increase serum concentrations and predispose to toxicity. Agents causing
hypokalaemia or intracellular potassium deficiency, hypomagnesaemia,
hypercalcaemia and hypothyroidism can increase myocardial sensitivity to
digoxin, despite satisfactory therapeutic concentrations. 
Clinical presentation 
Clinical features of toxicity include constitutional effects such as lethargy
and weakness; gastrointestinal effects including  anorexia, nausea and 
vomiting; neurological effects including confusion, weakness, 
paraesthesiae and, rarely, fits and acute psychosis; ocular disturbances
including blurred vision, xanthopsia (yellow vision). Severe poisoning can 
cause hyperkalaemia (by inhibiting the myocardial membrane adenosine 
triphosphate (ATP) pump) and metabolic acidosis. 
Digoxin toxicity can cause any arrhythmia, and various conduction
disturbances. The commonest arrhythmia and, usually, an early sign of
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toxicity is the occurrence of ventricular ectopics, which frequently 
proceed to bigeminy, trigeminy or salvos. 
Arrhythmias arise from several actions of the drug, which include: 
• 	 enhanced automaticity, which can give rise to various atrial and 
ventricular tachyarrhythmias; 
• 	 excess vagal stimulation, predisposing to sinus bradycardia and 
atrioventricular (AV) block; 
• 	 a direct depressive effect on nodal tissue, further contributing to 
bradyarrhythmias. 
When these actions are present simultaneously, intoxication is 
highly likely and can cause the characteristic arrhythmia of atrial 
tachycardia with block. Other arrhythmias include junctional 
bradycardia, second or third degree AV block, ventricular tachycardia 
(VT) and ventricular fibrillation (VF). When concomitant medication 
elevates digoxin levels, the features of toxicity may depend on the agent 
added. For instance, quinidine predisposes to tachyarrhythmias, 
whereas verapamil and amiodarone predispose to bradycardia and 
AV block. 
Management 
If digoxin toxicity is suspected then the following steps should be 
taken: 
• 	 stop digoxin 
• 	 correct hypokalaemia if present 
• 	 check digoxin level 
• 	monitor cardiac rhythm and correct any sustained 

haemodynamically significant arrhythmia that occurs.
 
For acute overdoses, oral activated charcoal should be given to absorb any 
cardiac glycoside remaining in the gut and to interrupt the enterohepatic 
circulation. 
Ventricular ectopics, first degree AV block and AF with a slow rate but 
haemodynamic stability require no special therapy except drug 
withdrawal. 
For haemodynamically unstable bradyarrhythmias and AV block IV 
atropine 0.3–1 mg every 3–5 minutes to a total of 0.04 mg/kg body weight
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pacing should be instituted. Beta-adrenergic agonists, such as
isoprenaline, should be avoided because of the risk of precipitating more 
severe arrhythmias.
Supraventricular tachycardias can be treated with beta-blockers to control 
ventricular rate, but there is an increased risk of exacerbating AV
conduction disturbances. Therefore, an ultra-short-acting beta-blocker,
such as IV esmolol, should be used initially (see Appendix A). Ventricular
tachyarrhythmias can be treated with lidocaine and magnesium.
Magnesium possesses significant antiarrhythmic properties in the setting 
of digoxin toxicity. Phenytoin can be a useful treatment for ventricular or
supraventricular tachycardias initiated by digoxin, and should be given as
50–100 mg IV as a slow bolus, every 5 minutes, to a dose not exceeding 
600 mg. 
For life-threatening arrhythmias, digoxin-specific antibodies (Digibind)
are the treatment of choice. Digibind can be strikingly effective for 
life-threatening digoxin intoxication, especially when there are severe 
ventricular arrhythmias or hyperkalaemia. The reversal of toxicity is
rapid with few adverse effects, apart from the development of
hypokalaemia as the ATP pump activity is regained, and potassium is
transferred from the extracellular to intracellular space. The use of
Digibind should also be considered when more than 10 mg of digoxin has
been ingested by previously healthy adults (4 mg in children), or when
the steady-state serum concentration is greater than 10 ng/mL, or the 
serum potassium level is >5 mmol/L in the setting of severe intoxication. 
Digoxin levels may remain high, but most digoxin is bound to Fab 
fragments and is functionally inert. Therefore, measurement of
digoxin levels is not reliable or useful following the administration of 
Digibind. Box 8.1 summarizes the calculation for the administration of 
Digibind.
The risk of provoking dangerous arrhythmias with electrical 
cardioversion is greatly increased in the presence of digoxin toxicity and is
in proportion to the cardioversion energy used. Therefore, electrical 
cardioversion should only be used as a last resort for the treatment of 
life-threatening tachyarrhythmias, always starting at a low energy level 
(i.e. 10 J). Overdrive pacing can be considered in patients with refractory
ventricular arrhythmias. 
Haemodialysis is not useful because the drug has a large volume of
distribution and is extensively tissue bound.
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Box 8.1 Digibind indications and dosing regime 
Digibind administration is indicated for: 
Life-threatening arrhythmias or conduction disturbance 
Serum potassium levels greater than 5 mmol/L in the presence of severe 
intoxication 
Digoxin level >10 ng/mL 
The dose of antibody depends on the body load of cardiac glycoside, 
which has to be counteracted. When requesting levels it is important to 
specify whether digoxin or digitoxin is to be measured as the assays 
differ. 
To estimate the body load of digoxin or digitoxin from the amount 
ingested: 
The body load of digoxin or digitoxin � the amount 
ingested X 0.80 (mg) 
To calculate the body load of digoxin or digitoxin from the plasma or 
serum digoxin or digitoxin concentration: 
The estimated body load (mg � plasma (serum) concentration of 
digoxin (ng/mL) X 0.0056 X body weight (kg) 
The dose of antibody (Digibind) is about 60 times the body load 
(whether digoxin or digitoxin) rounded up to the nearest 40 mg. 
Sometimes up to 12 or 14 vials may be required. 
TRICYCLIC ANTIDEPRESSANT OVERDOSE 
Tricyclic antidepressants (TCADs) result in significant mortality when 
taken in overdose due to the cardiovascular effects of hypotension, 
myocardial depression and arrhythmias. The onset of toxicity is
rapid with the majority of deaths occurring within a few hours of
presentation. 
Clinical presentation 
Early clinical features are due to the anticholinergic effects of the drug, 
and include dilated pupils, dry skin, dry mouth, decreased bowel sounds
(ileus), urinary retention and tachycardia. Cardiovascular toxicity can 
rapidly ensue with the development of hypotension, arrhythmias and 
asystole. Toxicity results primarily from effects on the myocardial cell
action potential, direct effects on vascular tone and indirect effects
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TCADs can inhibit the fast-acting sodium channel and are therefore 
similar to class 1A antiarrhythmic drugs. Consequently, TCADs can 
impair cardiac conduction and prolong repolarization. They also have a 
negative inotropic effect due to inhibition of calcium entry into myocytes. 
The inhibition of sodium channels is pH dependent with acidosis
aggravating cardiotoxicity. Conversely, an increase in pH is protective by
improving cardiac conduction and reducing negative inotropic effects.
Impaired conduction in the His–Purkinje system slows propagation of the 
ventricular depolarization wave, and prolongs the QRS interval. QRS 
interval prolongation is the most distinctive feature of serious TCAD
overdose, and is usually seen as a non-specific conduction delay on the 
electrocardiogram (ECG). A QRS duration >120 ms is a good predictor of 
cardiac and neurological toxicity, whereas a QRS duration >160 ms is
predictive of ventricular arrhythmias. Prolongation of repolarization
causes an increase in QT interval, predisposing to Torsade de Pointes.
Non-uniform slowing may cause unidirectional block and re-entry
circuits to develop, analogous to ischaemic myocardium, resulting in VT; 
VT may be difficult to distinguish from sinus tachycardia in the presence
of prolonged QRS and PR intervals (P waves may be obscured by the 
preceding T wave). A 12-lead ECG may help reveal P waves not visible on a 
rhythm strip. VF is usually a terminal rhythm that occurs as a
complication of VT or hypotension. The PR interval in TCAD overdose is
often prolonged, but second or third degree AV block is rare. Sinus 
tachycardia is the most common rhythm disorder seen and is present in
more than 50 per cent of patients. 
Management 
Management is generally supportive, with monitoring of respiration and 
cardiac rhythm. Owing to the possibility of rapid deterioration, 
intravenous access is recommended. A 12-lead ECG should be obtained
because it may reveal QRS prolongation that is not evident on the single 
lead of a cardiac monitor.
The anticholinergic effects may delay gastric emptying, and a large, single 
dose of activated charcoal administration should be considered,
particularly if ingestion has occurred within an hour of presentation.
Any hypoxia and electrolyte or metabolic disturbances should be
corrected. Even in the absence of acidosis, if there is cardiac involvement 
(QRS prolongation >140 ms, ventricular arrhythmias) or hypotension,
50 mmol sodium bicarbonate should be administered slowly (see
Appendix A). Because marked alkalosis can be physiologically 
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detrimental, arterial blood pH should not exceed 7.5–7.55. Treatment for 
sinus tachycardia is not generally needed. First degree AV block requires
no treatment, second (type II) or third degree AV block should be
managed with temporary transvenous pacing. Any unstable ventricular 
tachyarrhythmias should be treated with direct current cardioversion 
(DCC); if recurrent, lidocaine should be administered. The use of other 
antiarrhythmic agents is limited, and may aggravate cardiotoxicity. 
Overdrive pacing should be considered in patients with refractory
ventricular arrhythmias. Seizures should be treated with diazepam, as
other anticonvulsant agents such as phenytoin may aggravate hypotension
and arrhythmias. If seizures cannot be adequately controlled, paralysis
and ventilation are indicated to prevent further acidosis. A fluid challenge 
often corrects mild hypotension and may facilitate the management of
more severe hypotension, which can be treated with inotropic and 
vasopressor agents. Noradrenaline is the vasopressor of choice, although
dobutamine may be effective in the presence of a low cardiac output but 
adequate filling pressures. 
SUBSTANCE ABUSE 
It is estimated that almost one in four people in developed countries have
misused recreational drugs at some time during their life. Therefore, 
independent of clinical practice, most doctors will have to manage 
patients with the ill effects associated with recreational drug abuse at 
some point during their career. In addition to their effects on the central 
nervous system, many of these agents induce profound changes in the 
heart and circulation, which are responsible for a significant proportion of 
drug-related morbidity. The purpose of this section is to review the 
cardiovascular complications associated with some of the commonly
misused recreational drugs. 
Cocaine, crack, amphetamine and ecstasy 
Pharmacology 
These drugs all share similar adverse effects on the cardiovascular system, 
related predominantly to sympathetic nervous system activation. Cocaine 
and its freebase form, ‘crack’, act by inhibiting the noradrenaline re-uptake 
transporter in peripheral nerve terminals as well as stimulating central 
nervous system outflow. Circulating catecholamine concentrations can be
elevated as much as five-fold in cocaine users. Cocaine has a short serum 
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metabolized and excreted in the urine over a 2-week period. At high doses,
cocaine can impair myocardial electrical conduction and contractility by
blocking fast sodium and potassium channels and inhibiting calcium entry 
into myocytes. Amphetamine and its derivative ecstasy produce indirect
sympathetic activation by releasing noradrenaline, dopamine and
serotonin from central and autonomic nervous system terminals. The 
plasma half-life varies from as little as 5 hours to 20–30 hours depending 
on urine flow and pH (elimination is increased in acidic urine). Compared
to cocaine, amphetamine lacks the local anaesthetic effect of inhibiting fast
sodium channels. 
Clinical effects 
Sympathetic activation can lead to varying degrees of tachycardia,
vasoconstriction, unpredictable blood pressure effects and arrhythmias,
depending on the dose taken and the presence or absence of coexisting 
cardiovascular disease. Although hypertension is common, hypotension
as a result of paradoxical central sympathetic suppression, a late relative 
catecholamine-depleted state or acute myocardial depression can occur.
Myocardial depression may be caused by ischaemia, a direct toxic effect of
the drug or mechanical complications (acute aortic rupture, tension
pneumothorax, pneumopericardium, etc.). 
Chest discomfort is a common symptom associated with cocaine,
affecting 40 per cent of emergency department attenders following use of
cocaine. Myocardial infarction occurs in up to 6 per cent of such patients
in the United States, although a significant proportion may not offer a 
history of chest pain at all. Cocaine-related infarction usually occurs early 
(within 3 hours) after cocaine use, but events may occur several hours 
later owing to persistence of metabolites in the circulation. Both cocaine 
and amphetamine can cause myocardial ischaemia and infarction in
patients with or without coronary artery disease. The underlying
mechanisms are unclear, but may be related to the elevated catecholamine 
concentrations, which result in an increase in myocardial oxygen
demand, coronary artery spasm, platelet aggregation and thrombus
formation. Cocaine can produce a procoagulant effect by decreasing 
concentrations of protein C and antithrombin III, and potentiating 
thromboxane production. Chronic use of cocaine and amphetamine can 
cause repetitive episodes of coronary spasm and paroxysms of
hypertension, which may result in endothelial damage, coronary artery 
dissection and acceleration of atherosclerosis. Creatine kinase
concentrations can be elevated in both cocaine and amphetamine abusers,
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and are therefore not reliable indicators of myocardial injury. This
elevation of creatine kinase is probably due to rhabdomyolysis.
Consequently, serum troponin concentrations, which are more sensitive 
and specific for the detection of myocardial necrosis, should be measured
in patients in whom cocaine- or amphetamine-related myocardial
infarction (MI) is suspected. 
Paroxysmal increases in blood pressure can lead to aortic dissection or
valvular damage that increases the risk of endocarditis affecting mainly 
left-sided heart valves. Endocarditis is often associated with unusual 
organisms such as Candida, Pseudomonas or Klebsiella, and frequently 
has an aggressive clinical course with marked valvular destruction,
abscess formation and a need for surgical intervention. Prolonged
administration of cocaine or amphetamines can also lead to a dilated 
cardiomyopathy. Aetiological mechanisms include repeated episodes of 
subendocardial ischaemia and fibrosis, and myocyte necrosis produced by
exposure to excessive catecholamine concentrations, infectious agents
and heavy metal contaminants (manganese is present in some cocaine 
preparations). Non-cardiogenic pulmonary oedema and pulmonary
hypertension can also occur with cocaine and amphetamine abuse.
Although the precise underlying mechanism remains unknown, a direct
toxic effect or alterations in central autonomic nervous system pulmonary 
vasculature regulation has been suggested. 
The adverse cardiovascular changes and sympathetic stimulation 
associated with cocaine and amphetamine ingestion predispose to 
myocardial electrical instability, precipitating a wide and unpredictable 
range of supraventricular and ventricular tachyarrhythmias. The 
presence of fibrotic scars, myocardial ischaemia and left ventricular
hypertrophy can act as a substrate for re-entrant arrhythmias. The class 1 
antiarrhythmic effect of cocaine can impair cardiac conduction causing
prolongation of the PR, QRS complex and QT intervals, and a wide range 
of bradyarrhythmias including sinus arrest and higher degrees of AV
block. 
Some cocaine users practise drug inhalation in association with a 
forced Valsalva manoeuvre (the positive ventilatory pressure increases 
drug absorption and therefore can enhance the drug’s effect), which can, 
rarely, be complicated by a pneumothorax or pneumopericardium. 
Sudden cardiovascular collapse may occur as a result of myocardial
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Management 
Similar principles apply to the management of the cardiovascular
complications associated with these drugs. If the patient is agitated and 
anxious, then a benzodiazepine in sedative dosages should be
administered as this can attenuate some of the cardiac and central 
nervous system toxicity. 
In the treatment of hypertension, beta-blockers should be avoided, as they
may be associated with unopposed alpha-mediated vasoconstriction 
leading to paradoxical increase in blood pressure and coronary artery 
vasoconstriction. The combined alpha- and beta-blocker drug, labetalol, 
is theoretically preferable to selective beta-blockers. However, the 
alpha-blocking effect is relatively weak and therefore labetalol can also
exacerbate hypertension. Hypertension can be safely managed with either 
an alpha-blocker such as phentolamine or with vasodilators such as
hydralazine, nitrates and nitroprusside. When hypertensive crises lead to
the mechanical complication of aortic dissection or acute valve rupture,
emergency cardiothoracic surgery may be required. 
Myocardial ischaemia should be treated initially with oxygen, aspirin and 
benzodiazepine. If there is continuing ischaemia, then vasodilators such 
as nitrates or phentolamine should be administered in an attempt to
reverse residual coronary artery spasm. Patients with persistent ST
segment elevation should undergo primary angioplasty. Among patients 
undergoing coronary stenting, the potential of non-compliance with
antiplatelet medication should be borne in mind when choosing the type
of stent. 
The majority of arrhythmias are short lived and terminate spontaneously 
as the drug is metabolized and cardiac function returns to normal. 
Consequently, antiarrhythmic agents should be avoided if possible.
Supraventricular or ventricular tachyarrhythmias associated with
haemodynamic compromise require urgent DCC. Sustained
haemodynamically tolerated supraventricular arrhythmias should be
treated initially with adenosine. In the presence of a hyperadrenergic
state, the short-lived inhibitory effect of adenosine may be a disadvantage, 
allowing reinduction of the arrhythmia. If adenosine is unsuccessful or
the arrhythmia rapidly returns, the co-administration of an alpha-blocker 
in combination with a beta-blocker may be effective. In ‘body packers’ 
suffering from overdose after rupture of ingested packets of cocaine,
calcium antagonist may accelerate gastrointestinal drug absorption by
inducing splanchnic vasodilatation. Furthermore, cocaine has a complex 
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and highly variable effect on myocyte calcium metabolism, producing an
unpredictable clinical response to calcium antagonist. For these reasons,
it may be preferable to avoid giving calcium antagonists to patients 
suspected of cocaine abuse. Bradyarrhythmias can be treated with
atropine; however, its effect may be attenuated in the presence of a 
hyperadrenergic state, and temporary cardiac pacing may be necessary. In
the presence of sustained ventricular tachyarrhythmias, lidocaine and 
magnesium have an acceptable safety and efficacy profile (despite 
theoretical concerns relating to the shared class 1 effects of cocaine and 
lidocaine). There is currently no reliable information on the safety and 
efficacy of other antiarrhythmic drugs. 
In animal studies using cocaine, the administration of sodium bicarbonate 
has been shown to have a beneficial effect on myocardial electrical 
stability. However, this may occur at the expense of inducing paradoxical 
intracellular acidosis or adverse systemic metabolic changes, leading to 
detrimental effects on myocardial function. Similarly, in severe cases of
amphetamine overdose, a forced acid diuresis may be successful in rapidly 
clearing amphetamine from the blood and limiting toxicity, but major 
detrimental metabolic changes in the acid–base balance can be induced.
These treatments require intensive and expert monitoring and should be
performed only by clinicians with previous metabolic experience. 
Lysergic acid diethylamide and psilocybin 
Pharmacology 
Lysergic acid diethylamide (LSD) and psilocybin (magic mushrooms) are
commonly abused hallucinogenic agents that are structurally related, and 
have similar physiological, pharmacological and clinical effects. LSD is
about 100 times more potent than psilocybin. Street mushrooms are often 
adulterated with LSD. Both drugs are indole derivatives and chemically 
resemble serotonin. Their mechanisms of action are complex and include 
agonist, partial agonist and antagonist effects at various serotonin 
receptors. The clinical effects are related to their serotonergic, 
dopaminergic and adrenergic activities. LSD is metabolized by the liver 
and has a plasma half-life of 100 minutes. 
Clinical effects 
The adrenergic effects of these drugs are usually mild and do not produce 
the profound sympathetic storms seen with cocaine and amphetamine. 
Symptoms corresponding to general sympathetic arousal include dilated 
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cardiovascular complications are rarely serious, supraventricular
tachyarrhythmias and MI have been reported. Changes in serotonin-
induced platelet aggregation and sympathetically induced arterial 
vasospasm have been suggested as mechanisms contributing to these 
complications. 
Management 
Management is usually supportive, as the majority of symptoms resolve 
within 12 hours. Agitated patients should be sedated with a
benzodiazepine. The use of neuroleptic agents should be avoided as they
can intensify toxic effects. Supraventricular arrhythmias can be treated 
with adenosine or verapamil. Apart from benzodiazepines,
pharmacological intervention for mild to moderate hypertension is
usually not required. Treatment for dangerously high blood pressure and 
myocardial ischaemia should follow the same general principles described 
for cocaine and amphetamine. 
Narcotic analgesics 
Pharmacology 
Morphine and its semi-synthetic analogue heroin are the most commonly 
misused narcotic analgesics. When used alone or in combination with
other drugs, they account for over 40 per cent of drug-related deaths. 
Heroin is slowly metabolized to morphine, which has a plasma half-life of 
2–3 hours. 
Clinical effects 
Narcotic agents act centrally on the vasomotor centre to increase
parasympathetic and reduce sympathetic activity. This effect, combined
with histamine release from mast cell degranulation, can result in
bradycardia and hypotension. Drug-induced bradycardia along with
enhanced automaticity can precipitate an increase in atrial and 
ventricular ectopic activity, AF, idioventricular rhythm or potentially 
lethal ventricular tachyarrhythmias. Some narcotic drugs (such as the 
synthetic agent, dextropropoxyphene, a constituent of co-proxamol) have
additional sodium channel blocking effects, causing ECG QRS 
prolongation, and further contributing to their pro-arrhythmic potential. 
It is recognized that methadone, commonly used in treating opioid
addiction, delays cardiomyocyte repolarization, resulting in ECG QT 
prolongation, which is associated with Torsade de Pointes. 
Bacterial endocarditis, affecting mainly right-sided cardiac structures, is a 
well-known complication of intravenous narcotic drug abuse, sometimes
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associated with pulmonary abscesses. Heroin overdose can cause
non-cardiogenic pulmonary oedema, the onset of which can be delayed
for up to 24 hours after admission. As the oedema fluid has the same 
protein concentration as plasma, and the pulmonary capillary wedge 
pressure is normal, a disruption in alveolar-capillary membrane integrity 
has been suggested as a mechanistic cause. 
Management 
Initial management centres around ensuring an adequate airway, 
breathing and circulation. In the presence of respiratory depression, 
severe hypotension and bradycardia, administration of repeated boluses 
or an infusion of a narcotic receptor antagonist, naloxone (Narcan), will
be required, as detailed in Appendix A. In severe hypotension, the
insertion of a pulmonary flow catheter may be needed to help guide fluid 
and inotropic administration, and avoid inappropriate administration of
diuretics in patients with non-cardiogenic pulmonary oedema, which 
requires intensive ventilatory support. 
There are no useful published data to guide selection of antiarrhythmic 
agents for the treatment of supraventricular and ventricular 
tachyarrhythmias. In the first instance, patients should be investigated,
and hypoxic, metabolic and electrolyte deficits corrected. As the misused 
drug is rapidly metabolized, the majority of arrhythmias are short lived,
and it is therefore preferable to avoid the use of antiarrhythmic agents
where possible to minimize the risk of pro-arrhythmic interactions. If
treatment is needed for supraventricular arrhythmia, conventional agents
such as adenosine, beta-blockers, verapamil and digoxin have been 
recommended. Ventricular arrhythmias should be managed along 
conventional lines. Persistent bradycardia may require atropine or 
temporary cardiac pacing. 
Volatile substance abuse 
The abuse of volatile substances is an increasing problem amongst 
young male adolescents. The products used are legal, cheap and easily 
available. Abusers generally employ deep breathing techniques with the 
volatile substances contained in a plastic bag or bottle, a crisp packet or a 
soaked handkerchief to maximize the inhaled concentration of the 
substance. 
Clinical effects 
Following inhalation, feelings of euphoria, excitement and invulnerability 





















DRUG RELATED CARDIAC PROBLEMS 
to be the main cause of death from volatile substance abuse. Volatile 
substances may induce supraventricular or ventricular tachyarrhythmias
by sympathetic activation or by myocardial sensitization to circulating 
catecholamines. Some abusers directly spray the substances into the oral
cavity, which can result in intense vagal stimulation and a reflex
bradycardia. Profound bradycardia can evolve into asystole or secondary 
ventricular tachyarrhythmias. Some volatile compounds can reduce
sino-atrial node automaticity, prolong the PR interval and induce
atrioventricular block. Myocardial ischaemia and infarction have been
reported and are believed to be caused by a combination of coronary
vasospasm, hypoxia or excessive sympathetic stimulation. Hypoxia can 
occur as a result of respiratory depression, aspiration, the placement of
bags over the head and neck, intense laryngeal oedema and spasm, and the 
formation of carboxyhaemoglobin or methaemoglobin. Some volatile 
substances are structurally related to the agents used in general
anaesthesia, and can therefore cause myocardial depression and 
hypotension. Chronic abuse can induce a poorly characterized
cardiomyopathy. 
Management 
Patients should be managed in a calm non-threatening environment, with
sedation if necessary. Hypoxia and chemical disturbances should be
corrected to optimize myocardial electrical stability. Haemodynamically
unstable tachyarrhythmias require prompt electrical cardioversion. 
Profound bradyarrhythmias may be treated cautiously with atropine or
temporary cardiac pacing. Hypotension can be treated with intravenous
fluids, guided by a pulmonary artery catheter, if necessary. Inotropic 
agents are best avoided, if possible, as they may induce refractory
ventricular tachyarrhythmias in the electrically unstable myocardium. 
Calcium administration may help to reverse myocardial depression. In
patients with sustained tachyarrhythmias, beta-blockers or amiodarone 
may help to combat sympathetic activation and are the antiarrhythmic 
drugs of choice. Cardiac ischaemia should be managed with oxygen, 




Cannabis is the most widely consumed recreational drug. It has a plasma
half-life of 20–30 hours and can be detected in the urine for several days in
occasional users, and up to months in heavy users. 















DRUG RELATED CARDIAC PROBLEMS 
Clinical effects 
Cannabis has a biphasic effect on the autonomic nervous system, 
depending on the dose absorbed. Low or moderate doses can increase
sympathetic and reduce parasympathetic activity, producing a 
tachycardia and an increase in cardiac output. In contrast, higher doses 
inhibit sympathetic and increase parasympathetic activity, resulting in
bradycardia and hypotension. Reversible ECG abnormalities affecting the 
P and T waves, and the ST segment, have been reported. It is not clear 
whether these changes occur as a direct result of cannabis, independent of
its effect on the heart rate. 
Supraventricular and ventricular ectopic activity can occur, and 
arrhythmias possibly relating to cannabis use have been reported. In
patients with ischaemic heart disease, cannabis increases the frequency of
anginal symptoms at low levels of exercise and may be a trigger for the 
onset of an acute MI. This is believed to occur as a result of drug-induced
increase in blood pressure, heart rate and myocardial contractility,
increasing myocardial oxygen demand. 
Management 
In the absence of major underlying structural heart disease, the 
autonomically mediated changes in heart rate and blood pressure are 
usually well tolerated and therefore no treatment is needed. Where 
necessary, hypotension usually responds to intravenous fluid 
administration. For significant bradycardia, atropine can be administered.
Patients presenting with unstable angina or MI should be treated
conventionally. 
KEY POINTS 
• 	The abuse of recreational drugs is common and it is inevitable 
that doctors will have to manage and treat their associated ill 
effects. 
• 	Recreational drugs are complex and can induce profound changes in
cardiovascular function, both acutely and chronically. 
• 	Recreational drugs are often taken together, which can result in
complex synergistic interactions with potentially detrimental 
effects. 
• 	A high index of suspicion with early intervention and management is
often the key to successful treatment. 
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BACKGROUND 
Acute pericarditis is a clinical syndrome caused by inflammation of the
pericardium and characterized by chest pain, a pericardial friction rub and
electrocardiographic abnormalities. It is more common in adult males than
in women and young children. Common causes include idiopathic, viral,
bacterial, uraemia, post-myocardial infarction, trauma and neoplasms
(Table 9.1). After myocardial infarction, pericarditis can occur within
1–4 days, or, less commonly, after 1–4 weeks as part of Dressler’s syndrome,
a systemic inflammatory condition thought to result from an autoimmune
reaction to myocardial necrosis. The pericardial reaction can be purulent,
haemorrhagic, fibrinous or serofibrinous. Complications may result in
restriction of cardiac filling, either as a result of blood or fluid trapped in
the pericardial sac (cardiac tamponade) or from thickening of the
pericardium (constrictive pericarditis). These conditions may be prevented
if diagnosis and management are undertaken early. 
CLINICAL FEATURES 
Pericarditis often presents with sharp chest pain, localized retrosternally or
in the left precordial region, and exacerbated by breathing, coughing,
moving or lying flat. The pain often radiates to the trapezius ridge, but may
also radiate into the neck, jaw, arms, or upper abdomen and can therefore
mimic an ACS or an acute abdomen. The pain is relieved by sitting up and
leaning forward. As the pericardium is well innervated, acute
inflammation may cause intense pain and initiate vagal reflexes. There may
be a history of prodromal symptoms, which can include fever, malaise and
myalgia. Dyspnoea may occur because of splinting of the chest from pain or
















Bacterial: staphylococci, streptococci, rheumatic fever,
 
Haemophilus influenzae, Salmonella, tuberculosis, 

Neisseria meningitidis, Neisseria gonorrhoeae, syphilis





  Others: Mycoplasma pneumoniae, Legionella, psittacosis,
 








Secondary, e.g. lung, breast, leukaemia, lymphoma, 
melanoma, Kaposi’s sarcoma, colon 
Connective tissue
disease                      
     SLE, Still’s disease, rheumatoid arthritis, systemic 
sclerosis, mixed connective tissue disease, polyarteritis 
nodosa 
  Drug-induced Hydralazine, methyldopa, minoxidil, procainamide, 
 dantrolene, daunorubicin, doxorubicin,
cyclophosphamide and methysergide 
Post-myocardial
  injury
        Post-MI, Dressler’s syndrome, trauma,  
 post-pericardiotomy, pacemaker insertion, cardiac
diagnostic procedures 
Other  Idiopathic, uraemia, hypothyroidism, sarcoidosis, Behçet 
disease, radiation, oesophageal rupture 
PERICARDITIS 
Table 9.1  Causes of pericarditis 
A pericardial friction rub is often present and is best heard along the left
sternal edge with the patient leaning forward. The persistence of the rub 
throughout inspiration and expiration as well as when the breath is held
can help distinguish a pericardial rub from a left-sided pleural rub. Large 
effusions can compress the base of the left lobe of the lung, causing an area
of dullness and bronchial breath sounds just below the angle of the left
scapula (Ewart’s sign). 
DIAGNOSIS 
General 
Non-specific markers of inflammation including white cell count (WCC),
erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are 
usually raised. Cardiac enzymes may be elevated if the inflammation
extends to the myocardium, and for this reason cardiac isoenzymes cannot 
always be used to differentiate between acute pericarditis and ACS.
Cardiac troponins are frequently elevated, but do not necessarily indicate a 
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PERICARDITIS 
worse outcome. Other specific haematological, biochemical and serological 
investigations are dependent on the suspected aetiology and include: 
• 	 urine and electrolytes (U&Es); 
• 	 antistreptolysin O titres, anti-Dnase B titre, throat swabs (acute 
rheumatic fever); 
• 	 blood cultures; 
• 	 acute and convalescent viral titres, monospot or Paul–Bunnell test 
(Epstein–Barr virus), cold agglutinins (mycoplasma), fungal 
precipitins;. 
• 	 sputum, urine and faecal samples for microbiology; 
• 	Heaf test (tuberculosis); 
• 	 autoantibodies (lupus, rheumatoid arthritis, systemic sclerosis, etc.); 
• 	 thyroid function tests. 
Chest x-ray can be normal, or the heart shadow may be enlarged, 
suggesting the presence of a pericardial effusion. There may be pleural 
effusions but pulmonary congestion, if present, indicates associated 
myocarditis. 
Electrocardiogram 
ECG changes (Figure 9.1) can occur a few hours or days after the onset of 
pericardial pain and are characterized initially by concordant, concave ST 
segment elevation in all leads except leads aVR, V1 and sometimes V2 
(these leads show reciprocal ST depression). There is often PR segment 
depression associated with ST elevation (and sometimes PR elevation with 
ST depression). The following evolutionary changes then occur: 
isoelectric ST segment with flattened T waves, isoelectric ST segment with 
T inversion and finally reversion of T waves to normal. These changes are 
different from cardiac ischaemia (Table 9.2). It should be emphasized that 
they may not follow an exact sequence and some patients may present 
with only ST elevation and a return to normal without T inversion. 
Alternatively, T inversion may be the first sign, since the acute process was 
missed. Pericardial effusion can produce low voltage QRS complexes and 
electrical alternans (see Chapter 11). 
Echocardiography 
Echocardiography is valuable for determining the presence and size of a 
pericardial effusion and monitoring progress if the effusion is drained or 
treated conservatively. Furthermore, any contractile dysfunction resulting 








































































 Myocardial infarction Pericarditis 
Convex ST elevation Concave ST elevation 
ST elevation and T inversion    Isoelectric ST segment with
T flattening and later T inversion 
Loss of R-wave voltage and Q waves  Return to normal 
PERICARDITIS 
Table 9.2  Progression of the electrocardiographic changes of pericarditis
compared with myocardial infarction 
MANAGEMENT 
The first step is to establish whether the pericarditis is related to an
underlying medical problem that requires specific therapy; for instance, 
uraemic pericarditis will require urgent dialysis. 
Non-specific therapy consists of bed rest until pain and fever have
disappeared, and the administration of anti-inflammatory agents such as
aspirin (600–900 mg every 4–6 hours), ibuprofen (200–400 mg every 
6 hours) or indomethacin (25–50 mg every 6 hours). In the randomized 
COPE study, the addition of colchicine to aspirin was shown to be more 
effective than aspirin monotherapy for the treatment of acute pericarditis. 
The dose given was 1-2 mg during the first 24 h, followed by a 
maintenance dose of 0.5-1 mg daily for 3 months. Combination therapy 
was associated with quicker symptom resolution as well as a much
reduced recurrence rate. Similarly, the same combination was more 
effective than aspirin alone for recurrent episodes. With the exception of
aspirin, anti-inflammatory drugs should be used cautiously in
post-infarction pericarditis as they can affect scar formation and 
predispose to myocardial rupture. Some therapeutic studies have
indicated that corticosteroid treatment is associated with more frequent
recurrent pericarditis. In general, corticosteroids should be reserved for 
those with underlying rheumatalogic conditions or intolerance to the 
agents discussed above.
Antibiotics should be restricted to cases of purulent pericarditis and
documented antibiotic-sensitive micro-organisms. Anticoagulants should
be discontinued unless there is strong evidence for the development of
thromboembolic complications. If anticoagulants must be continued,
such as in patients with mechanical heart valves, intravenous heparin, 
which has a short half-life and whose action can easily be reversed with
protamine sulphate, should be used. Patients should then be examined















Large (≥ 2cm) circumferential pericardial effusion on echo 
History of anticoagulant use 
History of, or concurrent, malignancy (particularly lung, breast, 
leukaemia or lymphoma) 
Chest trauma including surgery 
Fever exceeding 38°C 
Subacute onset (days to weeks) 
Immunosuppression 
Evidence for myocarditis 
Atypical ECG evolution 
Pulsus paradoxus 
 Significantly raised acute phase reactants and very high troponin 
PERICARDITIS 
Table 9.3  High-risk features of pericarditis 
Adapted with permission from Spodick (2008) pp.: 398–9. 
The diagnostic yield of pericardial aspiration is poor, and this procedure 
should not routinely be performed in acute pericardits. However,
aspiration of the fluid may be needed to confirm a diagnosis, particularly 
if purulent disease is suspected, and/or to treat cardiac tamponade. 
Recurrent effusions may require the formation of a pericardial window,
balloon pericardiotomy or the instillation of chemotherapeutic agents. 
Acute idiopathic pericarditis is usually benign but may rapidly constrict
or pursue a relapsing course before burning out. Late complications of
pericarditis include pericardial fibrosis and/or calcification, resulting
in constrictive pericarditis (particularly seen after episodes of
tuberculous pericarditis), or a mixture of both effusive and constrictive
pericardial disease. Studies have suggested that there are certain
clinical and investigational features which may portend an adverse
prognosis. A recent proposal suggested that cases of pericarditis
without high-risk features (Table 9.3) can be observed for a few hours
prior to discharge. 
KEY POINTS 
• 	There are a number of causes of acute pericarditis but idiopathic, viral 
and post-MI pericarditis are the commonest. 
• 	Occasionally the pain of pericarditis can mimic an acute abdomen or
MI; however, in the majority of cases pericarditis has characteristic 
clinical and electrocardiographic features. 














• 	Most symptoms resolve with rest and non-steroidal anti-inflammatory
agents. 
• 	With the exception of aspirin, non-steroidal anti-inflammatory drugs 
and steroids should be used cautiously in post-infarction pericarditis as
they can affect scar formation and predispose to myocardial rupture. 
• 	 Late complications include effusive and/or constrictive pericardial 
disease. 
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BACKGROUND 
In developed countries, cardiac trauma represents one of the leading 
causes of death in those under the age of 40 years. Young males are more 
likely to be affected than females. Road traffic accidents and physical
violence are responsible for the majority of cases, although the incidence
of iatrogenic causes as a result of intravascular and intracardiac 
catheterization as well as cardiopulmonary resuscitation (CPR) is
currently rising. Advances in initial resuscitation and surgical
management mean more patients are surviving the initial insult. 
Cardiac trauma is divided into penetrating and non-penetrating injuries. Both
mechanisms can lead to myocardial rupture, contusion, laceration, pericardial
insult, coronary injury, valvular damage, arrhythmias and conduction
abnormalities. Cardiac trauma is easily overlooked as attention is diverted to
more obvious skeletal and multisystem injuries. As a result, haemodynamic
instability can rapidly develop with devastating results. A high index of
clinical suspicion with the early use of diagnostic techniques is essential and is
often the key to successful management. It is important for physicians to have
a good working knowledge of cardiac trauma to enable them to diagnose the
occurrence of these conditions and manage the non-surgical components. 
NON -PENETRATING CARDIAC TRAUMA 
Non-penetrating cardiac trauma usually occurs following the application 
of direct external physical forces to the chest wall. The incidence of cardiac 
damage following this type of injury is estimated to be 10–16 per cent. 
Non-penetrating cardiac trauma most often is the result of road traffic 
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Box 10.1 Con sequences of non -penetrating 
cardiac trauma 
Myocardium Coronary artery injury 
•  Contusion • Laceration 
• Laceration • Dissection 
• Rupture • Fistulae 
– Free wall • Rupture 
– Septum • Thrombosis 
– Valvular apparatus 
Conduction disturbances 
• Aneurysm, pseudoaneurysm • Bundle branch block 
Pericardial injury 
• Laceration • Bifascicular block 
• Pericarditis • Atrioventricular block 
• Post-pericardiotomy • Atrial arrhythmias 
syndrome •  Ventricular tachyarrhythmias 
• Constrictive pericarditis • Sinus node dysfunction 
Aortic dissection Commotio cordis (sudden cardiac 
death) 
accidents (as the heart is compressed between the steering wheel or seat 
belt, and the sternum and spine) but can also occur as the result of falls,
fights and sporting injuries. Box 10.1 summarizes the injuries that can 
develop as a consequence of non-penetrating cardiac trauma. 
Cardiac contusion is considered the most common injury to the heart 
following blunt trauma. Cardiac contusion usually produces no significant
symptoms and can easily go unrecognized. Subepicardial and 
subendocardial petechiae, bruising, haematoma, lacerations and
full-thickness myocardial damage, later followed by necrosis, fibrosis and 
aneurysm formation, can occur. The key symptom is precordial pain
resembling that of myocardial infarction (MI) but unrelieved with nitrates.
Other sites of chest trauma may confuse the clinical picture, but unlike
injury to the thoracic wall, pain from cardiac contusion is not affected by
breathing. There may be inappropriate tachycardia, gallop rhythm and a 
pericardial rub. The electrocardiogram (ECG) may show non-specific 
ST-T wave changes (Figure 10.1), findings of pericarditis, loss of R-wave
amplitude and even pathological Q waves depending on the degree of
injury. Localized injury to the conducting system can give rise to varying 
degrees of atrioventricular (AV) block, intraventricular conduction defects














































































































































































































































































































































(AF), atrial and ventricular ectopics, ventricular tachycardia (VT) and 
ventricular fibrillation (VF) can also occur. 
Cardiac-specific enzymes such as CK-MB isoenzyme, troponin T or
troponin I can be used to make a diagnosis of cardiac contusion.
Transthoracic echocardiography may show pericardial effusion,
regional wall motion abnormalities, valve dysfunction and chamber
enlargement. Up to 25 per cent of trauma patients cannot be
satisfactorily imaged with transthoracic echocardiography and a
transoesophageal echocardiogram (TOE) is a superior alternative. With
the exception of anticoagulation and thrombolytic therapy, the
treatment of cardiac contusion is similar to that of acute coronary
syndrome (ACS). Arrhythmia or cardiogenic shock can occur within the
first 48 hours after presentation. Therefore cardiac monitoring is
essential in the initial phase if there is echocardiographic or marked
ECG change. Troponin is released earlier than in classical ACS;
therefore, when negative on admission, troponin should be rechecked
4–6 hours later. In uncomplicated cases treatment is initially with bed
rest and analgesia. Non-steroidal anti-inflammatory drugs are not
advised as they can interfere with myocardial healing. Complete
recovery usually occurs, as patients are often young with an otherwise
healthy heart. Some patients may develop left ventricular impairment as
healing is by fibrosis in a similar manner as following ACS. 
CARDIAC RUPTURE 
Rupture of the free wall, interventricular septum, heart valves, papillary
muscles or chordae tendineae can occur acutely owing to the direct force 
of the injury or may be delayed up to 2 weeks resulting from necrosis. 
Rupture of the thoracic aorta commonly occurs at the aortic isthmus, just
below the origin of the left subclavian artery. These complications are 
usually fatal. Patients may present with signs and symptoms of acute 
cardiac tamponade, severe congestive heart failure with a new murmur or
haemorrhagic shock. If indicated, pericardiocentesis may be life saving.
Meticulous fluid resuscitation and early surgical intervention is the 
definitive treatment for most patients. 
PERICARDIAL INJURY 
Trauma to the pericardium can range from contusion to laceration or
rupture allowing herniation of the heart. Clinical findings include a 
PERICARDIAL INJURY 229 

















pericardial friction rub and ST-T wave changes on the ECG characteristic 
of pericarditis. Complications such as haemopericardium and tamponade 
can occur. In the case of cardiac herniation, the heart becomes entrapped, 
there may be impaired filling and occasionally compression of the 
coronary arteries. There may be evidence of a displaced heart and 
pneumopericardium on a chest x-ray. The ECG can show a new shift in
axis or bundle branch block. The only therapy for cardiac herniation is
surgical repositioning. Uncomplicated pericarditis can be treated with
non-steroidal anti-inflammatory agents. Recurrent pericardial effusions
associated with pericardial pain, pyrexia and a friction rub can sometimes 
occur. It is similar to the post-pericardiotomy syndrome and is treated 
with non-steroidal anti-inflammatory agents. Constrictive pericarditis
can occur as a late sequel and the treatment is total pericardiectomy. 
CORONARY ARTERY INJURY 
Coronary artery trauma can lead to laceration, dissection, rupture and 
fistulae formation. ACS can occur if a coronary artery becomes occluded.
A previously normal coronary artery may sustain disruption of the 
intima, subintimal haemorrhage and obstructive intraluminal thrombus
formation on the injured arterial wall. The left anterior descending artery 
is most frequently affected due to its anterior position, followed by the 
proximal right coronary artery. The circumflex and left main stem are 
rarely affected. It may be impossible to differentiate from cardiac 
contusion without the use of coronary angiography. In patients with
continuing pain and ECG changes consistent with evolving ACS it is
reasonable to undertake coronary angiography with a view to 
percutaneous coronary intervention (PCI). However, this must be
balanced against the risks in a patient with multiple associated injuries as
antiplatelets and anticoagulation are required. Discussion with senior 
colleagues is essential.
COMMOTIO CORDIS 
Sudden death may occur in young sport participants when a small hard
ball (such as a cricket ball) or other projectile (lacrosse ball, hockey puck, 
karate kick) strikes the victim in the precordium. This phenomenon is
termed commotio cordis and affects children and adolescents 5–15 years 
of age without pre-existing heart disease. It is the second most common
cause of sudden cardiac death in young athletes after hypertrophic 
cardiomyopathy. Characteristically, there is no structural damage to the 













thoracic cavity or heart. The causative precordial blows are often not 
perceived as unusual for the sporting event involved or of sufficient 
magnitude to cause death. It is believed that an appropriately timed 
precordial blow, during the electrically vulnerable phase of ventricular 
repolarization (15–30 ms before the T-wave peak), can induce a
ventricular tachyarrhythmia and subsequently death. At present, early 
basic and advanced life support, and ensuring adequate chest protection, 
are the only effective treatments against this phenomenon. 
PENETRATING CARDIAC TRAUMA 
Penetrating cardiac trauma is increasingly common with the majority
being caused by gunshot and stab wounds, although shrapnel, fractured 
ribs, intracardiac diagnostic and therapeutic catheters can also produce 
penetrating cardiac injury. Penetrating wounds often result in laceration
of the pericardium, as well as the underlying myocardium. One or more 
chambers, the interventricular and interatrial septa, valvular apparatus 
and coronary arteries may be involved. Box 10.2 summarizes the 
complications of penetrating cardiac trauma. In the case of stab wounds, 
the chamber most commonly involved is the right ventricle because of its 
anterior position followed by the left ventricle. Forty per cent of
penetrating cardiac injuries are to the ventricles. Twenty-three per cent
are to the right atrium and 3 per cent to the left atrium. Clinical
presentation is dependent on the size of the wound and the location of the 
structures injured. If the pericardium remains open, blood can pass freely 




– Free wall 
– Septum 
– Valvular apparatus 








• Bundle branch block 
• Bifascicular block 
• Atrioventricular block 
















into the mediastinum and pleural space, causing haemorrhagic shock and 
massive haemothorax on chest x-ray. This is commonly seen in large or
right ventricular wounds. However, if the pericardium does not permit
free drainage because its opening has been obstructed by a blood clot, 
adjacent lung tissue or other structures, then blood accumulates within
the pericardial space, causing cardiac tamponade. Under these 
circumstances, the chest x-ray will show a normal size cardiac silhouette, 
as the acute and rapid accumulation of fluid within the pericardial space 
does not allow distension of the pericardium. Echocardiography can be
useful for diagnosing pericardial effusions, foreign bodies in the heart and 
intracardiac shunts. 
Initial management includes securing the airway, establishing venous
access and appropriately administered intravenous fluids and blood. The 
offending object should remain in situ until exploratory surgery can be
carried out. Patients who fail to respond to resuscitation and suddenly 
decompensate, should undergo immediate thoracotomy and repair of any 
treatable cardiac trauma. The incidence of late sequelae can be as high as
20 per cent and includes atrial and ventricular septal defects, tricuspid 
and mitral valve lacerations, and coronary injury. These complications 
may be missed on initial examination, only becoming apparent after a few 
days or weeks because of fibrous retraction of wound edges, resolution of
oedema, ventricular enlargement and lysis of occluding clots. It is
therefore essential that all post-cardiac trauma patients are closely 
monitored while in hospital and also in the outpatient clinic. Not 
surprisingly, penetrating cardiac injuries are usually immediately fatal, 
with the victim dying before reaching hospital. 
KEY POINTS 
• 	Cardiac trauma is a leading cause of death under the age of 40 years. 
• 	 It is divided into penetrating and non-penetrating injuries, which can 
both lead to myocardial rupture, contusion, laceration, pericardial 
insult, coronary injury, valvular damage, arrhythmias and conduction
abnormalities. 
• 	 It is easily overlooked and should always be considered in anyone
presenting with skeletal and multisystem injuries. 
• 	A high index of clinical suspicion with the early use of diagnostic 
techniques is essential and is often the key to successful management. 
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BACKGROUND 
Cardiac tamponade is an emergency clinical syndrome that occurs
when blood or f luid fills the pericardial space, raising intrapericardial
pressure and preventing ventricular diastolic filling. Consequently,
venous pressures are greatly increased, and there is a reduction in stroke
volume and cardiac output with the development of shock. The
development of tamponade relates to the rapidity of f luid accumulation
and the distensibility of the pericardium rather than the quantity of
f luid. If accumulation is rapid, or if left ventricular function is
compromised for other reasons, as little as 250 mL may be sufficient to
produce tamponade. In contrast, it may take in excess of a litre of f luid
to produce tamponade if it accumulates over a long period of time. Some
common causes of cardiac tamponade are listed in Box 11.1. 
CLINICAL PRESENTATION 
Patients typically present with cardiogenic shock,  with hypotension, 
cold-clammy peripheries, oligo-anuria and associated agitation. 
Untreated, this condition can be rapidly fatal. In the setting of a more 
slowly developing tamponade, patients appear less ill and may present 
with anorexia, weakness and signs of biventricular failure such as
shortness of breath, peripheral oedema and hepatomegaly. There may be
an accompanying tachycardia, and the presence of pulsus paradoxus (an 
inspiratory decrease in amplitude of the palpated pulse or measured blood
pressure) is supportive of the diagnosis. The jugular venous pressure 
(JVP) is markedly elevated with a prominent x descent and absent y
descent. A positive Kussmaul’s sign (an inspiratory increase in the JVP) is











process and epicardial constriction is present, in addition to an effusion.
The apex beat may not be palpable and the heart sounds are soft or even 
absent. There may be a pericardial friction rub. 
In addition to a sinus tachycardia, the electrocardiogram (ECG) may 
show abnormalities of pericarditis, low voltage complexes and electrical 
alternans (alteration in QRS amplitude on a beat-to-beat basis as the 
heart continually alters its axis within the fluid-filled pericardial sac). 
The chest x-ray can show an enlarged globular heart shadow if the 
effusion is chronic or a normal cardiac silhouette if the tamponade 
develops acutely as seen during cardiac rupture or laceration. The lung 
fields are usually clear.
Although cardiac tamponade is very much a clinical diagnosis,
echocardiography is the definitive investigation. Echocardiography will
show the effusion and demonstrate the best approach for drainage. In
tamponade, diastolic collapse of the low-pressure right heart chambers is
evident, with right ventricular collapse being a more specific finding than
right atrial collapse. Doppler indices showing reduced mitral and 
increased tricuspid inflow velocities with respiration are also specific 
features for demonstrating tamponade. Echocardiography can also
CLINICAL PRESENTATION 235 
Box 11.1  Causes of cardiac tamponade 
• 	 Malignant disease 
• 	 Post-infective pericarditis 
• 	 Rupture of the free wall post-myocardial infarction 
• 	 Uraemia 
• 	 Iatrogenic; post-diagnostic (cardiac catheterization) or 
therapeutic procedures (pacemaker electrode insertion, 
angioplasty, etc.), anticoagulation 
• 	 Chest trauma 
• 	 Radiation 
• 	 Hypothyroidism 
• 	 Dissecting aortic aneurysm 
• 	 Post-pericardiotomy syndrome 
• 	 Dressler’s syndrome 
• 	 Connective tissue diseases, e.g. rheumatoid arthritis, systemic 
lupus erythematosus, etc. 
• 	 Idiopathic 
 236 MANAGEMENT 
CARDIAC TAMPONADE 
exclude other causes of systemic venous hypertension and arterial 
hypotension such as constrictive pericarditis, cardiac dysfunction and 
right ventricular dysfunction. 
MANAGEMENT 
If haemodynamic compromise is present, intravenous fluids or inotropic 
agents can be administered to maintain haemodynamic support, while 
preparing the patients for pericardiocentesis (see below). Cardiac 
tamponade associated with cardiac trauma or aortic dissection requires 
immediate surgical intervention. 
Pericardiocentesis 
• 	Pericardial aspiration should ideally be performed with full x-ray 
screening, rhythm monitoring and resuscitation facilities readily 
available. Echocardiography can be used to guide pericardial 
aspiration as it allows visualization of the pericardial space, the 
myocardium and the aspiration needle. It can therefore give an 
indication of the best line of approach. 
• 	 The patient is placed at 30–45° to pool the pericardial fluid anteriorly 
and inferiorly. The patient is then connected to an ECG monitor. 
• 	A long 18-gauge needle should be used. The V1 lead from an ECG 
machine can be connected to the metal hub of the needle via a 
sterile alligator clip to provide continuous monitoring from the tip 
of the puncture needle. 
• 	Although several sites have been advocated for pericardiocentesis, 
the subxiphoid approach is preferred as it is extrapleural and avoids 
the coronary, pericardial and internal mammary arteries. The skin 
is cleaned and lignocaine infiltrated between the left side of the 
xiphisternum and the adjacent left costal margin, with the point 
directed towards the left shoulder, 45° to the skin. 
• 	The needle is advanced while periodically aspirating and injecting 
small amounts of lignocaine. The needle is advanced until fluid is 
aspirated, indicating that the needle has reached the pericardial 
space. If using ECG monitoring, ST elevation indicates that the tip 
of the needle is in contact with the myocardium. Alternatively, the 
injection of a few millilitres of contrast media can be used to 
determine if the needle is in the pericardial space or within a 






dispersed, then the needle is in a cardiac chamber. By contrast, the 
sluggish layering of contrast media inferiorly indicates that the 
needle is within the pericardial space. When using 
echocardiography rather than x-ray screening, injection of a few 
millilitres of agitated saline can be used to confirm the tip position 
by observing the appearance of microbubbles within the 
pericardial space. Failure of the bloody fluid to clot is further 
evidence that it is not from within the heart. 
• 	The syringe is removed and a guidewire inserted under radiological 
or echocardiographic control. A pre-dilated pigtail drainage 
catheter is then inserted. Fluid can then be aspirated from the 
catheter. Removal of only 100 mL can produce a dramatic 
improvement in haemodynamic status. A connection is made to a 
collection bag if there is any possibility of fluid re-accumulating. 
• 	Pericardial fluid should be sent for microbiology (microscopy, 
aerobic and anaerobic culture and sensitivity, including requests 
for fungal and tuberculous investigations), biochemistry (protein 
and glucose) and cytology. 
• 	The catheter is generally removed after 24–48 hours, to reduce the 
chance of infection. 
• 	 A post-procedure chest x-ray is obtained to exclude a pneumothorax. 
Rarely, following the removal of large amounts of pericardial fluid, 
sudden ventricular dilatation and acute pulmonary oedema may develop. 
This is probably related to a sudden increase in pulmonary venous blood 
flow, following the relief of pericardial compression in the presence of 
ventricular dysfunction. 
KEY POINTS 
• 	Cardiac tamponade is a clinical diagnosis caused by a critically 
increased volume of fluid within the pericardium obstructing inflow of
blood to the ventricles. 
• 	Consider the diagnosis in any patient in a haemodynamically collapsed
state, with a raised JVP, reduced heart sounds, low-voltage complexes 
on the ECG and clear lung fields. 
• 	Pericardiocentesis should be done only by those experienced in
performing the procedure. 








Callahan JA, Seward JB, Nishimura RA, et al. Two dimensional echocardiographically 
guided pericardiocentesis: experience in 117 consecutive patients. Am J Cardiol
1985; 55: 476–84. 
Guberman B, Fowler NO, Engel PJ, Gueron M, Allen JM. Cardiac tamponde in medical 
patients. Circulation 1981; 64: 633–40. 
Krikorian JG, Hancock EW. Pericardiocentesis. Am J Med 1978: 65: 808–14. 
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 Dobutamine Body weight (kg) 
 infusion rate
((g/kg/min) 50 60 70 80 90 
2.5  1.5  1.8  2.1  2.4  2.7 
5  3.0  3.6  4.2  4.8  5.4 
10  6.0  7.2  8.4  9.6 10.8 
15  9.0 10.8 12.6 15.4 16.2 





Table A.1 Dobutamine administration. Add 250 mg (5 mL of 50 mg/mL 
solution) in 45 mL of 5% dextrose or normal saline (giving a concentration of 
5000(g/mL). Commence infusion at 2.5 (g/kg/min initially, slowly increasing 
to a maximum of 20(g/min. The following table gives infusion rates in 
mL/h for a solution of 5000(g/mL according to dose required and body 
weight 
Table A.2 Dopamine administration. Add 400 mg (10 mL of 40 mg/mL 
solution) to 40 mL of 5% dextrose to give a total volume of 50 mL, and a 
drug concentration of 8000 (g/mL. The following table gives infusion 






50 60 70 80 90 
2.5 0.9 1.1  1.3  1.5  1.7 
5 1.9 2.3  2.6  3.0  3.4 
10 3.8 4.5  5.2  6.0  6.8 
15 5.7 6.8  7.8  9.0 10.2 
20 7.6 9.0 10.4 12.0 13.6 
APPENDIX A: INTRAVENOUS CARDIAC DRUG REGIMENS 257 
 
Appendices 
Table A.3 Short-acting insulin (Actrapid) sliding scale. Add 50 units of 
Actrapid in 50 mL of normal saline to give a concentration of 1 unit/mL. 
The following table gives the infusion rates depending on the BMs 





>20 6 (and urgent diabetologist review) 
aInsulin-dependent diabetics require a maintenance infusion of 0.5 units/h. 
258 APPENDIX A: INTRAVENOUS CARDIAC DRUG REGIMENS 
 
Laboratory values 
Biochemistry Reference range 
Na 135–145 mmol/L 
K  3.  
Cl 95–105 mmol/L 
Mg 0.75–1.05 mmol/L 
Urea 2.5–6.5 mmol/L 
Creatinine 70–120 mmol/L 
Creatinine clearance  80–140mL/min 
Bicarbonate 24–30 mmol/L 
Fasting glucose  3.5–5.5mmol/L 
Calcium (total)  2.12–2.65mmol/L 
Calcium (ionized) 1.0–1.25 mmol/L 
Phosphate 0.8–1.45 mmol/L 
Alanine aminotransferase  5–35 iu/L 
Alkaline phosphatase  30–300 iu/L (adults) 
Bilirubin  3–17(mol/L 
Albumin 35–50 g/L 
Aspartate transaminase (AST) 5–35 iu/L 
Lactic dehydrogenase (LDH) 70–250 iu/L 
Creatine kinase (CK)a  25–195 iu/L (males) 
 25–170 iu/L (females) 
CK-MB mass  <5(g/L 
CK-MB mass:CK ratio >3 (MI likely) 
Troponin T <0.05(g/L 
Troponin Ib  <0.1(g/L 
C reactive protein <8 mg/L 
Appendices 
APPENDIX B: LABORATORY VALUES AND USEFUL FORMULAE 
5–5mmol/L  
Continued 






Free T4 9–22 pmol/L 
TSH 0.5–5.7 mu/L 
aCK values in healthy Afro-Caribbeans may be increased 2–3 times the quoted reference limit. 
bAssay dependent, therefore check reference in laboratory. 






HCO3 23–33 mmol/L 
O2 saturation 93–98% 
H1 36–44 mmol/L 
Base excess ±2mmol/L 
a7.6 mmHg = 1 kPa. 
Haematology Reference range 
Hb 13.5–18.0 g/dL (males) 
11.5–16.0 g/dL (females) 
WCC 4–11 3 109/L 
Neutrophils 2–7.5 3 109/L 
40–75% WCC 
Lymphocytes 1.3–3.5 3 109/L 
20–45% WCC 
Eosinophils 0.04–0.44 3 109/L 
1–6% WCC 
Basophils 0–0.1 3 109/L 
0–1% WCC 
ESR (increases with age) <20 mm in 1 hour (rough guide) 
Age ÷ 2 (males) 
(Age + 10) ÷ 2 (females) 




150–  400 X 109/L 
10–14 s 





















Haemodynamic pressures and parameters Reference range 
Left ventricle
 Systolic 100–140 mmHg 
End diastolic 3–12 mmHg 
Right ventricle
 Systolic 15–30 mmHg 
End diastolic 2–8 mmHg 
Aortic
 Systolic 100–140 mmHg
 Diastolic 60–90 mmHg 
Mean (diastolic + 1/3 pulse pressure)a 70–105 mmHg 
Pulmonary artery
 Systolic 15–30 mmHg
 Diastolic 4–12 mmHg
 Mean 9–18 mmHg 
Wedge (left atrium)
 Mean 2–12 mmHg 
A wave 3–15 mmHg 
V wave 2–10 mmHg 
Right atrium
 Mean 2–8 mmHg 
A wave 2–10 mmHg 
APPENDIX B: LABORATORY VALUES AND USEFUL FORMULAE 261 





V wave 2–10 mmHg 
Systemic vascular resistance 700–1600 dyn X s X cm -5 
Total pulmonary resistance 100–300 dyn X s X cm -5 
Pulmonary vascular resistance 20–130 dyn X s X cm -5 
Cardiac output 5.5–9 L/min 
Cardiac index 2.6–4.2 L/min/m2 
aPulse pressure = difference between systolic and diastolic pressures. 
Electrocardiography and echocardiography Reference range 
P wave width <110 ms (lead II) 
P wave height <2.5 mm (lead II) 
PR interval 120–200 ms 
QRS duration <120 ms 
QT intervala 440 ms (males) 
460 ms (female) 
Aortic root 2–3.7 cm 
Aortic cusp separation 1.5–2.6 cm 
Left atrium 1.9–4 cm 
Left ventricle diameter (end systole) 2.5–4.1 cm 
Left ventricle diameter (end diastole) 3.5–5.6 cm 
Left ventricular posterior wall thickness (end systole) 0.9–1.3 cm 
Left ventricular posterior wall thickness (end diastole) 0.7–1.1 cm 
Interventricular septal wall thickness (end systole) 0.9–1.8 
Interventricular septal wall thickness (end diastole) 0.7–1.1 cm 
Right ventricle (end diastole) 2.3 cm 
Ratio of septum to posterior wall thickness 1.3:1 
Fractional shortening 30–40% 
Ejection fraction 50–85% 
aWhen using drugs known to prolong the QT interval, discontinue or reduce dose if QT interval is 




Bazett’s formula    QT interval (seconds)  � (corrected QT interval) RR internal (seconds) 
LDL-cholesterol  � Total cholesterol -
(Friedwald’s equation)  (triglyceride 1 HDL - cholesterol) 
2.19   
(Formula only valid for triglyceride concentrations < 4.5 mmol/L) 
Cockroft and Gault formula for estimating 
creatinine clearance (mL/min) �
  (140   - age in years) X (weight in kg) 
72  serum creatinine in mg / dL    X
(for women multiply formula by 0.85; mg/dL = μmol/L � 88.4) 
� Height (cm) X Weight (kg)  Body surface area �  
3600 
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